Chimeric receptors to steap1 and methods of use thereof
Engineered immune cells with CARs targeting STEAP1 are used to treat prostate cancer and other diseases by enhancing the immune system's ability to recognize and destroy cancer cells, addressing the need for improved therapeutic agents.
Patent Information
- Application Number
- UA202100696
- Authority / Receiving Office
- UA · UA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-07-18
- Filing Date
- 2019-07-17
- Publication Date
- 2026-10-21
- Estimated Expiration
- 2039-07-17
AI Technical Summary
There is a need for additional therapeutic agents that can effectively inhibit cancer progression, particularly in prostate cancer, including androgen receptor inhibitor-resistant prostate cancer, and for improved therapies targeting STEAP1-related disorders.
Engineered immune cells, such as CAR-T cells, are developed with chimeric antigen receptors (CARs) that specifically target STEAP1, incorporating antigen-binding molecules, costimulatory domains, and activation domains to enhance their ability to recognize and destroy cancer cells, and are introduced into subjects to treat diseases like prostate cancer.
The engineered immune cells effectively target and destroy cancer cells expressing STEAP1, providing a therapeutic option for prostate cancer and other diseases, including metastatic castration-resistant prostate cancer.
Smart Images

Figure 00000190_0000 
Figure 00000190_0001 
Figure 00000191_0000
Abstract
Description
Prostate cancer is the most commonly diagnosed type of cancer in men, with the exception of skin cancer. With an estimated 28,170 deaths in 2012, prostate cancer is the second leading cause of cancer death in the world. cause of cancer death in men. Hormone therapy, chemotherapy, radiation or A combination of these treatments is used to treat late-stage disease. Despite the above-mentioned advances in prostate cancer therapy, there is a great need for additional therapeutic agents that can effectively inhibit cancer progression prostate, including androgen receptor inhibitor in prostate cancer gland, which was not treated. Engineered immune system cells have been shown to have the desired properties in therapeutic treatment, particularly in oncology. The two main types of engineered immune cells systems are cells that contain chimeric antigen receptors (called "CAR" or "CAR-T") and T-cell receptors ("TCR"). Such engineered cells are engineered to provide them with specificity for antigen with preservation or enhancement of their ability to recognize and destruction of the target cell. Chimeric antigen receptors may comprise, for example, (i) antigen-specific component ("antigen-binding molecule"), (ii) one or more costimulatory domains and (iii) one or more activating domains. Each domain can be heterogeneous, i.e. composed of sequences derived from different protein chains. Cells immune system cells expressing a chimeric antigen receptor (such as T cells) can used in various types of therapy, including cancer therapy. It should be understood that The costimulatory polypeptides defined herein can be used to enhance activation of CAR-expressing cells against target antigens, thus increasing the effectiveness adoptive immunotherapy. T cells can be engineered to have specificity for one or several desired targets. For example, T cells can be transduced with DNA or other genetic material encoding an antigen-binding molecule, such as one or more single-chain variable fragments ("scFv") antibodies in combination with one or more signaling molecules and / or one or more activation domains, such as CD3- zeta. In addition to the ability of CAR-T cells to recognize and destroy target cells, successful T-cell therapy benefits from the ability of CAR-T cells to persist and retain the ability to proliferate in response on antigen. There is a need to identify new and improved therapies for the treatment of diseases and STEAP1-related disorders. BRIEF DESCRIPTION OF THE INVENTION The present invention relates to engineered immune cells (such as CAR or TCR), antigen-binding molecules (including without limitation antibodies, scFv, heavy and / or light chains and CDRs of these antigen-binding molecules) with specificity for STEAP1. The chimeric antigen receptors of the present invention typically comprise: (i) a STEAP1-specific antigen-binding molecule, (ii) one or more costimulatory domains and (iii) one or several activation domains. It should be understood that each domain may be heterogeneous and, thus, thus, consist of sequences derived from different protein chains. In some embodiments, the present invention relates to a chimeric antigen receptor that contains an antigen-binding molecule that specifically binds to STEAP1, where the antigen-binding the molecule comprises at least one of: (a) a heavy chain variable region CDR1 comprising an amino acid sequence that differs from the sequence under SEQ ID NO:89, 99, 109, 119, 129 or 139 by no more than 3, 2, 1 or 0 amino acid residues; (b) CDR2 of the variable region heavy chain containing an amino acid sequence that differs from the sequence under SEQ ID NO:90, 100, 110, 120, 130 or 140 by no more than 3, 2, 1 or 0 amino acid residues; (c) CDR3 variable region of the heavy chain containing an amino acid sequence that differs from sequences under SEQ ID NO:91, 101, 111, 121, 131 or 141 by no more than 3, 2, 1 or 0 amino acid residues; (d) CDR1 of the variable region of the light chain containing the amino acid a sequence that differs from the sequence under SEQ ID NO:94, 104, 114, 124, 134 or 143 is not more than 3, 2, 1 or 0 amino acid residues; (e) CDR2 of the light chain variable region, containing an amino acid sequence that differs from the sequence under SEQ ID NO:95, 105, 115, 125, 135 or 145 by no more than 3, 2, 1 or 0 amino acid residues; (f) CDR3 variable regions of the light chain containing an amino acid sequence that differs from the sequence under SEQ ID NO:96, 106, 116, 126, 136 or 146 by no more than 3, 2, 1 or 0 amino acid residues. In other embodiments, the chimeric antigen receptor further comprises at least one costimulatory domain. In additional embodiments, the chimeric antigen receptor additionally contains at least one activation domain. In certain embodiments, the costimulatory domain is a signaling region from CD28, CD28T, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, programmed cell death protein 1 (PD-1), induced T-cell costimulator (ICOS), functionally associated antigen 1 lymphocytes (LFA-1, CD1-la / CD18), CD3-gamma, CD3-delta, CD3-epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig-alpha (CD79a), DAP-10, Fc-gamma receptor, MHC class I molecules, TNF receptor proteins, immunoglobulin protein, cytokine receptor, integrins, signaling molecules lymphocyte activation (SLAM proteins), NK cell activating receptors, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, Nkp80 (KLRF1), Nkp44, Nkp30, Nkp46, CD19, CD4, CD8-alpha, CD8-beta, IL-2R-beta, IL-2R-gamma, IL-7R-alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, LFA-1, ITGAM, CDl lb, ITGAX, CDl lc, ITGBl, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, a ligand that specifically binds to CD83, or any combination thereof. In some embodiments, the costimulatory domain is derived from 4-1BB. In other embodiments, the costimulatory domain is derived from 4-1BB. In one embodiment, the costimulatory domain is derived from OX40. See also Hombach et al., Oncoimmunology. 2012 Jul. 1; 1(4): 458–466. In still other embodiments, the costimulatory domain comprises ICOS, as described in [Guedan et al., August 14, 2014; Blood: 124 (7) and Shen et al., Journal of Hematology & Oncology (2013) 6:33]. In still other embodiments, the costimulatory domain comprises CD27, as [described in Song et al., Oncoimmunology. 2012 1; 1(4): 547-549]. In certain embodiments, the CD28 costimulatory domain comprises SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8. In additional embodiments, the CD8 costimulatory domain comprises SEQ ID NO:14. In additional embodiments, the activation domain comprises CD3, CD3- zeta or CD3-zeta, which have the sequence presented under SEQ ID NO:10. In other embodiments, the present invention relates to a chimeric antigen receptor, wherein the costimulatory domain comprises SEQ ID NO:2, and the activating domain comprises SEQ ID NO:10. The present invention further relates to polynucleotides encoding chimeric antigen receptors, and vectors that contain polynucleotides. The vector may be, for example, a retroviral vector, DNA vector, plasmid, RNA vector, adenoviral vector, adeno-associated virus-based vector, lentiviral vector or any combination thereof. The present invention further relates to cells immune system containing vectors. In some embodiments, the lentiviral vector is is the pGAR vector. Illustrative immune cells include, but are not limited to, T cells, infiltrating lymphocytes tumor-infiltrating cells (TILs), NK cells, TCR-expressing cells, dendritic cells, or NK-T cells. T cells may be autologous, allogeneic, or heterologous. In other embodiments, the present invention the invention relates to pharmaceutical compositions containing the immune agents described in this document cells. In certain embodiments, the present invention relates to antigen-binding molecules (and chimeric antigen receptors containing these molecules) which contain at least one of: (a) a VH region that differs from the amino acid sequence of the 2F3 VH region by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues, and a VL region that differs from amino acid sequence of the 2F3 VL region by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues; (b) a VH region that differs from the amino acid sequence of the 11C2 VH region by no more than by 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues, and a VL region that differs from amino acid sequence of the VL region of 11C2 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues; (c) a VH region that differs from the amino acid sequence of the 1A1 VH region by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues, and a VL region that differs from amino acid sequence of the VL region of 1A1 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues; (d) a VH region that differs from the amino acid sequence of the 7A4 VH region by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues, and a VL region that differs from amino acid sequence of the VL region of 7A4 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues; and (e) a VH region that differs from the amino acid sequence of the 7A5 VH region by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues, and a VL region that differs from amino acid sequence of the VL region of 7A5 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues; (f) a VH region that differs from the amino acid sequence of the 14C1 VH region by no more than by 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues, and a VL region that differs from amino acid sequence of the VL region of 14C1 by no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 or 0 amino acid residues; and where the VH and VL region or regions are linked by at least one linker. In other embodiments, the present invention relates to antigen binding molecules (and chimeric antigen receptors containing these molecules), where the linker provides at least one of the scFv- G4S linker and Whitlow scFv linker. In other embodiments, the present invention relates to vectors encoding polypeptides according to of the present invention, and immune cells that contain these polypeptides. Preferred immune system cells include T cells, tumor-infiltrating lymphocytes (TILs), NK cells, cells expressing TCR, dendritic cells or NK-T cells. T cells can be autologous, allogeneic or heterologous. In other embodiments, the present invention relates to isolated polynucleotides encoding chimeric antigen receptor (CAR) or T-cell receptor (TCR) that contain an antigen-binding molecule that specifically binds to STEAP1, where the antigen-binding The molecule contains the CDR3 variable region of the heavy chain (VH), which contains the amino acid sequence under SEQ ID NO:19 or SEQ ID NO:27. The polynucleotides may further comprise activation domain. In preferred embodiments, the activation domain is CD3, more preferably CD3-zeta, more preferably the amino acid sequence represented by SEQ ID NO:9. In other embodiments, the present invention includes a costimulatory domain, such as CD28, CD28T, OX40, 4-1BB / CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte functionally associated antigen-1 (LFA-1 (CDl la / CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig-alpha (CD79a), DAP-10, Fc-gamma receptor, MHC class I molecule, TNF, TNFr, integrin, signaling molecule lymphocyte activation, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8-alpha, CD8-beta, IL-2R-beta, IL-2R-gamma, IL-7R-alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA- 6, CD49f, ITGAD, CDl-ld, ITGAE, CD103, ITGAL, CDl-la, LFA-1, ITGAM, CDl-lb, ITGAX, CDl-lc, ITGBl, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, CD83 ligand or fragments or combinations thereof. Preferred costimulatory domains are listed below. The present invention further relates to methods of treating a disease or disorder in a subject, who needs it, which involve the introduction into the subject of antigen-binding molecules, CAR, TCR, polynucleotides, vectors, cells or compositions according to the present invention. Suitable for treatment diseases include but are not limited to prostate cancer, including metastatic castration-resistant prostate cancer. BRIEF DESCRIPTION OF GRAPHIC MATERIALS FIG. 1 depicts analysis of STEAP1 expression on the cell surface in human cell lines. by flow cytometry. FIG. 2 depicts CAR expression in primary human T cells electroporated with using mRNA encoding different CARs. FIG. 3 depicts the cytolytic activity of CAR-electroporated T cells against multiple cell lines. FIG. 4, which includes FIGS. 3A and 3B, depicts the production of IFNγ, IL-2, and TNFα by electroporated CAR T cells. FIG. 5 depicts CAR expression in primary lentivirally transduced human T cells. from two healthy donors. FIG. 6 shows a map of the pGAR vector. DETAILED DESCRIPTION OF THE INVENTION It should be understood that chimeric antigen receptors (CAR or CAR-T) and T-cell receptors (TCR) are receptors created through genetic engineering. These engineered receptors can easily be inserted into and expressed by immune cells, including T cells, according to the methods, known in the art. With CAR, one receptor can be programmed to recognize both specific antigen, and, in the case of binding to this antigen, to activate the immune cell for attack and destroy the cell carrying this antigen. When these antigens exist on tumor cells, an immune cell that expresses CAR can target and destroy a tumor cell. CARs can be engineered to bind to an antigen (for example, an antigen on cell surface) by incorporating an antigen-binding molecule that will interact with this The target antigen. Preferably, the antigen-binding molecule is an antibody or its fragment, and more preferably one or more single-chain antibody fragments ("scFv"). ScFv is a fragment of a single-chain antibody that contains the variable regions of the heavy and light antibody chains linked together. See [U.S. Patent Nos. 7,741,465 and 6,319,494, and Eshhar et al., Cancer Immunol Immunotherapy (1997) 45: 131-136]. ScFv retains the ability of the parent antibody specifically interact with the target antigen. scFv are preferred for use in chimeric antigen receptors, as they can be engineered to be expressed as part of a single chain with other CAR components. Id. See also [Krause et al., J. Exp. Med., Volume 188, No. 4, 1998 (619–626); Finney et al., Journal of Immunology, 1998, 161: 2791-2797]. It will be understood that the antigen-binding molecule is typically contained in the extracellular portion of the CAR. so that it is able to recognize and bind to the antigen of interest. Bispecific and multispecific CARs are within the scope of this invention with a specificity greater than one target of interest. Costimulatory domains. Chimeric antigen receptors may include costimulatory domains. (signaling) domains to enhance their activity. See [U.S. Patent Nos. 7,741,465 and 6,319,494, and Krause et al. and Finney et al. (supra), Song et al., Blood 119:696-706 (2012); Kalos et al., Sci Transl. Med. 3:95 (2011); Porter et al., N. Engl. J. Med. 365:725-33 (2011) and Gross et al., Annu. Rev. Pharmacol. Toxicol. 56:59–83 (2016)]. For example, CD28 is a costimulatory protein that is naturally found in T cells. The complete native amino acid sequence of CD28 is described in the illustrative NCBI sequence: NP_006130.1. The complete native nucleic acid sequence of CD28 is described in NCBI illustrative sequence: NM_006139.1. Certain domains of CD28 are used in chimeric antigen receptors. In one embodiment, In this embodiment, a new extracellular domain of CD28, called "CD28T", can be used, and it has been unexpectedly discovered to provide certain useful properties when used in construction CAR. The nucleotide sequence of the CD28T molecule, including the extracellular domain of CD28T, transmembrane and intracellular domains of CD28, represented by SEQ ID NO:1: CTTGATAATGAAAAGTCCAACGGAACAATCATTCACGTGAAGGGGCAAGCACCTCTGTCCGTCACCCT TGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTTGTTACTCTC TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTA CATGAATATGACTCCACGCCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAG ATTTCGCTGCCTATCGGAGC. The corresponding amino acid sequence is presented under SEQ ID NO:2: LDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSK RSRLLHSDYM NMTPRRPGPT RKHYQPYAPP RDFAAYRS. The nucleotide sequence of the extracellular portion of CD28T is presented under SEQ ID NO:3: CTTGATAATGAAAAGTCCAACGGAACAATCATTCACGTGAAGGGGCAAGCACCTCTGTCCGTCACCCT TGTTCCCTGGTCCCATCCAAGCCA. The corresponding amino acid sequence of the extracellular domain of CD28T is presented under SEQ ID NO:4: LDNEKSNGTI IHVKGKHLCP SPLFPGPSKP. The nucleotide sequence of the transmembrane domain of CD28 is presented under SEQ ID NO:5: TTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTTACTCTCTGCTCGTCACCGTGGCTTTTA TAATCTTCTGGGTT. The amino acid sequence of the transmembrane domain of CD28 is presented below. SEQ ID NO:6: FWVLVVVGGV LACYSLLVTV AFIIFWV. The nucleotide sequence of the intracellular signaling domain of CD28 is presented under SEQ ID NO:7: AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCC ACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGC. The amino acid sequence of the intracellular signaling domain of CD28 is presented below. SEQ ID NO:8: RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS. Additional CD28 sequences suitable for use in the present invention include: the nucleotide sequence of CD28, represented by SEQ ID NO:11: ATTGAGGTGATGTATCCACCGCCTTACCTGGATAACGAAAAGAGTAACGGTACCATCATTCACGTGA AAGGTAAACACCTGTGTCCTTCTCCCCTCTTCCCCGGGCCATCAAAGCCC. The corresponding amino acid sequence is presented under SEQ ID NO:12: IEVMYPPPYLDNEKSNGTIIHVKGKHLCPSPLFPGPSKP Other suitable extracellular or transmembrane sequences may be derived from CD8. Nucleotide sequence of a suitable extracellular and transmembrane domain of CD8 presented under SEQ ID NO:13: GCTGCAGCATTGAGCAACTCAATAATGTATTTTTAGTCACTTTGTACCAGTGTTCTTGCCGGCTAAGC CTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGCCTCTGTCCCTGC GCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGACTGGATTTCGCCTGCGA TATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCTGCTGTCCCTGGTCATCACGCTCTA TTGTAATCACAGGAAC. The corresponding amino acid sequence is presented under SEQ ID NO:14: AAALSNSIMYFSHFVPVFLAPKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCNHRN. Other suitable intracellular signal sequences can be derived from 41-BB. The nucleotide sequence of a suitable intracellular signaling domain 41-BB is presented under SEQ ID NO:15: CGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCAAACAGCCGTTTATGAGGC CGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAGGAGGAGGAGGGCGGGTG CGAACTG. The corresponding amino acid sequence is presented under SEQ ID NO:16: RFSVVKRGRKKLLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL. Suitable costimulatory domains within the scope of the present invention can be obtained, among others other sources, from CD28, CD28T, OX40, 4-1BB / CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte functionally associated antigen-1 (LFA-1 (CDl la / CD18), CD247, CD276 (B7-H3), LIGHT (a member of the tumor necrosis factor superfamily 14; TNFSF14), NKG2C, Ig-alpha (CD79a), DAP-10, Fc-gamma receptor, MHC class I molecules, TNF, TNFr, integrin, lymphocyte activation signaling molecule, BTLA, Toll ligand receptor, ICAM-1, B7- H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8-alpha, CD8-beta, IL-2R-beta, IL-2R-gamma, IL-7R-alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl-ld, ITGAE, CD103, ITGAL, CDl-la, LFA-1, ITGAM, CDl-lb, ITGAX, CDl-lc, ITGBl, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, CD83 ligand or fragments or combinations thereof. Activation domains CD3 is a T-cell receptor element on native T cells and has been shown to be an important intracellular activating element in CAR. In a preferred embodiment CD3 is CD3-zeta, the nucleotide sequence of which is presented under SEQ ID NO:9: AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAAC GAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGA TGGGTGGCAAACCAAGACGAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATG GCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTA CCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. The corresponding amino acid of intracellular CD3-zeta is represented by SEQ ID NO:10: RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR. DOMAIN ORIENTATION It should be understood that structurally these domains correspond to the positions relative to the immune cell. Thus Thus, these domains may be part of (i) a "hinge" or extracellular (EC) domain, (ii) transmembrane (TM) domain and / or (iii) intracellular (cytoplasmic) domain (IC). The intracellular component often contains in part a member of the CD3 family, predominantly CD3-zeta, which is capable of activating a T cell upon binding of an antigen-binding molecule to its target. In In one embodiment, the hinge domain typically consists of at least one costimulatory domain, as defined in this document. It should also be understood that the hinge region may also contain several or all members of the family. immunoglobulins such as IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM or fragments thereof. Illustrative CAR designs according to the present invention are presented in Table 1. Table 1 Name of the scFv construct Costimulatory domain Activation domain 2F3-CD28T-CD28-41BB 2F3 CD28T, 4-1BB CD3-zeta 2F3-CD28T-CD28 2F3 CD28T CD3-zeta 2F3-CD28T-41BB 2F3 4-1BB CD3-zeta 2F3-C8K-CD28 2F3 CD28T CD3-zeta 2F3-C8K-41BB 2F3 4-1BB CD3-zeta 11C2-CD28T-CD28- 41BB 11C2 CD28T, 4-1BB CD3-zeta 11C2-CD28T-CD28 11C2 CD28T CD3-zeta 11C2-CD28T-41BB 11C2 4-1BB CD3-zeta 11C2-C8K-CD28 11C2 CD28T CD3-zeta 11C2-C8K-41BB 11C2 4-1BB CD3-zeta 1A1-CD28T-CD28-41BB 1A1 CD28T, 4-1BB CD3-zeta 1A1-CD28T-CD28 1A1 CD28T CD3-zeta 1A1-CD28T-41BB 1A1 4-1BB CD3-zeta 1A1-C8K-CD28 1A1 CD28T CD3-zeta 1A1-C8K-41BB 1A1 4-1BB CD3-zeta 7A4-CD28T-CD28-41BB 7A4 CD28T, 4-1BB CD3-zeta 7A4-CD28T-CD28 7A4 CD28T CD3-zeta 7A4-CD28T-41BB 7A4 4-1BB CD3-zeta 7A4-C8K-CD28 7A4 CD28T CD3-zeta 7A4-C8K-41BB 7A4 4-1BB CD3-zeta 7A5-CD28T-CD28-41BB 7A5 CD28T, 4-1BB CD3-zeta 7A5-CD28T-CD28 7A5 CD28T CD3-zeta 7A5-CD28T-41BB 7A5 4-1BB CD3-zeta 7A5-C8K-CD28 7A5 CD28T CD3-zeta 7A5-C8K-41BB 7A5 4-1BB CD3-zeta 14C1-CD28T-CD28- 41BB 14C1 CD28T, 4-1BB CD3-zeta 14C1-CD28T-CD28 14C1 CD28T CD3-zeta 14C1-CD28T-41BB 14C1 4-1BB CD3-zeta 14C1-C8K-CD28 14C1 CD28T CD3-zeta 14C1-C8K-41BB 14C1 4-1BB CD3-zeta CELL-RELATED DOMAINS It should be understood that with respect to the cell carrying the receptor, engineered T cells are of the invention comprise an antigen-binding molecule (such as scFv), an extracellular domain (which may include a "hinge" domain), a transmembrane domain, and an intracellular domain. The intracellular domain includes at least a partial activation domain, which is preferably consists of a member of the CD3 family, such as CD3-zeta, CD3-epsilon, CD3-gamma, or parts thereof. In addition Furthermore, it should be understood that an antigen-binding molecule (e.g., one or more scFv) designed in such a way that it is located in the extracellular part of the molecule / structure, so that it is capable of recognizing and communicating with its target or targets. Extracellular domain. The extracellular domain is useful for signaling and for efficient lymphocyte responses to antigen. The extracellular domains used in the present invention can derived from (i.e. containing) CD28, CD28T, CD8, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, programmed cell death protein 1 (PD-1), inducible T-cell costimulator (ICOS), lymphocyte functionally associated antigen 1 (LFA-1, CD1-la / CD18), CD3-gamma, CD3-delta, CD3-epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig-alpha (CD79a), DAP-10, Fc- gamma receptor, MHC class 1 molecule, TNF receptor proteins, immunoglobulin protein, receptor cytokine, integrins, signaling lymphocyte activation molecules (SLAM proteins), activating NK cell receptors, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, Nkp80 (KLRF1), Nkp44, Nkp30, Nkp46, CD19, CD4, CD8- alpha, CD8-beta, IL-2R-beta, IL-2R-gamma, IL-7R-alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, LFA-1, ITGAM, CDl lb, ITGAX, CDl lc, ITGBl, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, a ligand that specifically binds to CD83, or any combination thereof. The extracellular domain may be derived either from a natural or synthetic source. As described in this document, extracellular domains often contain a hinge portion. This is part of extracellular domain, sometimes called a "spacer" region. According to the present invention various hinge sites can be used, including costimulatory molecules, as discussed above, as well as immunoglobulin (Ig) sequences or other suitable molecules for achieving the desired given distance from the target cell. In some embodiments, the entire extracellular region comprises a hinge region. In some embodiments, the hinge region comprises CD28T or EC domain of CD28. Transmembrane domain. CAR can be designed to contain transmembrane domain that is fused to the extracellular domain of CAR. Similarly, it can be fused to the intracellular domain of CAR. In one embodiment, a CAR a transmembrane domain that is naturally associated with one of the domains in CAR. In some cases the transmembrane domain can be selected or modified by amino acid substitutions so as to avoid binding of such domains to transmembrane domains of the same or other surface membrane proteins in order to minimize interactions with other members receptor complex. The transmembrane domain can be derived either from the natural or from synthetic source. If the source is natural, then the domain can come from any membrane-bound or transmembrane protein. Transmembrane regions are particularly applicable, used in the present invention may be derived from (i.e., contain) CD28, CD28T, CD8, OX-40, 4- 1BB / CD137, CD2, CD7, CD27, CD30, CD40, programmed cell death protein 1 (PD-1), induced T-cell costimulator (ICOS), lymphocyte functionally associated antigen 1 (LFA-1, CD1-la / CD18), CD3-gamma, CD3-delta, CD3-epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig-alpha (CD79a), DAP-10, Fc-gamma receptor, MHC class 1 molecules, TNF- receptor proteins, immunoglobulin protein, cytokine receptor, integrins, activation signaling molecules lymphocytes (SLAM proteins), NK cell activating receptors, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, Nkp80 (KLRF1), Nkp44, Nkp30, Nkp46, CD19, CD4, CD8-alpha, CD8-beta, IL-2R-beta, IL-2R-gamma, IL-7R-alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, LFA-1, ITGAM, CDl lb, ITGAX, CDl lc, ITGBl, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, a ligand that specifically binds to CD83, or any combination thereof. Optionally, short linkers may form bonds between all or some of the extracellular, transmembrane and intracellular domains of CAR. In one embodiment, the transmembrane domain in the CAR of the present invention is CD8 transmembrane domain. In one embodiment, the CD8 transmembrane domain comprises the transmembrane portion of the nucleic acid sequence under SEQ ID NO:13. In another embodiment In one embodiment, the transmembrane domain of CD8 comprises a nucleic acid sequence that encodes the transmembrane amino acid sequence contained in SEQ ID NO:14. In certain embodiments, the transmembrane domain in the CAR of the present invention is CD28 transmembrane domain. In one embodiment, the CD28 transmembrane domain comprises nucleic acid sequence under SEQ ID NO:5. In one embodiment, the transmembrane The CD28 domain contains a nucleic acid sequence that encodes an amino acid sequence under SEQ ID NO:6. In another embodiment, the transmembrane domain of CD28 comprises the amino acid sequence under SEQ ID NO:6 Intracellular (cytoplasmic) domain. Intracellular (cytoplasmic) domain engineered T cells of the present invention may provide activation of at least one of normal effector functions of an immune cell. The effector function of a T cell can be, for example, cytolytic activity or helper activity, including cytokine secretion. It will be understood that suitable intracellular molecules include (i.e., contain) without restriction CD28, CD28T, CD8, OX-40, 4-1BB / CD137, CD2, CD7, CD27, CD30, CD40, protein 1 programmed cell death (PD-1), induced T-cell costimulator (ICOS), functionally lymphocyte-associated antigen 1 (LFA-1, CD1-la / CD18), CD3-gamma, CD3-delta, CD3-epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig-alpha (CD79a), DAP-10, Fc-gamma receptor, MHC class I molecule, TNF receptor proteins, immunoglobulin protein, cytokine receptor, integrins, signaling lymphocyte activation molecules (SLAM proteins), NK cell activating receptors, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, Nkp80 (KLRF1), Nkp44, Nkp30, Nkp46, CD19, CD4, CD8-alpha, CD8-beta, IL-2R-beta, IL-2R- gamma, IL-7R-alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CDl ld, ITGAE, CD103, ITGAL, CDl la, LFA-1, ITGAM, CDl lb, ITGAX, CDl lc, ITGBl, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE / RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Lyl08), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG / Cbp, CD19a, a ligand that specifically binds to CD83, or any combination thereof. In a preferred embodiment, the cytoplasmic domain of the CAR may be constructed such that it contains the CD3-zeta signaling domain alone or in combination with any other the desired cytoplasmic domain(s) applicable in the context of CAR according to the given invention. For example, the cytoplasmic domain of the CAR may comprise a portion of the CD3-zeta chain and costimulatory signaling region. Cytoplasmic signal sequences in the cytoplasmic signaling portion of CAR according to the data invention can be linked to each other in a random or predetermined order. In one preferred embodiment, the cytoplasmic domain is designed so that contain a CD3-zeta signaling domain and a CD28 signaling domain. In another embodiment the cytoplasmic domain is designed to contain the CD3-zeta signaling domain and the 4-1BB signaling domain, where cytoplasmic CD28 contains a nucleic acid sequence, represented by SEQ ID NO:15, and the amino acid sequence represented by SEQ ID NO:16.. In In another embodiment, the cytoplasmic domain in the CAR of the present invention is designed so that to contain part of CD28 and CD3-zeta, where cytoplasmic CD28 contains the nucleic acid sequence acid sequence represented by SEQ ID NO:7, and the amino acid sequence represented by SEQ ID NO:8. The nucleic acid sequence of CD3-zeta is presented as SEQ ID NO:9, and the amino acid sequence the sequence is presented under SEQ ID NO:8. It should be understood that one preferred orientation of the CAR according to the present invention involves an antigen-binding domain (such as scFv) in tandem with a costimulatory domain and activation domain. The costimulatory domain may contain one or more of the extracellular part, a transmembrane part and an intracellular part. In addition, it should be understood that multiple costimulatory domains can be used in tandem. In some embodiments, nucleic acids comprising a promoter are provided, operably linked to a first polynucleotide encoding an antigen-binding molecule, at least one costimulatory molecule and an activation domain. In some embodiments, the nucleic acid construct is contained in a viral vector. In In some embodiments, the viral vector is selected from the group consisting of retroviral vectors, murine leukemia virus-based vectors, SFG vectors, adenovirus vectors, lentiviral vectors, adeno-associated virus (AAV)-based vectors, virus-based vectors herpes and vaccinia virus-based vectors. In some embodiments, the nucleic acid contained in the plasmid. The present invention further relates to isolated polynucleotides that encode chimeric antigen receptors. receptors, and vectors containing polynucleotides. Any of the following may be suitable for the present invention: which vector is known in the art. In some embodiments, the vector is a viral vector. In some embodiments, the vector is a retroviral vector (such as pMSVG1), DNA vector, murine leukemia virus-based vector, SFG vector, plasmid, RNA vector, adenoviral vector, baculovirus vector, Epstein-Barr virus-based vector, papovavirus vector, vector based on vaccinia virus, vector based on herpes simplex virus, vector based on based on adeno-associated virus (AAV), lentiviral vector (such as pGAR) or any of them combination. The pGAR vector map is shown in fig. 6. Послигдовність pGAR є наступною: CTGACGCGCCCTGTAGGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGC TACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGG CTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGA CCCCAAAAACTTGATTAGGGTGATGGTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCC TTTGACGTTGGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATC TCGGTCTTATTCTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAATGAGCTGATTTA ACAAAAAATTTAACGCGAATTTTAACAAAAATTAACGCTTACAATTTGCCATTCGCCATTCAGGCTGCGCA ACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTATTACGCCAGCTGGCGAAAGGGGGATGTGC TGCAAGGCGATTAAGTTGGGTAACGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGCCAGTG AATTGTAATACGACTCACTATAGGGCGACCCGGGGATGGCGCGCCAGTAATCAAATTACGGGGTCATTA GTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCC AACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCAT TGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCA AGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTA TGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGCTGATGCGGTTTTGGC AGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCA ATGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGA CGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTGGTTTAGTGAACCGGGGT CTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTC AATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGAT CCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGA AAGGGAAACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGGCGA GGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAGAGAGATGGGTGC GAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATGGGAAAAAATTCGGTTAAGGCCAGGGGG AAAGAAAAAATATAAATTAAAACATATAGTATGGGCAAGCAGGGAGCTAGAACGATTCGCAGTTAATCCT GGCCTGTTAGAAACATCAGAAGGCTGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGA TCAGAAGAACTTAGATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAA AAGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACCGCACAGCAA GCCGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGGAGAAGTGAATTATATAAATA TAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCACCAAGGCAAAGAGAAGAGTGGTGCAGAGAGA AAAAAGAGCAGTGGGAATAGGAGCTTTGTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCG CAGCGTCAATGACGCTGACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATT TGCTGAGGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAG GCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGG AAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGAGTAATAAATCTCTGGAACAGATTTGG AATCACACGACCTGGATGGAGTGGGACAGAGAAAATTAACAATTACACAAGCTTAATACACTCCTTAATTG AAGAATCGCAAAACCAGCAAGAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTG GAATTGGTTTAACATAACAAATTGGCTGTGGTTATAAAATTATTCATAATGATAGTAGGAGGCTTGGTAG GTTTAAGAATAGTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGATATTCACCATTATCGTTTT CAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCGAAGGAATAGAAGAAGAAGGTGGGAGAGA GAGACAGAGACAGATCCATTGATTAGTGAACGGATCTCGACGGTATCGGTTTAACTTTTAAAAAGAAAAG GGGGGATTGGGGGGTACAGTGCAGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAA GAATTACAAAACAAATTACAAAATTCAAAATTTTATCGCGATCGCGGAATGAAAGACCCCACCTGTAGG TTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAATACATAACTGAGAATAGAGAAGTT CAGATCAAGGTTAGGAACAGAGAGACAGCAGAATATGGGCCAAACAGGATATCTGTGGTAAGCAGTTC CTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCCCAGATGCGGTCCCGCCCTCAGCAGTTTCTAGAGA ACCATCAGATGTTTCCAGGGTGCCCCAAGGACCTGAAAATGACCCTGTGCCTATTTGAACTAACCAAT CAGTTCGCTTCTCGCTTCTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTC ACTCGGCGCGCCAGTCCTTCGAAGTAGATCTTTGTCGATCCTACCATCCACTCGACACACCCGCCAGC GGCCGCTGCCAAGCTTCCGAGCTCTCGAATTAATTCACGGTACCCACCATGGCCTAGGGAGACTAGTC GAATCGATATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTT TTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTC TCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGC GTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCT TTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCT GCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAGCTGACGTCCTTT TCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGC CCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCC TTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCCTGGTTAATTAAAGTACCTTTAAG ACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGACTGGAAGGGCG AATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGTCTCTCTGGTTAGACCAGATCTGA GCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTT CAAGTAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTG TGGAAAATCTCTAGCAGGCATGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAG AATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCT GCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGT TTTTTGGCGCGCCATCGTCGAGGTTCCCTTTAGTGAGGGTTAATTGCGAGCTTGGCGTAATCATGGTCA TAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGT GTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCC AGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGCGGTTTGCG TATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGG TATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGT GAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTC CGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATA AAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCG GATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCA GTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGC GCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCC ACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAA CTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAG AGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCA GATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGTG GAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTA AATTAAAATGAAGTTTTAAATCTAAGTAAAGTATATGAGTAAACTTGGTCTGACAGTTACCAATGCTT AATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTG TAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACG CTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTG CAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAA TAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTC ATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAG CTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGC ACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAG TCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGC GCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGAT CTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACT TTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGAC ACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCAT GAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAA GTGCCAC (SEQ ID NO:147) Suitable additional illustrative vectors include, for example, pBABE-puro, pBABE-neo largeTcDNA, pBABE-hygro-hTERT, pMKO.1 GFP, MSCV-IRES-GFP, pMSCV PIG (empty plasmid Puro IRES GFP), pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE, MSCV IRES luciferase, pMIG, MDH1-PGK- GFP_2.0, TtRMPVIR, pMSCV-IRES-mCherry FP, pRetroX GFP T2A Cre, pRXTN, pLncEXP and pLXIN-Luc. In some embodiments, the engineered immune cell is a T cell, a lymphocyte, tumor-infiltrating cell (TIL), NK cell, TCR-expressing cell, dendritic cell, or NK-T- cell. In some embodiments, the cell is isolated or obtained from peripheral blood. In some In embodiments, the cell is isolated or derived from peripheral blood mononuclear cells. (PBMC). In some embodiments, the cell is isolated or derived from bone marrow. In some In some embodiments, the cell is isolated or obtained from umbilical cord blood. In some embodiments, the cell is isolated or obtained from umbilical cord blood. In some embodiments, the cell is a human cell. In some embodiments, the cell is transfected or transduced with a nucleic acid vector using a method selected from group consisting of electroporation, sonoporation, biolistics (e.g. Gene Gun), lipid transfection, polymer transfection, nanoparticles or polyplexes. In some embodiments, chimeric antigen receptors are expressed in engineered immune cells that contain nucleic acids according to this application. These chimeric antigen receptors according to of this application may in some embodiments comprise (i) an antigen binding molecule (such as as scFv), (ii) a transmembrane region and (iii) a T-cell activation molecule or region. ANTIGEN-BINDING MOLECULES Antigen binding molecules are within the scope of this invention. As used herein, the term "antigen binding molecule" means any a protein that binds a specific target antigen. In this application, a specific target antigen is is a STEAP1 protein or a fragment thereof. Antigen binding molecules include, without limitation antibodies and their binding portions, such as immunologically functional fragments. Peptibodies (i.e. Fc-fusion molecules containing peptide binding domains) are another example of suitable antigen-binding molecules. In some embodiments, the antigen-binding molecule binds to an antigen on a tumor. In some embodiments, the antigen binding molecule binds to the antigen on the a cell involved in a hyperproliferative disease, or with a viral or bacterial antigen. In some embodiments, the antigen binding molecule binds to STEAP1. In additional embodiments, the antigen binding molecule binds to STEAP1. In embodiments, the antigen-binding molecule is an antibody or fragment thereof, including one or more of their complementarity determining regions (CDRs). In additional In embodiments, the antigen-binding molecule is a single-chain variable fragment (scFv). The term "immunologically functional fragment" (or "fragment") of an antigen-binding molecule means a type of antigen-binding molecule containing a portion (regardless of how this (partly produced or synthesized) antibody that lacks at least some amino acids, present in the full-length chain, but which is still capable of specifically binding to the antigen. Such fragments are biologically active because they bind to the target antigen and can compete with other antigen-binding molecules, including intact antibodies, for binding with a given epitope. In some embodiments of the present invention, the fragments are neutralizing fragments. In some embodiments, the fragments may block or reduce the activity of STEAP1. In one aspect, such a fragment will retain at least one CDR present in full-length light or heavy chains, and in some embodiments will contain one heavy chain and / or light chain or a portion thereof. These fragments can be obtained by using recombinant DNA techniques or can be obtained, for example, using enzymatic or chemical cleavage of antigen-binding molecules, including intact antibodies. Immunologically functional immunoglobulin fragments include, but are not limited to, scFv fragments, Fab fragments (Fab', F(ab')2, etc.), one or more CDRs, diabody (variable domain of heavy chain) chain on the same polypeptide as the light chain variable domain, joined by using a short peptide linker that is short enough to prevent pairing between two domains in the same chain), domain antibodies and single-chain antibodies. These fragments may be obtained from any source that is a mammal, including without limitation human, mouse, rat, camelid or rabbit. As will be understood by one skilled in the art, The antigen-binding molecule may include non-protein components. Variants of antigen binding molecules are also within the scope of this invention, for example, light chain variable regions and / or heavy chain variable regions, each of which characterized by at least 70-80%, 80-85%, 85-90%, 90-95%, 95-97%, 97-99% or more 99% identity with the amino acid sequences of the sequences described herein. In some cases, such molecules contain at least one heavy chain and one light chain, then as in other cases, variant forms contain two identical light chains and two identical heavy chains (or subparts thereof). One skilled in the art will be able to determine suitable variants of antigen-binding molecules described in this document using well-known techniques. In certain In some embodiments, one skilled in the art can identify suitable regions of the molecule that can be change without disrupting its activity by targeting areas that are not considered important for activity. In certain embodiments, the polypeptide structure of the antigen-binding molecules is based on on antibodies, including without limitation monoclonal antibodies, bispecific antibodies, miniantibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as "antibody mimetics"), chimeric antibodies, humanized antibodies, human antibodies, fusion antibodies (sometimes referred to herein as document "antibody conjugates") and fragments thereof, respectively. In some embodiments, the the antigen-binding molecule contains or consists of avimers. In some embodiments, an antigen-binding molecule that binds to STEAP1 is administered separately. In other embodiments, the antigen binding molecule that binds to STEAP1 is administered as part of a CAR, TCR, or other immune cell. In such immune cells, the antigen-binding a molecule that binds to STEAP1 may be under the regulation of the same promoter region or a separate promoter. In some embodiments, genes encoding proteins and / or The antigen-binding molecule that binds to STEAP1 may be contained in separate vectors. The present invention also relates to pharmaceutical compositions comprising an antigen-binding a STEAP1 binding molecule, together with a pharmaceutically acceptable diluent, carrier, solubilizer, emulsifier, preservative and / or excipient. In some embodiments In some embodiments, the pharmaceutical compositions will include more than one other antigen-binding molecule that binds to STEAP1. In certain embodiments, the pharmaceutical compositions will include more than one antigen-binding molecule that binds to STEAP1, where the antigen-binding STEAP1 binding molecules bind more than one epitope. In some embodiments, different antigen-binding molecules will not compete with each other for binding to STEAP1. In other embodiments, the pharmaceutical composition may be selected for parenteral administration. delivery, for inhalation or for delivery through the gastrointestinal tract, for example orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art. In certain embodiments, to maintain the composition at physiological pH or in in the case of a slightly lower pH, typically a pH in the range of about 5 to about 8, buffers are used. In some embodiments of the present invention, when provided parenteral administration, the therapeutic composition may be in the form of a pyrogen-free a parenterally acceptable aqueous solution containing the desired antigen-binding molecule, which binds to STEAP1, with or without additional therapeutic agents, in a pharmaceutically an acceptable carrier medium. In certain embodiments, the carrier medium for parenteral administration is injection is sterile distilled water in which the antigen-binding molecule, which binds to STEAP1, with or without at least one additional therapeutic agent formulated as a sterile isotonic solution, properly stored. In certain In some embodiments, the preparation may involve assembling the desired molecule with polymeric compounds (such as polylactic acid or polyglycolic acid), granules or liposomes, which can provide controlled or delayed release of the product, which can be delivered by depot injection. In certain embodiments, the implantable product for drug delivery can be used to introduce the desired molecule. In some embodiments, the antigen binding molecule is used as a tool diagnostics or validation. The antigen-binding molecule can be used to analyze the amount of STEAP1 present in the sample and / or subject. In some embodiments, the diagnostic the antigen binding molecule is not neutralizing. In some embodiments, the antigen binding molecules disclosed herein are used or provided in a kit for analysis and / or method of detecting STEAP1 in mammalian tissues or cells for the purpose of screening / diagnosis of a disease or disorder associated with changes in STEAP1 levels. The kit can contain an antigen-binding molecule that binds STEAP1, together with means for displaying binding of an antigen-binding molecule that binds to STEAP1, if present, and optionally STEAP1 protein levels. Antigen binding molecules should be further understood with the following definitions and descriptions. The "Fc" region contains two heavy chain fragments that contain the CH1 and CH2 domains of the antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by through hydrophobic interactions of CH3 domains. A "Fab fragment" contains one light chain and the CH1 and variable regions of one heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. chains. A "Fab" fragment contains one light chain and a portion of one heavy chain, which contains the VH domain and the CH1 domain, as well as the region between the CH1 and CH2 domains, so that between the two heavy chains of two Fab' fragments can form an interchain disulfide bond with formation of the F(ab')2 molecule. The "F(ab')2 fragment" contains two light chains and two heavy chains, which contain part of the constant region between the CH1 and CH2 domains, so that between the two heavy chains an interchain disulfide bond is formed. Thus, the F(ab')2 fragment consists of two Fab' fragments, which are held together by a disulfide bond between two heavy chains. The "Fv region" contains variable regions from both the heavy and light chains, but does not contain constant sections. "Single-chain variable fragment" ("scFv", also called "single-chain antibody") refers to Fv molecules in which the variable regions of the heavy and light chains are connected by a flexible linker to form a single polypeptide chain that forms the antigen-binding site. See [PCT application WO88 / 01649 and U.S. Patent Nos. 4,946,778 and 5,260,203], the disclosures of which are incorporated herein by reference. document by reference in their entirety. A "bivalent antigen-binding molecule" contains two antigen-binding sites. In some In some cases, the two binding sites are characterized by the same antigenic specificity. Bivalent antigen-binding molecules can be bispecific. "Multispecific antigen-binding "molecule" is a molecule that targets more than one antigen or epitope. "Bispecific", A "dual-specific" or "bifunctional" molecule is a hybrid molecule, respectively an antigen-binding molecule or antibody having two different antigen-binding sites. Two the binding sites of a bispecific antigen-binding molecule will bind two different epitopes, which may be located on the same or different target proteins. An antigen-binding molecule is said to "specifically bind" its target antigen if if the dissociation constant (Kd) is ~lx 10-7 M. An antigen-binding molecule specifically binds an antigen with "high affinity", if the Kd is 1-5 × 10-9 M, and with "very high affinity", in the case where Kd is l-5×10-10 M. In one embodiment, the antigen binding molecule is characterized by a Kd of 10-9 M. In one embodiment, the dissociation rate is < 1×10-5. In other embodiments, the antigen binding molecules will bind to Human STEAP1 with a Kd of from about 10-7 M to 10-13 M, and in another embodiment antigen-binding molecules will bind with a Kd of 1.0-5×10-10. An antigen-binding molecule is said to be "selective" when it binds to one target more closely than with the second target. The term "antibody" refers to an intact immunoglobulin of any isotype or fragment thereof, which can compete with the intact antibody for specific binding to the target antigen, and includes, for example, chimeric, humanized, fully human, and bispecific antibodies. "Antibody" is is a type of antigen-binding molecule as defined herein. Intact antibody will typically contain at least two full-length heavy chains and two full-length light chains chains, but in some cases may include fewer chains, such as antibodies that found naturally in camelids, may contain only heavy chains. Antibodies may be derived exclusively from a single source or may be chimeric, i.e. different parts of an antibody can be derived from two different antibodies, as further described below. Antigen-binding molecules, antibodies or binding fragments can be produced in hybridomas using recombinant DNA techniques or by enzymatic or chemical cleavage intact antibodies. Unless otherwise specified, the term "antibody" includes, in addition to antibodies containing two full-length heavy chains and two full-length light chains, their derivatives, variants, fragments and muteins, examples of which are described below. In addition, unless explicitly excluded, antibodies include respectively monoclonal antibodies, bispecific antibodies, miniantibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as "antibody mimetics"), chimeric antibodies, humanized antibodies, human antibodies, fusion antibodies (sometimes referred to herein as "antibody conjugates") and their fragments. As a rule, variable regions are characterized by the same general structure with respect to conserved framework regions (FR) connected by 3 hypervariable regions (i.e. "CDRs"). CDR of the two chains of each pair are typically aligned along the framework regions, which can provide binding to a specific epitope. From the N-terminus to the C-terminus, the variable regions of both the lung and heavy chains typically contain domains FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. By agreement The CDR regions in the heavy chain are generally referred to as CDR1, CDR2, and CDR3 HC. The CDR regions in light chain are usually called CDR1, CDR2 and CDR3 LC. The assignment of amino acids to each domain generally corresponds to the definitions according to Kabat [Seqs of Proteins of Immunological Interest (NIH, Bethesda, MD (1987 and 1991)) or [Chothia (J. Mol. Biol., 196:901-917 (1987); Chothia et al., Nature, 342:878-883 (1989)]. To define or approximate CDR regions, one can use various methods of analysis, including not only the Kabat or Chothia definition, but also the definition according to AbM. The term "light chain" includes the full-length light chain and fragments thereof that have the sequence of the variable region sufficient to ensure binding specificity. The full-length light chain includes a variable region domain VL and a constant region domain CL. The variable region domain of the light chain is located at the amino terminus of the polypeptide. Light chains include kappa chains and lambda chains. The term "heavy chain" includes the full-length heavy chain and fragments thereof that have the sequence of the variable region sufficient to ensure binding specificity. The full-length heavy chain contains a variable region domain VH and three constant region domains. CH1, CH2 and CH3 regions. The VH domain is located at the amino terminus of the polypeptide, and the CH domains are located at the carboxyl end, with CH3 being closest to the carboxyl end of the polypeptide. Heavy chains can belong to any isotype, including IgG (including subtypes IgG1, IgG2, IgG3, and IgG4), IgA (including subtypes IgA1 and IgA2), IgM and IgE. The term "variable region" or "variable domain" refers to a portion of the light and / or heavy chain of an antibody, typically comprising approximately 120-130 amino-terminal amino acids in the heavy chain and approximately 100-110 amino-terminal amino acids in the light chain. Variable region antibody, as a rule, determines the specificity of a particular antibody with respect to its target. Variability is unevenly distributed across antibody variable domains; it is concentrated in subdomains of each of the variable regions of the heavy and light chains. These subdomains are called "hypervariable regions" or "complementarity determining regions" (CDRs). More The conservative (i.e., non-hypervariable) parts of variable domains are called "framework" regions (FRM or FR) and provide a framework for the six CDRs in three-dimensional space with the formation of an antigen-binding surface. Each of the variable domains found in nature, the heavy and light chains contain four FRM regions (FR1, FR2, FR3 and FR4), which acquire mostly β-sheet configuration, connected by three hypervariable regions, which form loops that connect, and in some cases form, part of the β-sheet structure. The hypervariable regions in each chain are held together in close proximity by using FRM and with hypervariable regions from another chain contribute to the formation antigen-binding site [see Kabat et al., loc. cit.]. The term "CDR" and its plural "CDRs" refer to the complementarity determining region, three of which are which give binding character to the variable region of the light chain (CDR-L1, CDR-L2 and CDR- L3), and three more give binding character to the variable region of the heavy chain (CDR-H1, CDR- H2 and CDR-H3). The CDRs contain most of the residues responsible for the specific interactions of the antibody with antigen, and therefore contribute to the functional activity of the antibody molecule: they are the main determinants of antigen specificity. The precise definition of the boundaries and dimensions of CDRs is the subject of various classifications and numbering systems. Accordingly, CDRs can be specified according to Kabat, Chothia, contact, or any other system. definition of boundaries, which includes the numbering system described in this document. Despite the boundaries, different, each of these systems has a certain degree of overlap, representing the so-called "hypervariable regions" in variable sequences. Therefore, the definition of CDRs according to these systems may differ in length and boundary areas relative to the adjacent frame area. See for example Kabat (approach based on interspecific sequence variability), Chothia (an approach based on crystallographic studies of antigen-antibody complexes) and / or MacCallum [Kabat et al., loc. cit.; Chothia et al., J. Moi. Biol, 1987, 196: 901-917 and MacCallum et al., J. Moi. Biol, 1996, 262: 732]. Another standard for characterizing the antigen binding site is the definition of AbM, used in Oxford Molecular's AbM antibody modeling software. See, for example, [Protein Sequence and Structure Analysis of Antibody Variable Domains. In Antibody Engineering Lab Manual (Ed.: Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg]. In those cases where two residue identification techniques identify areas as overlapping, but not identical regions, they can be combined to define a hybrid CDR. However, the numbering according to with the so-called Kabat system being predominant. Typically, CDRs form a loop structure that can be classified as canonical structure The term "canonical structure" refers to the basic conformation of the chain that is assumed by antigen-binding loops (CDRs). As a result of comparative structural studies, it was revealed that that five of the six antigen-binding loops have only a limited set of available conformations. Each canonical structure can be characterized by the helical angles of the polypeptide backbone. Therefore, corresponding loops between antibodies may be characterized by a high degree of three-dimensional similarity structures, despite the high amino acid variability in most parts of the loops [Chothia and Lesk, J. Moi. Biol., 1987, 196: 901; Chothia et al., Nature, 1989, 342: 877; Martin and Thornton, J. Moi. Biol. 1996, 263: 800]. In addition, there is a relationship between the structure that the loop acquires and the amino acid sequences surrounding it. The conformation of a particular canonical class is determined by the length loops and amino acid residues located in key positions within the loop, and also in a conservative framework (i.e. outside the loop). Therefore, the distribution into a specific canonical class can be made based on the presence of these key amino acid residues. The term "canonical structure" may also include aspects relating to linear sequence antibodies, e.g. as listed according to Kabat [Kabat et al.], cited therein). Scheme (system) Kabat numbering is a widely used standard for numbering amino acid residues of the antibody variable domain in a sequential manner and is the preferred scheme used in to this invention, which is also mentioned elsewhere in this document. To determine the canonical Additional structural factors can also be used to construct antibody structures. For example, those differences that are not fully reflected in the Kabat numbering can be described by the system numbering according to Chothia et al. and / or identified by other techniques, e.g. crystallography and two-dimensional or three-dimensional computer modeling. Accordingly, the specified sequence antibodies can be placed in a canonical class, which allows, among other things, identification corresponding sequences of framework regions (for example, based on the requirement to include different canonical structures into the library). The numbering system of amino acid sequences of antibodies according to Kabat and structural features described by Chothia et al, loc. cit, as well as their significance for the interpretation of canonical aspects of antibody structure described in the literature. Structural subunits and three-dimensional configurations Immunoglobulins of various classes are well known in the art. For a review of antibody structure, see [Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, eds. Harlow et al., 1988]. Light chain CDR3 and, in particular, heavy chain CDR3 may constitute the most important antigen binding determinants within the variable regions of the light and heavy chains. In some In antibody-based constructs, the heavy chain CDR3 apparently constitutes the main contact area between antigen and antibody. In vitro selection schemes in which only CDR3 is altered can be used to alter the binding properties of an antibody or determine which residues contribute to antigen binding. Therefore, CDR3 is generally the largest source of molecular diversity within the antibody binding site. For example, H3 may be as short as two amino acids long residues or more than 26 amino acids. The term "neutralization" refers to an antigen-binding molecule, scFv or antibody, respectively. that bind to a ligand and prevent or reduce the biological effect of that ligand. This can be carried out, for example, by directly blocking the binding site on the ligand or by binding to a ligand and changing the ligand's ability to bind with indirect mechanisms (such as structural or energetic changes in the ligand). In some embodiments In some embodiments, the term may also refer to an antigen-binding molecule that interferes with a protein with which it is bound to perform a biological function. The terms "target" or "antigen" refer to a molecule or part of a molecule capable of binding by an antigen-binding molecule. In some embodiments, the target may have one or multiple epitopes. The term "compete" when used in the context of antigen-binding molecules that compete for the same epitope, means competition between antigen-binding molecules, as determined by an assay in which the antigen-binding molecule being tested (e.g., an antibody or its immunologically functional fragment), prevents or inhibits (e.g., reduces) the specific binding of an illustrative antigen-binding molecule to antigen. To determine whether one antigen-binding molecule competes with another, one can apply numerous types of competitive binding assays, for example: solid-phase direct or indirect radioimmunoassay (RIA), solid-phase direct or indirect enzyme-linked immunosorbent assay assay (EIA), competitive sandwich assay [Stahli et al., 1983, Methods in Enzymology 9:242-253]; solid-phase direct EIA with biotin-avidin [Kirkland et al., 1986, J. Immunol. 137:3614-3619], solid-phase analysis using direct labeling, solid-phase sandwich analysis with using direct labeling [Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press]; solid-phase RIA using direct labeling using 1-125 as the label [Morel et al., 1988, Molec. Immunol. 25:7-15]; solid-phase direct EIA with biotin-avidin [Cheung, et al., 1990, Virology 176:546-552] and RIA using direct labeling [Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82]. The term "epitope" includes any determinant capable of binding an antigen-binding molecule, such as an scFv, antibody or immune cell of the present invention. An epitope is a region of an antigen that is bound by an antigen-binding molecule, the target of which is is this antigen, and if the antigen is a protein it includes specific amino acids that directly bind to an antigen-binding molecule. The terms "label" or "labeled" as used in this document refer to the inclusion of detectable marker, for example, by incorporating a radioactively labeled amino acid or attachment of biotin fragments to the polypeptide that can be detected by labeled avidin (e.g., streptavidin containing a fluorescent marker or having enzymatic activity, which can be detected by optical or colorimetric methods). In some embodiments In some embodiments, the label or marker may also be therapeutic. The prior art is known and may Various methods of labeling polypeptides and glycoproteins can be used. According to the present invention, "on-off" type switches may be included in this document. "shutdown" or other types of control switching techniques. These techniques may include the use of dimerization domains and optional dimerization activators of such domains. These techniques include, for example, techniques [described by Wu et al., Science 2014 350 (6258)] with by using FKBP / Rapalog dimerization systems in certain cells, the content of which is fully incorporated herein by reference. Additional dimerization technologies are described, for example, in [Fegan et al. Chem. Rev. 2010, 110, 3315–3336], as well as [US Patent Nos. 5,830,462; 5834266; 5869337 and 6165787], the contents of which are also incorporated herein in their entirety by by reference. Additional dimerization pairs may include cyclosporin-A / receptor cyclophilin, estrogen / estrogen receptor (optional with tamoxifen), glucocorticoids / glucocorticoid receptor, tetracycline / tetracycline receptor, vitamin D / receptor vitamin D. Additional examples of dimerization technology can be found, for example, in [WO 2014 / 127261, WO 2015 / 090229, US 2014 / 0286987, US 2015 / 0266973, US 2016 / 0046700, US Patent No. 8486693, US 2014 / 0171649 and US 2012 / 0130076], the contents of which are incorporated herein by reference in their entirety. using the link. TREATMENT METHODS With adoptive immunotherapy, native T cells can be (i) isolated from the patient, (ii) genetically engineered to express a chimeric antigen receptor (CAR) that binds to at least one tumor antigen, (iii) propagated ex vivo to a larger population engineered T cells and (iv) re-injected into the patient. See, for example, [U.S. Patent Nos. 7741465 and 6319494, Eshhar et al. (Cancer Immunol, supra); Krause et al. (supra); Finney et al]. (supra). Once the engineered T cells are re-injected into the patient, they mediate immune response against cells expressing tumor antigen. See, for example, [Krause et al., J. Exp. Med., Volume 188, No. 4, 1998 (619–626)]. This immune response involves the secretion of IL-2 and other cytokines. T cells, clonal expansion of T cells that recognize tumor antigen, and T-mediated cells specifically kill cells containing the target. See [Hombach et al., Journal of Immun. 167: 6123–6131 (2001)]. Thus, in some aspects, the present invention provides a method of treating or preventing a condition associated with undesirable and / or elevated levels of STEAP1 in a patient, which includes administering to a patient in need thereof an effective amount of at least one isolated antigen binding molecule, CAR or TCR disclosed herein. Methods of treating diseases or disorders, including cancer, are provided. In some embodiments In one embodiment, the present invention relates to the generation of a T-cell-mediated immune response in a subject comprising administering to the subject an effective amount of engineered immune cells according to In some embodiments, the T-cell-mediated immune response directed against a target cell or target cells. In some embodiments, the the immune cell contains a chimeric antigen receptor (CAR) or T-cell receptor (TCR). In In some embodiments, the target cell is a tumor cell. In some aspects, the present invention the invention represents a method of treating or preventing a malignant neoplasm, wherein said method comprising administering to a subject in need thereof an effective amount of at least one isolated antigen binding molecule described herein. In some aspects the present invention provides a method for treating or preventing a malignant neoplasm, wherein said method comprising administering to a subject in need thereof an effective amount of at least one immune cell, wherein the immune cell comprises at least one chimeric antigen receptor, T- a cellular receptor and / or a selected antigen-binding molecule as described herein. In some aspects, the present invention provides a pharmaceutical composition comprising: at least one antigen binding molecule as described herein, and pharmaceutically an acceptable excipient. In some embodiments, the pharmaceutical composition further comprises contains an additional active ingredient. Antigen binding molecules, CARs, TCRs, immune cells, etc. of the present invention can be used to treat diseases associated with STEAP1 expression, including without prostate cancer, and in one preferred embodiment metastatic castration-resistant prostate cancer. It should be understood that target doses for CAR+ / CAR-T+ / TCR+ cells can range from 1×106 to 2×1010 cells / kg, preferably 2×106 cells / kg, more preferably. It should be understood that doses higher than and below this range may be appropriate for certain subjects and appropriate dose levels may be determined by the physician as necessary. In addition, according to the present invention, there may be provided multiple doses of cells. Also provided are methods of reducing the size of a tumor in a subject, comprising administering to a subject of an engineered cell of the present invention, wherein the cell comprises a chimeric antigen receptor receptor, T-cell receptor or chimeric antigen receptor based on a T-cell receptor, which contain an antigen binding molecule that binds to an antigen on a tumor. In some embodiments In one embodiment, the subject has a solid tumor or blood malignancy, such as lymphoma or leukemia. In some embodiments, the engineered cell is delivered to the tumor bed. In In some embodiments, the cancer is located in the bone marrow of the subject. In some embodiments, the engineered cells are autologous T cells. In In some embodiments, the engineered cells are allogeneic T cells. In some embodiments, the engineered cells are allogeneic T cells. In some embodiments, the engineered cells are heterologous T cells. In some embodiments, the engineered cells are heterologous T cells. In embodiments, engineered cells according to this application are transfected or transduced in vivo. In other embodiments, the engineered cells are transfected or transduced ex vivo. The methods may further include administering one or more chemotherapeutic agents. In In some embodiments, the chemotherapeutic agent is an agent for chemotherapeutic lymphodepletion (pretreatment). Useful treatment regimens using pretreatment, together with corresponding useful biomarkers, described in prior applications for [U.S. patents 62 / 262143 and 62 / 167750], which are incorporated herein by reference in their entirety. They describe, for example, methods for pre-treating a patient who requires T-cell therapy. cells, which involves administering specific beneficial doses of cyclophosphamide to the patient (from 200 mg / m2 / day to 2000 mg / m2 / day) and certain doses of fludarabine (from 20 mg / m2 / day to 900 mg / m2 / day). A preferred dosing regimen includes treating the patient with daily administration of the patient receives approximately 500 mg / m2 / day of cyclophosphamide and approximately 60 mg / m2 / day of fludarabine for three days before administering a therapeutically effective amount of engineered T cells. In other embodiments, the antigen-binding molecule is transduced (or otherwise engineered) cells (such as CAR or TCR) and a chemotherapeutic agent are administered in an amount that effective for treating a disease or condition in a subject. In some embodiments, compositions comprising the immune effectors disclosed herein CAR-expressing cells can be administered in combination with any number of chemotherapeutic agents Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXANTM); alkyl sulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa and uredopa; ethylenimines and methylamelamines, in including altretamine, triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and reduced trimethylol melamine; nitrogen mustards such as chlorambucil, chlornaphazine, chlorphosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembhin, phenesterone, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorzotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomycins, actinomycin, anthramycin, azaserine, bleomycins, cactinomycin, calichimycin, carabicin, carminomycin, carcinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcelomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamicin, rhodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, cynostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprin, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; inhibitors of cortical hormone synthesis adrenal gland, such as aminoglutethimide, mitotane, trilostane; folic acid supplements, such as as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfomitine; elliptinium acetate; etoglucide; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; Mopidamol; Nitracrine; Pentostatin; Phenamet; Pirarubicin; Podophyllic Acid; 2-Ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"- trichlorotriethylamine; urethane; vindesine; dacarbazine; manomustine; mitobronitol; mitolactol; pipobroman; gacitosin; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (TAXOLTM, Bristol-Myers Squibb) and docetaxel (TAXOTERE®, Rhone-Poulenc Rorer); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogues such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylomitine (DMFO); derivatives retinoic acid, such as TargretinTM (bexarotene), PanretinTM (alitretinoin); ONTAKTM (denileukin- diftitox); esperamycins; capecitabine and pharmaceutically acceptable salts, acids or derivatives of each of above. This definition also includes antihormonal agents that regulate or suppress the action of hormones on the tumor, such as antiestrogens, including, for example, tamoxifen, raloxifene, 4(5)-imidazoles that inhibit aromatase, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Farestone); and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; and pharmaceutically acceptable salts, acids or derivatives thereof each of the above. If necessary, combinations of chemotherapeutic agents are also administered, including but not limited to CHOP, i.e. cyclophosphamide (Cytoxan®), doxorubicin (hydroxydoxorubicin), vincristine (Oncovin®), and prednisone. In some embodiments, the chemotherapeutic agent is administered at the same time or during one week after administration of the engineered cell or nucleic acid. In other embodiments the chemotherapeutic agent is administered for 1 to 4 weeks or 1 week to 1 month, from 1 week to 2 months, from 1 week to 3 months, from 1 week to 6 months, from 1 week to 9 months or from 1 week to 12 months after the injection of the engineered cell or nucleic acid. In other In embodiments, the chemotherapeutic agent is administered at least 1 month prior to cell administration. or nucleic acid. In some embodiments, the methods further comprise administering two or more chemotherapeutic agents. In combination with the compositions described in this document, various additional therapeutic agents. For example, potentially useful additional therapeutic agents include PD-1 inhibitors, such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), pembrolizumab, pidilizumab, and atezolizumab, as well as CTLA-4 inhibitors such as ipilimumab (Yervoy®). Additional therapeutic agents suitable for use in combination with the present invention include: include but are not limited to abiraterone acetate, apalutamide, bicalutamide, cabazitaxel, casodex (bicalutamide), degarelix, docetaxel, enzalutamide, Erleada® (apalutamide), flutamide, goserelin acetate, Jevtana® (Cabazitaxel), Leuprolide Acetate, Lupron® (Leuprolide Acetate), Lupron Depot (leuprolide acetate), Lupron Depot-Ped (leuprolide acetate), Mitoxantrone hydrochloride, Nilandron® (nilutamide), nilutamide, Provenge® (sipuleucel-T), radium-223 dichloride, sipuleucel-T, taxotere (docetaxel), Viadur (leuprolide acetate), Xofigo (radium-223 dichloride), Xtandi (enzalutamide), Zoladex (goserelin acetate) or Zytiga (abiraterone acetate). In additional embodiments, a composition comprising an immune cell comprising a CAR may be administered with an anti-inflammatory agent. Anti-inflammatory agents or medications include without restrictions steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone), nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, drugs that inhibit TNF activity, cyclophosphamide and mycophenolate. Examples of NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors and sialylates. Examples of analgesics include acetaminophen, oxycodone, tramadol or propoxyphene hydrochloride. Examples of glucocorticoids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone or prednisone. Illustrative biological modifiers responses include molecules directed against cell surface markers (e.g., CD4, CD5 etc.), cytokine inhibitors such as TNF antagonists (e.g. etanercept (ENBREL®), adalimumab (HUMIRA® and infliximab (REMICADE®)), chemokine inhibitors, and adhesion molecule inhibitors. Biological response modifiers include monoclonal antibodies as well as recombinant forms molecules. Examples of DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, sulfasalazine, hydroxychloroquine, gold (oral (auranofin) and intramuscularly) and minocycline. In some embodiments, the compositions described herein are administered together with a cytokine. As used in this document, the term "cytokine" refers to proteins released by one a population of cells that act on another cell as intercellular mediators. Examples of cytokines are lymphokines, monokines, and traditional polypeptide hormones. Cytokines include growth hormones such as such as human growth hormone, N-methionyl variant of human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones, such as follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and luteinizing hormone (LH); hepatocyte growth factor (HGF); fibroblast growth factor (FGF); prolactin; placental lactogen; Mullerian inhibitory substance; peptide associated with mouse gonadotropin; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors (NGFs), such as NGF-beta; platelet-derived growth factor; transforming growth factor growth factors (TGFs), such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon-alpha, -beta, and -gamma; colony-stimulating factors (CSFs), such as macrophage-CSF (M-CSF); granulocyte- macrophage-CSF (GM-CSF) and granulocyte-CSF (G-CSF); interleukins (IL), such as IL-1, IL-1- alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15, tumor necrosis factor, is such such as TNF-alpha or TNF-beta; and other polypeptide factors including LIF and KIT ligand (KL). As used herein, the term "cytokine" includes proteins from natural sources or from recombinant cell cultures, as well as biologically active equivalents of cytokines with native consistency. In some aspects, the present invention provides an antigen binding molecule that binds to STEAP1 with a Kd of less than 100 pM. In some embodiments, the antigen binding the molecule binds with a Kd of less than 10 pM. In other embodiments, the antigen-binding molecule binds with a Kd of less than 5 pM. METHODS OF OBTAINING For the production of polynucleotides, polypeptides, vectors, antigen-binding molecules, immune cells, compositions, etc. according to the present invention, various known techniques can be used. Before in vitro manipulations or genetic modification of immune cells described in this document, cells may be obtained from a subject. In some embodiments, the immune cells include T cells. T cells can be obtained from a number of sources, including mononuclear peripheral blood cells (PBMC), bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from the focus of infection, ascites, pleural effusion, spleen tissue, and tumors. In In some embodiments, T cells can be obtained from a dose of blood collected from a subject, from using any number of techniques known to one of ordinary skill in the art, such as distribution FICOLLTM. The cells can preferably be obtained from the circulating blood of an individual using apheresis. Typically, the apheresis product contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, erythrocytes, and platelets. In some embodiments cells collected by apheresis can be washed to remove the plasma fraction and placed in an appropriate buffer or medium for further processing. Cells can be washed with with PBS. It should be understood that a washing step may be used, for example, with using a semi-automatic flow centrifuge, e.g. cell processing equipment CobeTM 2991, Baxter CytomateTM, etc. After washing, cells can be resuspended in various biocompatible buffers or other saline solution with or without buffer. In some embodiments During the procedure, unwanted components of the apheresis sample can be removed. In certain embodiments, T cells are isolated from PBMCs by lysing red blood cells and depletion of monocytes, for example by centrifugation in a PERCOLLTM gradient. Specific T cell subpopulations, such as CD28+, CD4+, CD8+, CD45RA+, and CD45RO+ T cells, may be further isolated using positive or negative selection methods known in the art. For example, enrichment of a T-cell population by negative selection can be achieved by using a combination of antibodies directed against surface markers unique to negatively selected cells. One method for use in this document is sorting and / or selecting cells by by negative magnetic immunoadhesion or flow cytometry, which uses a cocktail monoclonal antibodies directed against cell surface markers present on the negative selected cells. For example, to enrich CD4+ cells by negative selection, a cocktail Monoclonal antibodies typically include antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8. Flow cytometry and cell sorting can also be used to isolate populations that of interest, cells for use in this invention. PBMCs can be used directly for genetic modification of immune cells (such as CAR or TCR) using the methods described herein. In some embodiments In practice, after PBMC isolation, T lymphocytes can be further isolated, and at the same time as cytotoxic, and helper T lymphocytes can be sorted into uninfected subpopulations, memory cells and effector T cells either before or after genetic modification and / or propagation. In some embodiments, the CD8+ cells are further sorted into those that have not been exposed, central memory cells and effector cells by identifying cell surface antigens that are associated with each of these types of CD8+ cells. In some embodiments, the expression Phenotypic markers of central memory T cells include CD45RO, CD62L, CCR7, CD28, CD3 and CD127 and is negative for granzyme B. In some embodiments, the central memory T cells are CD45RO+, CD62L+, CD8+ T cells. In some embodiments, the effector T cells are negative for CD62L, CCR7, CD28 and CD127 and positive for granzyme B and perforin. In In some embodiments, the CD4+ T cells are further sorted into subpopulations. For example, CD4+ T- helper cells can be sorted into unaffected, central memory cells, and effector cells by identifying cell populations that have surface cell antigens. Immune cells, such as T cells, can be genetically modified after being isolated from using known methods, or immune cells can be activated and multiplied (or differentiated in the case of progenitor cells) in vitro before genetic modification. In another In one embodiment, immune cells, such as T cells, are genetically modified using the methods described in this document chimeric antigen receptors (e.g., transduced by viral vector containing one or more nucleotide sequences encoding CAR), and then activated and / or expanded in vitro. Methods for activating and expanding T cells are known in the art. and are described, for example, in [U.S. Patent No. 6,905,874; U.S. Patent No. 6,867,041; U.S. Patent No. 6,797,514 and PCT WO2012 / 079000], the contents of which are incorporated herein by reference in their entirety. reference. Such methods typically involve contacting PBMCs or isolated T cells with a stimulatory agent and a costimulatory agent, such as antibodies to CD3 and CD28, usually attached to a pellet or other surface, in a culture medium with appropriate cytokines, such as IL-2. Antibodies to CD3 and CD28 attached to the same bead serve as "surrogate" antigen-presenting cells (APCs). One example is the Dynabeads® system, a system activation / stimulation of CD3 / CD28 for physiological activation of human T cells. In other embodiments, T cells can be activated and stimulated to proliferate by using feeder cells and appropriate antibodies and cytokines using methods such as those described in US Patent No. 6040177; [US Patent No. 5827642 and WO2012129514], the contents of which are in full incorporated herein by reference. Certain methods for obtaining constructs and engineered immune cells of the present invention described in the application under [PCT / US15 / 14520], the contents of which are incorporated herein in their entirety by via link. Additional methods for obtaining constructs and cells can be found in the previous application for [U.S. Patent No. 62 / 244036], the contents of which are hereby incorporated in their entirety by reference. using the link. It should be understood that PBMCs may additionally include other cytotoxic lymphocytes, such as NK- cells or NKT cells. An expression vector carrying the coding sequence of a chimeric receptor, such as disclosed herein, can be introduced into a population of donor T cells, NK cells or Human NKT cells. Successfully transduced T cells carrying the expression vector can be sorted using flow cytometry to isolate CD3-positive T cells, and then propagated to increase the number of these CAR-expressing T cells, in addition to activating cells using antibodies to CD3 and IL-2 or other methods known in the art, as described in elsewhere in this document. For cryopreservation of CAR-expressing T cells for storage and / or preparation for human use using standard procedures. In one embodiment Transduction, cultivation and / or propagation of T cells in vitro is carried out during absence of animal products, except those of human origin, such as fetal calf serum and fetal bovine serum. For cloning polynucleotides, a vector can be introduced into a host cell (an isolated cell) host), to ensure replication of the vector itself and thus amplify copies polynucleotide contained therein. Cloning vectors may contain sequence components that typically include, but are not limited to, the origin of replication, promoter sequences, sequences transcription initiation, enhancer sequences, and selectable markers. If necessary, these elements can be chosen by a specialist of medium qualification in this field. For example, the starting point The replication can be selected to promote autonomous replication of the vector in the host cell. In certain embodiments, the present invention provides isolated host cells that contain vector presented in this document. Host cells containing the vector may be useful for expression or cloning of the polynucleotide contained in the vector. Suitable host cells may include, without limitation, prokaryotic cells, fungal cells, yeast cells, or higher eukaryotic cells cells, such as mammalian cells. Suitable prokaryotic cells for this purpose include, but are not limited to, restrictions on eubacteria, such as gram-negative or gram-positive organisms, e.g. Enterobacteriaceae, such as Escherichia, e.g. E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g. Salmonella typhimurium, Serratia, e.g. Serratia marcescans, and Shigella, and also Bacilli such as B. subtilis and B. licheniformis, Pseudomonas such as P. aeruginosa, and Streptomyces. The vector may be introduced into the host cell using any suitable means, known in the art, including without limitation DEAE-dextran-mediated delivery, calcium phosphate precipitation method, cationic lipid-mediated delivery, transfection, liposome-mediated, electroporation, microparticle bombardment, gene delivery, receptor-mediated delivery, polylysine-mediated delivery, histone-mediated delivery, chitosan-mediated delivery, and peptides. Standard methods of transfection and transformation of cells for expression of the vector, which of interest are well known in the art. In a further embodiment, a mixture of different expression vectors can be used for genetic modification of the donor population of immune effector cells, where each vector encodes a different CAR, as disclosed herein. The resulting transduced immune effector cells form a mixed population of engineered cells, with In this case, a portion of the engineered cells express more than one different CAR. In one embodiment, the present invention provides a method of storing genetically modified engineered cells that express a CAR or TCR that targets the STEAP1 protein. This includes cryopreservation of immune cells to ensure that the cells remain viable during thawing. A portion of CAR-expressing immune cells can be cryopreserved using methods that known in the art to provide a continuous source of such cells for future treatment patients suffering from malignant neoplasms. If necessary, cryopreserved transformed immune cells can be thawed, grown, and propagated to produce more such cells. The term "cryopreservation" as used in this document refers to the preservation of cells by cooling to negative temperatures, such as (typically) 77 degrees Kelvin or - 196ºC (boiling point of liquid nitrogen). Cryoprotectants are often used at negative temperatures temperatures to prevent cell damage from freezing at low temperatures or warming to room temperature. Cryopreservatives and optimal cooling rate can protect cells from damage. Cryoprotectants that can be used according to this of the invention include, without limitation: dimethyl sulfoxide (DMSO) [Lovelock & Bishop, Nature (1959); 183: 1394-1395; Ashwood-Smith, Nature (1961); 190: 1204-1205), glycerin, polyvinylpyrrolidine (Rinfret, Ann. NY Acad. Sci. (1960); 85: 576) and polyethylene glycol (Sloviter & Ravdin, Nature (1962); 196: 48)]. The preferred cooling rate is 1° to 3°C / minute. The term "virtually pure" is used to indicate that a high level of of a given component. Preferably, the component is the predominant component present in the composition. Preferably, it is present at a level of more than 30%, more than 50%, more than 75%, more than 90% or even more than 95%, and the specified level is determined based on the ratio of dry weight to dry weight relative to the entire composition considered. At very high levels (e.g., at levels greater than 90%, more than 95% or more than 99%) the component can be considered to be in "pure form". Biologically active substances according to the present invention (including polypeptides, nucleic acid molecules) acids, antigen-binding molecules, fragments) can be presented in a form that is almost contains one or more contaminants with which it might otherwise be associated specified substance. When the composition contains almost no given pollutant, the pollutant the substance will be present at a low level (e.g. less than 10%, less than 5% or less 1% based on the dry weight to dry weight ratio specified above). In some embodiments, cells are assembled by first collecting them from a culture medium. medium, and then washing and concentrating the cells in the medium and container system, suitable for administration ("pharmaceutically acceptable" carrier), in a therapeutically effective amount. A suitable infusion medium may be any composition of isotonic medium, such as usually physiological saline, NormosolTM R (Abbott) or Plasma-LyteTM A (Baxter), but also 5% dextrose in water or lactated Ringer's solution may be used. The infusion medium may be supplemented with human serum albumin. The required number of cells for treatment in the composition is usually at least 2 cells (e.g., at least 1 of the central CD8+ memory T-cell subpopulation and at least 1 of the CD4+ helper T-cell subpopulations) or, as a rule, more than 102 cells and no more than 106, not more than or including 108 or 109 cells, and may be more than 1010 cells. The number of cells will be depend on the intended use for which the composition is intended and the type of cells included in The cell density required is usually greater than 106 cells / ml and usually greater than 107 cells / ml, usually 108 cells / ml or more. A clinically significant number of immune cells may be divided into several infusions, which in total equal or exceed 105, 106, 107, 108, 109, 1010, 1011 or 1012 cells. In some aspects of the present invention, in particular, since all introduced into the body cells will be redirected to a specific target antigen (STEAP1), a smaller dose can be administered number of cells in the range of 106 / kg (106 to 1011 per patient). CAR treatment can be administered several times at doses within these ranges. The cells may be autologous, allogeneic or heterologous to the patient undergoing therapy. The CAR-expressing cell populations of the present invention can be administered either individually or in combination. in the form of a pharmaceutical composition in combination with diluents and / or other components, such as IL-2 or other cytokines or cell populations. Pharmaceutical compositions of the present invention may contain a population of CAR or TCR expressing cells, such as T cells, as described in herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions may contain buffers such as such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; excipients (e.g., aluminum hydroxide) and preservatives. Compositions of the present invention mainly formulated for intravenous administration. Pharmaceutical compositions (solutions, suspensions, etc.) may include one or more of the following: next: sterile diluents such as water for injection, saline, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono- or diglycerides, which can serve as a solvent or suspending agent medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and tonicity adjusting agents such as sodium chloride or Dextrose. The drug for parenteral administration can be placed in ampoules, disposable syringes or multi-dose vials made of glass or plastic. A pharmaceutical composition which administered by injection, preferably sterile. It should be understood that undesirable effects can be minimized by transduction of immune cells (which containing one or more CAR or TCR) "suicide" genes. It may also be desirable to include induced "on" or "acceleration" switch in immune cells. Suitable techniques include use of inducible caspase-9 [US application 2011 / 0286980] or thymidine kinase before, after or simultaneously with transduction of cells with a CAR construct of the present invention. Additional methods of administration "suicide" genes and / or "on" switches include TALENS, zinc fingers, RNAi, siRNA, shRNA, antisense technology, and other methods known in the art. It should be understood that the descriptions in this document are for illustrative and explanatory purposes only and do not constitute limit the claimed invention. In this application, the use of the singular includes the plural, if specifically unless otherwise specified. The section headings used in this document are for organizational purposes only. and should not be construed as limiting the scope of the invention described. All documents or parts documents cited in this application, including without limitation patents, patent applications, articles, books and treatises fully incorporated into this document by reference in their entirety for any purpose. The following terms are used in accordance with this invention, unless otherwise specified otherwise, shall have the following meanings. In this application, the use of "or" means "and / or" unless otherwise indicated. In addition, the use of The term "including", as well as other forms such as "includes" and "included", is not limiting. In addition, terms such as "element" or "component" encompass both elements and components containing one unit, as well as elements and components that contain more than one subunit, unless specifically other specified. The term "STEAP1 activity" includes any biological effect of STEAP1. In some embodiments STEAP1 activity involves the ability of STEAP1 to interact or bind to a substrate or receptor. The terms "polynucleotide", "nucleotide" or "nucleic acid" include both single-stranded and double-stranded polymers of nucleotides. The nucleotides that make up a polynucleotide can be are ribonucleotides, or deoxyribonucleotides, or a modified form of any type nucleotide. These modifications include base modifications such as bromouridine and inosine derivatives, ribose modifications such as 2',3'-dideoxyribose, and internucleotide linkage modifications such as such as phosphorothioate, phosphorodithioate, phosphoroselenate, phosphorodiselenoate, phosphoroanilothioate, phosphoraniladate and phosphoramidate bonds. The term "oligonucleotide" refers to a polynucleotide containing 200 or fewer nucleotides. Oligonucleotides can be single-stranded or double-stranded, for example, for use in construction of a mutant gene. Oligonucleotides can be sense or antisense oligonucleotides. An oligonucleotide may contain a label, including a radioactive label, a fluorescent label, hapten, or antigenic tag for use in detection assays. Oligonucleotides can be used, for example, as PCR primers, cloning primers or hybridization probes. The term "regulatory sequence" refers to a polynucleotide sequence that can affect on the expression and processing of the coding sequences to which it is ligated. The nature of such regulatory sequences may depend on the host organism. In specific embodiments, Regulatory sequences for prokaryotes may include a promoter, ribosome binding site, and transcription termination sequence. For example, regulatory sequences for eukaryotes can include promoters containing one or a combination of transcription factor recognition sites, transcription enhancer sequences and transcription termination sequence. "Regulatory sequences" may include leader sequences (signal peptides) and / or sequences partners in the merger. As used in this document, the term "functionally linked" means that the components to which this term is applied are in a relationship that enables them to to perform their inherent functions under suitable conditions. The term "vector" refers to any molecule or structural unit (e.g., nucleic acid) acid, plasmid, bacteriophage, or virus) used to carry information that encodes protein, into a host cell. The term "expression vector" or "expression construct" refers to a vector, suitable for transformation of a host cell and contains nucleic acid sequences that direct and / or regulate (together with the host cell) the expression of one or more heterologous coding regions functionally linked to them. The expression construct can include without limitation sequences that affect or regulate transcription, translation and in the presence of introns affect RNA splicing of the coding region functionally related to them. The term "host cell" refers to a cell that has been transformed or is capable of be transformed by a nucleic acid sequence and as a result expresses a gene that constitutes interest. This term includes the progeny of the parent cell regardless of whether the given offspring according to the morphology or genetic structure of the original parent cell or not, according to conditions that the gene of interest is present. The term "transformation" refers to a change in the genetic characteristics of a cell, and in doing so, the cell has been transformed, if it has been modified to contain new DNA or RNA. For example, a cell is transformed when it is genetically modified compared to its natural state by introducing new genetic material through transfection, transduction or other techniques. After transfection or transduction, the transforming DNA can undergo recombination with the cell's DNA by physical integration into the cell's chromosome, or may temporarily persist as an episomal element without replication, or may replicate independently as a plasmid. A cell is considered to be stably transformed if the transforming DNA is replicated during cell division. The term "transfection" refers to the uptake of foreign or exogenous DNA by a cell. A number of techniques Transfection is well known in the art and disclosed herein. See, for example, [Graham et al., 1973, Virology 52:456; Sambrook et al., 2001, Molecular Cloning: A Laboratory Manual, supra; Davis et al., 1986, Basic Methods in Molecular Biology, Elsevier; Chu et al., 1981, Gene 13:197]. The term "transduction" refers to the process by which foreign DNA is introduced into a cell by by means of a viral vector. See [Jones et al., (1998). Genetics: principles and analysis. Boston: Jones & Bartlett Publ]. The terms "polypeptide" or "protein" refer to a macromolecule that contains an amino acid protein sequence, including deletions, additions and / or substitutions of one or more amino acids native sequence. The terms "polypeptide" and "protein" specifically encompass molecules that bind STEAP1 antigen, antibodies or sequences containing deletions, additions and / or substitutions of one or several amino acids of an antigen-binding protein. The term "polypeptide fragment" refers to a polypeptide that contains an amino-terminal deletion, a carboxy-terminal deletion and / or an internal deletion in comparable to the full-length native protein. Such fragments may also contain modified amino acids compared to the native protein. Useful polypeptide fragments include immunologically functional fragments of antigen-binding molecules. Useful fragments include without restriction of one or more CDR regions, variable domains of the heavy and / or light chain, part of other parts of the antibody chain, etc. The term "isolated" means that the substance (i) does not contain at least some other proteins with which it would normally be detected, (ii) does not actually contain other proteins from the same source, e.g., derived from the same species, (iii) separated from at least about 50 percent of the polynucleotides, lipids, carbohydrates or other materials with which it is associated in nature, (iv) functionally linked (by covalent or non-covalent interaction) to a polypeptide with which it is not associated in nature, or (v) not found in nature. A "variant" of a polypeptide (e.g., an antigen-binding molecule or antibody) comprises amino acid sequence, where in a given amino acid sequence one or more amino acid residues inserted, deleted and / or substituted compared to another polypeptide sequence. Variants include fusion proteins. The term "identity" refers to the relationship between the sequences of two or more polypeptide molecules or two or more nucleic acid molecules, as determined by alignment and comparison of sequences. "Percent identity" means the percentage of identical of amino acid or nucleotide residues in the compared molecules, and it is calculated based on the size of the smallest of the molecules being compared. For these calculations, gaps in the alignments (if any) mostly taken into account using a specific mathematical model or computer program (i.e. "algorithm"). To calculate the percent identity, the compared sequences are typically aligned in a way that gives the greatest match between the sequences. One example of a computer program, which can be used to determine the percentage of identity is the GCG software package, which includes GAP [Devereux et al., 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wisconsin, USA]. The GAP computer algorithm is used to align two polypeptides or polynucleotides for which the percentage of identity must be determined sequences. The sequences are aligned to obtain an optimal match to their corresponding amino acids or nucleotides ("match coverage", determined by the algorithm). In certain embodiments implementation in this algorithm also uses the standard comparison matrix [see Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., 1992, Proc. Natl. Acad. Sci. USA 89:10915-10919 for the BLOSUM 62 comparison matrix]. As used in this document, twenty standard (e.g., those that naturally occurring) amino acids and their abbreviated names are in accordance with generally accepted practice. See Immunology-A Synthesis [2nd Edition, Golub and Gren, Eds., Sinauer Assoc., Sunderland, Mass. (1991)], which is incorporated herein by reference for any purpose. Stereoisomers (e.g. D-amino acids) twenty traditional amino acids, unnatural amino acids such as alpha-, alpha-disubstituted amino acids, N-alkylamino acids, lactic acid and other unconventional Amino acids may also be suitable components for polypeptides of the present invention. Examples of non-standard amino acids include: 4-hydroxyproline, gamma-carboxyglutamate, epsilon- N, N, N-irimethyllysine, ε-N-acetyllysine, O-phosphoserine, N-acetylserine, N-formylmethionine, 3- methylhistidine, 5-hydroxylysine, sigma-N-methylarginine and other similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation system used in this document, the left direction is the direction towards the amino terminus, and the right direction is the direction towards carboxyl end according to standard practice and rules. Conservative amino acid substitutions may include amino acid residues that are not naturally occurring, which are typically introduced through chemical peptide synthesis rather than by synthesis in biological systems. They include peptidomimetics and other reverse or inverted forms of amino acid fragments. Naturally occurring residues can be divided into classes based on the general properties of the side chain: a) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; b) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; c) acidic: Asp, Glu; d) basic: His, Lys, Arg; e) residues that affect chain orientation: Gly, Pro; and f) aromatic: Trp, Tyr, Phe. For example, non-conservative substitutions may involve replacing a representative of one of these classes with representative of another class. Such residue substitutions can be introduced, for example, into regions of the human antibodies that are homologous to non-human antibodies or to non-homologous regions of the molecule. When changes are made to the antigen-binding molecule, the costimulatory or activating domains engineered T cells according to certain embodiments may include hydropathic amino acid index. Each amino acid was assigned a hydrophobicity index based on characteristics of its hydrophobicity and charge. They are as follows: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine / cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (- 0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1,3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9) and arginine (-4.5). See Kyte et al., J. Mol. Biol., 157:105- 131 (1982). It is known that certain amino acids can be replaced by other amino acids, which are characterized by a similar index or measure of hydrophobicity, and at the same time the proteins retain similar biological activity. It is also clear from the prior art that the substitution of similar amino acids can be effectively carried out on the basis of hydrophilicity, in particular if created in such a way biologically functional protein or peptide intended for use in immunological In embodiments, as in the present invention. Illustrative amino acid substitutions are set forth in Table 2. Table 2 Original residues Illustrative substitutions Preferred substitutions Ala Val, Leu, Ile Val Arg Lys, Gln, Asn Lys Asn Gln Gln Asp Glu Glu Cys Ser, Ala Ser Gln Asn Asn Glu Asp Asp Gly Pro, Ala Ala His Asn, Gln, Lys, Arg Arg Ile Leu, Val, Met, Ala, Phe, norleucine Leu Leu Norleucine, Ile, Val, Met, Ala, Phe Ile Lys Arg, 1,4-diaminobutyrate Arg acid, Gln, Asn Met Leu, Phe, Ile Leu Phe Leu, Val, Ile, Ala, Leu Tyr Pro Ala Gly Ser Thr, Ala, Cys Thr Thr Ser Ser Trp Tyr, Phe Tyr Tyr Trp, Phe, Thr, Ser Phe Val Ile, Met, Leu, Phe, Leu Ala, norleucine The term "derivative" refers to a molecule that includes a chemical modification other than an insertion, deletions or substitutions of amino acids (or nucleic acids). In some embodiments, the derivatives contain covalent modifications, including without limitation chemical bonding to polymers, lipids or other organic or inorganic moieties. In some embodiments, the implementation is chemically a modified antigen-binding molecule may have a longer half-life in the circulation than an antigen-binding molecule that is not chemically modified. In some embodiments, the derived antigen binding molecule is covalently modified to include one or several water-soluble polymeric attachments, including but not limited to polyethylene glycol, polyoxyethylene glycol or polypropylene glycol. Peptide analogs are commonly used in the pharmaceutical industry as non-peptide drugs with properties similar to those of the original peptide. These types non-peptide compounds are called "peptide mimetics" or "peptidomimetics". [Fauchere, J., Adv. Drug Res., 15:29 (1986); Veber & Freidinger, TINS, p.392 (1985); and Evans et al., J. Med. Chem., 30:1229 (1987)], which are incorporated herein by reference for any purpose. The term "therapeutically effective amount" refers to that amount of antigen-binding a molecule that binds to STEAP1, which has been shown to lead to a therapeutic response in Such therapeutically effective amounts can be readily determined by one of ordinary skill in the art. qualifications in this field. The terms "patient" and "subject" are used interchangeably and include subjects representing including humans and non-human animals, as well as subjects with officially diagnosed disorders, subjects without officially recognized disorders, subjects receiving medical care, subjects with risk of developing disorders, etc. The terms "treat" and "treatment" include types of therapeutic treatment, types of preventive treatments and routes of administration that reduce the risk of a subject developing a disorder or other risk factor. Treatment does not require complete cure of the disorder and includes options implementation, in which symptoms are reduced or underlying risk factors are addressed. The term "prevent" does not requires 100% elimination of the possibility of the phenomenon. Rather, it means that the probability of the phenomenon occurring was reduced in the presence of the compound or method. Standard methods can be used for recombinant DNA, oligonucleotide synthesis, and also for tissue cultivation and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification methods can be performed according to the manufacturer's specifications, or as commonly practiced in the art, or as described herein. The above methods and procedures can usually be carried out according to conventional methods well known in the art. prior art, and as described in various general and more specific references cited and are discussed in this specification. See, for example, [Sambrook et al., Molecular Cloning: A Laboratory Manual (2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989)], which is included in this document by reference for any purpose. The present invention will be further illustrated by the following sequences. CD28T, DNA, extracellular, transmembrane, intracellular domains CTTGATAATGAAAAGTC AAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAA GCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTTACTCTCTGCTCGTCACCGTGGCTTT TATAATCTTCTGGGTTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGC CGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAG C (SEQ ID NO:1) CD28T, extracellular, transmembrane, intracellular amino acids: LDNEKSNGTI IHVKGKHLCP SPLFPGPSKP FWVLVVVGGV LACYSLLVTV AFIIFWVRSK RSRLLHSDYM NMTPRRPGPT RKHYQPYAPP RDFAAYRS (SEQ ID NO:2) CD28T, DNA – extracellular CTTGATAATGAAAAGTCCAACGGAACAATCATTCACGTGAAGGGGCAAGCACCTCTGTCCGTCACCCT TGTTCCCTGGTCCATCCAAGCCA (SEQ ID NO:3) CD28T, amino acids – extracellular LDNEKSNGTI IHVKGKHLCP SPLFPGPSKP (SEQ ID NO:4) CD28, DNA, transmembrane domain TTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTTACTCTCTGCTCGTCACCGTGGCTTTTA TAATCTTCTGGGTT (SEQ ID NO:5) CD28, DNA, transmembrane domain: FWVLVVVGGV LACYSLLVTV AFIIFWV (SEQ ID NO:6) CD28, DNA, intracellular domain: AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCC ACAAGGAAACACTACCAGCCTTACGCACCACCTAGATTTCGCTGCCTATCGGAGC (SEQ ID NO:7) CD28, amino acids, intracellular domain RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS (SEQ ID NO:8) CD3-zeta DNA AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAAC GAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGA TGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATG GCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTA CCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG (SEQ ID NO:9) CD3-zeta, amino acids RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR (SEQ ID NO:10) CD28, DNA ATTGAGGTGATGTATCCACCGCCTTACCTGGATAACGAAAAGAGTAACGGTACCATCATTCACGTGA AAGGTAAACACCTGTGTCCTTCTCCCCTCTTCCCCGGGCCATCAAAGCCC (SEQ ID NO:11) CD28, amino acids IEVMYPPPYL DNEKSNGTII HVKGKHLCPS PLFPGPSKP (SEQ ID NO:12) CD8, amino acids, extracellular and transmembrane domains GCTGCAGCATTGAGCAACTCAATAATGTATTTTTAGTCACTTTGTACCAGTGTTCTTGCCGGCTAAGC CTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGCCTCTGTCCCTGC GCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGACTGGATTTCGCCTGCGA TATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCTGCTGTCCCTGGTCATCACGCTCTA TTGTAATCACAGGAAC (SEQ ID NO:13) CD8, amino acids, extracellular and transmembrane domains AAALSNSIMYFSHFVPVFLAPKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYI WAPLAGTCGVLLLSLVITLYCNHRN (SEQ ID NO:14) 4-1BB, DNA, intracellular domain CGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCAAACAGCCGTTTATGAGGC CGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAGGAGGAGGAGGGCGGGTG CGAACTG (SEQ ID NO:15) 4-1BB, amino acids, intracellular domain RFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO:16) Clone 2F3, HC, DNA CAGGTTCAGCTGCAGCAGTCTGGAGCTGAGATGATGAAGCCTGGGGCCTCAGTGAAGATATCCTG CAAGGCTACTGGCTACACATTCAGTACCTACTGGATAGAGTGGGTAAAGCAGAGGCCTGGACATGGCC TTGAGTGGATTGGAGAGATTTTACCTGGAAGTGGTAATACTGACTTCAATGAGAAGTTCAAGGGCAAGG CCACATTCACTGCAGATACATCCTCCGACACAGCCTACATGCATCTCAGCAGCCTGACATCTGAGGACT CTGCCGTCTATTACTGTACAAGATGGGGGTACTACGGTACTAGGGGGTACTTCAATGTCTGGGGCGCA GGGTCCACGGTCACCGTCTCCTCA (SEQ ID NO: 87) Clone 2F3, HC, amino acids – CDR under the name QVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEWMGEILPGSGNTDFNEKFQGR VTFTADTSSDTAYMELSSLRSEDTAVYYCTRWGYYGTRGYFNVWGQGTLVTVSS (SEQ ID NO: 88) Clone 2F3, HC, amino acids, CDR1: TYWIE (SEQ ID NO: 89). Clone 2F3, HC, amino acids, CDR2: EILPGSGNTDFNEKFQG (SEQ ID NO: 90). Clone 2F3, HC, amino acids, CDR3: WGYYGTRGYFNV (SEQ ID NO: 91). Clone 2F3, LC, DNA CAAATTGTTCTCACCCAGTCTCCAGCAATCATGTCTGCATCTCCAGGGGAGAAGGTCACCATAACGT GCAGTGCCAGCTCAAGTGTAAGTTACATGCACTGGTTCCAGCAGAAGCCAGGCACTTCTCCCAAACTCT GGATTTATAGCACCTCCAACCTGGCTTCTGGAGTCCCTGCTCGCTTCAGTGGCAGTGGATCTGGGACCT CTTACTCTCTCACAATCAGCCGAATGGAGGCTGAAGATGCTGCCACTTATTACTGCCAGCAAAGGCGTA GTTTCCCGTACACGTTCGGAGGGGGGACCAAGCTGGAAATTAAA (SEQ ID NO: 92) Clone 2F3, LC, amino acids (CDRs underlined) EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDY TLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIK (SEQ ID NO: 93) Clone 2F3, LC, CDR1, amino acids: RASSSVSYMH (SEQ ID NO: 94). Clone 2F3, LC, CDR2, amino acids: STSNLAS (SEQ ID NO: 95). Clone 2F3, LC, CDR3, amino acids: QQRRSFPYT (SEQ ID NO: 96). Clone 11C2, HC, DNA CAGATCCAGTTGGTGCAGTCTGGACCTGAACTGAAGAAGCCTGGAGAGACAGTCAAGATCTCCTGC AAGGCTTCTGGATATACCTTCACAAACTATGGAATGAACTGGGTGAAGCAGGCTCCAGGAAAGGGTTTA CAGTGGATGGGCTGGATGAACACTTATACTGGAGAGCCAACATATGCTGATGACTTCAAGGGACGGTTT GCCTTCTCTTTGGAAACCTCTGCCAGAACTGTCTCTTTGGACATCAACGACCTCAAAAATGAGGACACG GCTACATATTTCTGTACAAGAGCAGGGGGACAACTCAGGCCCGGGGCTATGGACTACTGGGGTCAAGG AACCTCAGTCACCGTCTCCTCA (SEQ ID NO:97) Clone 11C2, HC, amino acids (CDRs underlined) QLVQSGAEVKKPGATVKISCKASGYTFTNYGMNWVQQAPGQGLEWMGWMNTYTGEPTYADKFQGRV TFTLDTSARTVYMELSSLRSEDTAVYFCARAGGQLRPGAMDYWGQGTMVTVSS (SEQ ID NO:98) Clone 11C2, HC, amino acids, CDR1: NYGMN (SEQ ID NO:99). Clone 11C2, HC, amino acids, CDR2: WMNTYTGEPTYADKFQG (SEQ ID NO:100). Clone 11C2, HC, amino acids, CDR3: AGGQLRPGAMDY (SEQ ID NO:101). Clone 11C2, LC, DNA GACATTGTGCTGACCCAATCTCCAGCTTCTTTGGCTGTGTCTCTAGGGCAGAGGGCCACCATCTCC TGCAAGGCCAGCCAAAGTGTTGATTATGATGGTGATAGTTTTATGAACTGGTACCAACAGAAACCAGGA CAGCCACCCAAACTCCTCATCTATGTTGCATCCAATCTAGAATCTGGGATCCCAGACAGGTTTAGTGGC AGTGGGTCTGGGACAGACTTCACCCTCCAACATCCATCCTGTGGAGGAGGAGGATGCTGCAACCTATTAT TGTCAGCAAAGTAATGAGGAACCTCCGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA (SEQ ID NO: 102) Clone 11C2, LC, amino acids (CDRs underlined) DIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSFMNWYLQKPGQPPQLLIYVASNLESGVPDRFSGS GSGTDFTLKISRVEAEDVGVYYCQQSNEEPPTFGQGTKLEIK (SEQ ID NO: 103) Clone 11C2, LC, amino acids, CDR1: KASQSVDYDGDSFMN (SEQ ID NO: 104). Clone 11C2, LC, amino acids, CDR2: VASNLES (SEQ ID NO: 105). Clone 11C2, LHC, amino acids, CDR3: QQSNEEPPT (SEQ ID NO: 106). Clone 1A1, HC, DNA CAGATACAACTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTG TGTAGCGTCTGGATTCACCTTCAAGAACTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC TGGAGTGGGTGGCAGTTATTTGGTATGATGGAAGTAATGAATACTATGGAGACCCCGTGAAGGGCCGA TTCACCATCTCCCAGAGACAACTCCAAGAACATGTTGTATCTGCAAATGAACAGCCTGAGAGCCGATGAC ACGGCTGTGTATTACTGTGCGAGGTCGGGAATAGCAGTGGCTGGGGCCTTTGACTACTGGGGCCAGG GAACCCTGGTCACCGTCTCCTCA (SEQ ID NO: 107) Clone 1A1, HC, amino acids (CDR under the name) QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLEWMGEINPSSGRTNYNEKFKT RVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKLGPGPQYYAMDYWGQGTMVTVSS (SEQ ID NO: 108) Clone 1A1, HC, amino acids, CDR1: TYWMH (SEQ ID NO: 109). Clone 1A1, HC, amino acids, CDR2: EINPSSGRTNYNEKFKT (SEQ ID NO: 110). Clone 1A1, HC, amino acids, CDR3: LGPGPQYYAMDY (SEQ ID NO: 111). Clone 1A1, LC, DNA GAAATTGTGTTGACGCAGTCTCCAGACACCCTGTCTTTGTCTCCAGGGGAAAAGCCACCCTCTCCT GCAGGGCCAGTCAGAGTGTTAGCAGCAGCTTCTTGGCCTGGTACCAGCAGAAACCTGGACAGGCTCCC AGTCTCCTCATCTATGTTGCATCCAGAAGGGCCGCTGGCATCCCTGACAGGTTCAGTGGCAGTGGGTC TGGGACAGACTTCACTTCACCATCAGCAGACTGGAGCCTGAAGATTTTGGAATGTTTTACTGTCAACA CTATGGTAGGACACCATTCACTTTCGGCCCTGGGACCAAAGTGGATATCAAACGA (SEQ ID NO: 112) Clone 1A1, LC, amino acids (CDRs underlined) DIQMTQSPSSLSASVGDRVTITCHASQNINVWLSWYQQKPGKAPKLLIYKASKLHTGVPSRFSGSGSGT DFTLTISSLQPEDFATYYCQQGQSYPWTFGQGTKLEIK (SEQ ID NO:113) Clone 1A1, LC, amino acids, CDR1: HASQNINVWLS (SEQ ID NO: 114). Clone 1A1, LC, amino acids, CDR2: KASKLHT (SEQ ID NO: 115). Clone 1A1, LC, amino acids, CDR3: QQGQSYPWT (SEQ ID NO: 116). Clone 7A4, HC, DNA CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTG CAAGGCTTCTGGATACACCTTCACCGGCTACTATATACACTGGGTGCGACAGGCCCCTGAACAAGGGC TTGAGTGGATGGGATGGATCAACCCTAACAGTGGTGGCACAAACTATGCACAGAAGTTTCAGGGCAGG GTCACCATGGCCAGGGACACGTCCATCAGCACAGTTTACATGGACCTGAGCAGGCTGAGATCTGACGA CACGGCCGTGTATTACTGTGCGAGAATACCGGGTGGTAACTCGGTCTTTGACTACTGGGGCCAGGGAA CCCTGGTCACCGTCTCCTCA (SEQ ID NO: 117) Clone 7A4, HC, amino acids (CDR under the name) QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEWMGWMNPNNSGNTGYAQKFQG RVTMTRDTSISTAYMELSSLRSEDTAVYYCGRAGYYYYFGMDVWGQGTTVTVSS (SEQ ID NO: 118) Clone 7A4, HC, amino acids, CDR1: SYDIN (SEQ ID NO: 119). Clone 7A4, HC, amino acids, CDR2: WMNPNSGNTGYAQKFQG (SEQ ID NO: 120). Clone 7A4, HC, amino acids, CDR3: AGYYYYFGMDV (SEQ ID NO: 121). Clone 7A4, LC, DNA GACATCGTGATGACCCAGTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCAA CTGCAAGTCCACCCAGGTATTTTATACACCTCCAACAATAAGAACTTCTTAGCTTGGTACCAGCAGAAAA CCAGGGCAGCCTCCTAAACTGCTCATTTCCTGGGCATCTATCCGGGAATCCGGGGTCCCTGACCGATT CAGTGGCAGCGGGTCTGGGACAGATTTCGCTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAG TTTATTACTGTCAACAATATTTTAGTACTATGTTCAGTTTTGGCCAGGGGACCAAGCTGGAGATCAAACG A (SEQ ID NO: 122) Clone 7A4, LC, amino acids (CDRs underlined) EIVLTQSPGTLSLSPGERATLSCRAGQSVTSSSFAWYQQKPGQAPRLLIYQTSTRATGIPDRFSGSGSG TDFTLTISRLEPEDFAVYYCQQYGGSRSFGQGTKVELKR (SEQ ID NO: 123) Clone 7A4, LC, amino acids, CDR1: RAGQSVTSSSFA (SEQ ID NO: 124). Clone 7A4, LC, amino acids, CDR2: QTSTRAT (SEQ ID NO: 125). Clone 7A4, LC, amino acids, CDR3: QQYGGSRS (SEQ ID NO: 126). Clone 7A5, HC, DNA CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTG CACTGTCTCTGGTGGCTCCATCAGTAGTGGTGCATACTACTGGACTTGGATCCGCCAGCACCCAGGGA AGGGCCTGGAGTGGATTGGGTACATCCATTACAGTGGGAGCACCTACTCCAACCCGTCCCTCAAGAGT CGAATTACCATATCGTTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAACTCTGTGACTGCCGCG GACACGGCCGTGTATTACTGTGCGAGACAAGAGGACTACGGTGGTTTGTTTGACTACTGGGGCCAGGG AACCCTGGTCACCGTTTCCTCA (SEQ ID NO: 127) Clone 7A5, HC, amino acids (CDR under the name) QVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEWMGWMNPNNSGNTGYAQKFQG RVTMTRDTSISTAYMELSSLRSEDTAVYYCGRAGYYYYFGMDVWGQGTTVTVSS (SEQ ID NO: 128) Clone 7A5, HC, amino acids, CDR1: SYDIN (SEQ ID NO: 129). Clone 7A5, HC, amino acids, CDR2: WMNPNSGNTGYAQKFQG (SEQ ID NO: 130). Clone 7A5, HC, amino acids, CDR3: AGYYYYFGMDV (SEQ ID NO: 131). Clone 7A5, LC, DNA GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAATCACCCTCTCC TGCAGGGCCAGTCAGAGTGTTACCACCGACTTAGCCTGGTACCAGCAGATGCCTGGACAGGCTCCCCG GCTCCTCATCTATGATGCTTCCACCAGGGCCACTGGTTTCCCAGCCAGATTCAGTGGCAGTGGGTCTG GGACAGACTTCACGCTCACCATCAGCAGCCTGCAGGCTGAAGATTTTGCAGTTTATTACTGTCAACATTA TAAAACCTGGCCTCTCACTTTCGGCGGAGGGACTAAGGTGGAGATCAAACGA (SEQ ID NO: 132) Clone 7A5, LC, amino acids (CDRs underlined) EIVLTQSPGTLSLSPGERATLSCRAGQSVTSSSLAWYQQKPGQAPRLLIYQTSTRATGIPDRFSGSGSGT DFTLTISRLEPEDFAVYYCQQYGGSRAFGQGTKVELKR (SEQ ID NO: 133) Clone 7A5, LC, amino acids, CDR1: RAGQSVTSSSLA (SEQ ID NO: 134). Clone 7A5, LC, amino acids, CDR2: QTSTRAT (SEQ ID NO: 135). Clone 7A5, LC, amino acids, CDR3: QQYGGSRA (SEQ ID NO: 136). Clone 14C11, HC, DNA CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTG CACTGTCTCTGGTGGCTCCATCAGTAGTGGTGCATACTACTGGACTTGGATCCGCCAGCACCCAGGGA AGGGCCTGGAGTGGATTGGGTACATCCATTACAGTGGGAGCACCTACTCCAACCCGTCCCTCAAGAGT CGAATTACCATATCGTTAGACACGTCTAAGAACCAGTTCTCCCTGAAGCTGAACTCTGTGACTGCCGCG GACACGGCCGTGTATTACTGTGCGAGACAAGAGGACTACGGTGGTTTGTTTGACTACTGGGGCCAGGG AACCCTGGTCACCGTTTCCTCA (SEQ ID NO: 137) Clone 14C11, HC, amino acids (CDRs underlined) QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNSAQKFQ GRVTMTRDTSISTAYMELNRLRSDDTAVYYCARGWLQTYYFDNWGQGTLVTVSS (SEQ ID NO: 138) Clone 14C11, HC, amino acids, CDR1: GYYMH (SEQ ID NO: 139). Clone 14C1, HC, amino acids, CDR2: WINPNSGGTNSAQKFQG (SEQ ID NO: 140). Clone 14C1, HC, amino acids, CDR3: GWLQTYYFDN (SEQ ID NO: 141). Clone 14C11, LC, DNA GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAATCACCCTCTCC TGCAGGGCCAGTCAGAGTGTTACCACCGACTTAGCCTGGTACCAGCAGATGCCTGGACAGGCTCCCCG GCTCCTCATCTATGATGCTTCCACCAGGGCCACTGGTTTCCCAGCCAGATTCAGTGGCAGTGGGTCTG GGACAGACTTCACGCTCACCATCAGCAGCCTGCAGGCTGAAGATTTTGCAGTTTATTACTGTCAACATTA TAAAACCTGGCCTCTCACTTTCGGCGGAGGGACTAAGGTGGAGATCAAACGA (SEQ ID NO: 142) Clone 14C11, LC, amino acids (CDRs underlined) DIVMTQSPDSLAVSLGERATIYKKSSQTVLTSSNNKNFLAWYQQKLGQPPKLLISWASTRESGVPDRFS GSGSGTDFTLTISSLQAEDVAIYYCQHYYTSPLTFGGGTKVEIKR (SEQ ID NO: 143) Clone 14C11, LC, amino acids, CDR1: TVLTSSNNKNFLA (SEQ ID NO: 144). Clone 14C1, LC, amino acids, CDR2: WASTRES (SEQ ID NO: 145). Clone 14C1, LC, amino acids, CDR3: QHYYTSPLT (SEQ ID NO: 146). Construct S1-2F3-CD28T-CD28-41BB, DNA (signal sequence in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA AGCCAGCGGCTACACCTTCTCCACCTACTGGATCGAGTGGGTGAGACAGGCCCCGGACAGAGGCTGG AATGGATGGGAGAGATCCTGCCCGGCAGCGGCAACACCGACTTCAACGAGAAGTTCCAGGGCAGAGT GACCTTCACCGCCGATACCAGCAGCGACACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGATA CCGCCGTCTACTACTGCACCAGATGGGGCTACTACGGCACCAGGGGCTATTTCAACGTGTGGGGCCAG GGAACCCTCGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGGC TCCGAGATTGTGCTGACCCAGAGCCCTGCTACACTGAGCCTGAGCCCCGGCGAGAGAGCCACACTGA GCTGCAGAGCCAGCAGCAGCGTGAGCTACATGCACTGGTTCCAGCAAAAGCCCGGCCAGGCCCCTAG GCTGCTGATCTACAGCACATCCAACCTGGCCAGCGGCATCCCTGCCAGATTCAGCGGTTCTGGCTCCG GCACCGACTACACCCTGACCATCTCCAGCCTGGAGCCCGAGGACTTTGCCGTGTATTACTGCCAGCAG AGGAGGAGCTTCCCCTACACATTCGGCCAGGGCACCAAACTGGAGATCAAGGCCGCTGCCCTTGATAA TGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGG TCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCAC CGTGGCTTTTATAATCTTCTGGGTTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATG ACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGC CTATCGGAGCCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCAAACAGCCGTT TATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAGGAGGAGGAG GGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAA CCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGAC GGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCA CGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCT GCCACCTAGGCCAAGAGAAGTGGCAGCGGGGAGGGCGGGATCTCTCCTTACATGTGGGGACGTG GAAGAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTC TCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCCTCTACACTCAC TCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGAC AGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCC TTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCA GATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCC GGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAAC CTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGC CAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCC GGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGA GCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCG TGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGC CTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:17) Конструкція S1-2F3-CD28T-CD28-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEW MGEILPGSGNTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYCTRWGYYGTRGYFNVWGQGTLV TVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTS NLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIKAAALDNEKSNGTIIHVKGK HLCPSPLFPGSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHYQPYA PPRDFAAYRSRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQ QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRG KGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCDGVEENPGPMGAGATGRAMDGPRL LLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPC TECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYS DEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIAST VAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:18) Construction S1-2F3-CD28T-CD28, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA AGCCAGCGGCTACACCTTCTCCACCTACTGGATCGAGTGGGTGAGACAGGCCCCCGGACAGAGGCTG GAATGGATGGGAGAGATCCTGCCCGGCAGCGGCAACACCGACTTCCAACGAGAAGTTCCAGGGCAGAG TGACCTTCACCGCCGATACCAGCAGCGACACCGCCTATACATGGAACTGAGCAGCCTGAGAAGCGAGGAT ACCGCCGTCTACTACTGCACCAGATGGGGCTACTACGGCACCAGGGGGCTATTTCAACGTGTGGGGCCA GGGAACCCTCGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGAGATTGTGCTGACCCAGAGCCCTGCTACACTGAGCCTGAGCCCCGGCGAGAGAGCCACACTG AGCTGCAGAGCCAGCAGCAGCGTGAGCTACATGCACTGGTTCCAGCAAAGCCCGGCCAGGCCCCTA GGCTGCTGATCTACAGCACATCCAACCTGGCCAGCGGCATCCCTGCCAGATTCAGCGGTTCTGGCTCC GGCACCGACTACACCCTGACCATCTCCAGCCTGGAGCCCGAGGACTTTGCCGTGTATTACTGCCAGCA GAGGAGGAGCTTCCCCTACACATTCGGCCAGGGCACCAAACTGGAGATCAAGGCCGCTGCCCTTGATA ATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTG GTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCA CCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATAT GACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAA CTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGA CCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGG ATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGAC GGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCA CCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACGTGGAAG AAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTCTCCT GCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTCACTCCG GTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGACAGTC TGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGT ACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCAGATG TGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGC TCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAACCTAC AGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGCCAGC TGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCCGGAG CACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGAGCAG GACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCGTGAC GCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGG TAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:19) Construction S1-2F3-CD28T-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEW MGEILPGSGNTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYCTRWGYYGTRGYFNVWGQGTLV TVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTS NLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIKAAALDNEKSNGTIIHVKGK HLCPSPLFPGSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHYQPYA PPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCG DVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQT VCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGS GLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPP EGSDSTAPSTQEPEAPPEQDLIASTVVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAIAFKR (SEQ ID NO:20) Construct S1-2F3-CD28T-41BB, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA AGCCAGCGGCTACACCTTCTCCACCTACTGGATCGAGTGGGTGAGACAGGCCCCCGGACAGAGGCTG GAATGGATGGGAGAGATCCTGCCCGGCAGCGGCAACACCGACTTCAACGAGAAGTTCCAGGGCAGAG TGACCTTCACCGCCGATACCAGCAGCGACACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGAT ACCGCCGTCTACTACTGCACCAGATGGGGCTACTACGGCACCAGGGGCTATTTCAACGTGTGGGGCCA GGGAACCCTCGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGAGATTGTGCTGACCCAGAGCCCTGCTACACTGAGCCTGAGCCCCGGCGAGAGAGCCACACTG AGCTGCAGAGCCAGCAGCAGGCGTGAGCTACATGCACTGGTTCCAGCAAAAGCCCGGCCAGGCCCCTA GGCTGCTGATCTACAGCACATCCAACCTGGCCAGCGGCATCCCTGCCAGATTCAGCGGTTCTGGCTCC GGCACCGACTACACCCTGACCATCTCCAGCCTGGAGCCCGAGGACTTTGCCGTGTATTACTGCCAGCA GAGGAGGAGCTTCCCCTACACATTCGGCCAGGGCACCAAACTGGAGATCAAGGCCGCTGCCCTTGATA ATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTG GTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCA CCGTGGCTTTTATAATCTTCTGGGTTCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACA TTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTT CCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGT ATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTG GACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTC TCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGA GAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCT CTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCC TTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGA TGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAA CGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCT TGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCC ACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGC CGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCT GCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAG GAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCT GCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCC TGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAAC CGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGG ATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGC AGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:21) Construction S1-2F3-CD28T-41BB, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEW MGEILPGSGNTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYCTRWGYYGTRGYFNVWGQGTLV TVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTS NLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIKAAALDNEKSNGTIIHVKGK HLCPSPLFPGSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDG CSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNP QEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRG SLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQP CGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACR VCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWI TRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAY IAFCR (SEQ ID NO:22) Construct S1-2F3-C8K-CD28, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA AGCCAGCGGCTACACCTTCTCCACCTACTGGATCGAGTGGGTGAGACAGGCCCCCGGACAGAGGCTG GAATGGATGGGAGAGATCCTGCCCGGCAGCGGCAACACCGACTTCAACGAGAAGTTCCAGGGCAGAG TGACCTTCACCGCCGATACCAGCAGCGACACCGCCTACATGGAACTGAGCAGCCTGAGAAGCGAGGAT ACCGCCGTCTACTACTGCACCAGATGGGGCTACTACGGCACCAGGGGCTATTTCAACGTGTGGGGCCA GGGAACCCTCGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGAGATTGTGCTGACCCAGAGCCCTGCTACACTGAGCCTGAGCCCCGGCGAGAGAGCCACACTG AGCTGCAGAGCCAGCAGCAGGCGTGAGCTACATGCACTGGTTCCAGCAAAAGCCCGGCCAGGCCCCTA GGCTGCTGATCTACAGCACATCCAACCTGGCCAGCGGCATCCCTGCCAGATTCAGCGGTTCTGGCTCC GGCACCGACTACACCCTGACCATCTCCAGCCTGGAGCCCGAGGACTTTGCCGTGTATTACTGCCAGCA GAGGAGGAGCTTCCCCTACACATTCGGCCAGGGCACCAAACTGGAGATCAAGGCCGCTGCCTTCGTGC CTGTTTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGCACCAACTATCG CTTCCCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCCGTGCACACTAG AGGCCTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGGGGTACTGCTGC TGTCTCTGGTGATTACCCTCTACTGCAACCACAGAAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCG ATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTA GAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAG GGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCG CAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATG AGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGA AAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACAT GCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGT GGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCG CGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCT CTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTG CTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGC CTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGAT GCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGT GTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTC CAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGA TACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGA TGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGG CCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCA CAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGT GGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:23) Construction S1-2F3-C8K-CD28, amino acids (signal sequence is shown in bold; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEW MGEILPGSGNTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYYCTRWGYYGTRGYFNVWGQGTLV TVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTS NLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIKAAAFVPVFLPAKPTTTPA PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRSKRS RLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYD VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYD ALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTG LYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDA VCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTE RQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTR GTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:24) Structure S1-2F3-C8K-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGAGCGGAGCCGAGGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA AGCCAGCGGCTACACCTTCTCCACCTACTGGATCGAGTGGGTGAGACAGGCCCCCGGACAGAGGCTG GAATGGATGGGAGAGATCCTGCCCGGCAGCGGCAACACCGACTTCCAACGAGAAGTTCCAGGGCAGAG TGACCTTCACCGCCGATACCAGCAGCGACACCGCCTATACATGGAACTGAGCAGCCTGAGAAGCGAGGAT ACCGCCGTCTACTACTGCACCAGATGGGGCTACTACGGCACCAGGGGGCTATTTCAACGTGTGGGGCCA GGGAACCCTCGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGAGATTGTGCTGACCCAGAGCCCTGCTACACTGAGCCTGAGCCCCGGCGAGAGAGCCACACTG AGCTGCAGAGCCAGCAGCAGCGTGAGCTACATGCACTGGTTCCAGCAAAAGCCCGGCCAGGCCCCTA GGCTGCTGATCTACAGCACATCCAACCTGGCCAGCGGCATCCCTGCCAGATTCAGCGGTTCTGGCTCC GGCACCGACTACACCCTGACCATCTCCAGCCTGGAGCCCGAGGACTTTGCCGTGTATTACTGCCAGCA GAGGAGGAGCTTCCCCTACACATTCGGCCAGGGCACCAAACTGGAGATCAAGGCCGCTGCCTTCGTGC CTGTTTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGCACCAACTATCG CTTCCCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCCGTGCACACTAG AGGCCTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGGGGTACTGCTGC TGTCTCTGGTGATTACCCTCTACTGCAACCACAGAAACCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAA AGCTGCTGTACATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGC TCCTGCCGCTTTCCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGA TGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGT ATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCC CAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAA GGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATA CTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCG GGGATCTCTCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGA AGGGCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGA GGCCTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCG TCGCACAACCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATG TTGTCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCT GTGTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGG TGTGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACAC AGTATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGT GCACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGA GGAGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGT ACCCAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGAC AGTCATGGGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAG CATCTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:25) Construction S1-2F3-C8K-41BB, amino acids (signal sequence is shown in bold; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFSTYWIEWVRQAPGQRLEW MGEILPGSGNTDFNEKFQGRVTFTADTSSDTAYMELSSLRSEDTAVYYCTRWGYYGTRGYFNVWGQGTLV TVSSGGGGSGGGGSGGGGSEIVLTQSPATLSLSPGERATLSCRASSSVSYMHWFQQKPGQAPRLLIYSTS NLASGIPARFSGSGSGTDYTLTISSLEPEDFAVYYCQQRRSFPYTFGQGTKLEIKAAAFVPVFLPAKPTTTPA PRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRFSVV KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGR REEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTAT KDTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKE ACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCV EADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTV CEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQ PVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:26) Construction S1-11C2-CD28T-CD28-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGA GATTCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGAGCCACCGTGAAGATCAGCTGCAAG GCCAGCGGCTACACATTCACCAACTACGGCATGAACTGGGTGCAACAGGCCCCGGCCAGGGACTGG AGTGGATGGGCTGGATGAACACATACACCGGCGAGCCCACCTACGCCGACAAGTTCCAGGGCAGGGT GACATTCACACTCGATACCAGCGCCAGAACCGTGTATATGGAACTGAGCAGCCTGAGGAGCGAGGACA CCGCTGTGTACTTCTGCGCAAGGGCTGGAGGCCAGCTGAGACCTGGCGCTATGGACTACTGGGGCCA GGGCACCATGGTGACCGTGAGCTCCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCGTGCTGACCCAGACACCTCTCTCCCTGTCCGTGACCCCCGGACAGCCTGCCTCCATTT CCTGTAAGGCCTCCCAGAGCGTGGACTATGACGGCGACAGCTTCATGAACTGGTACCTGCAGAAGCCC GGACAACCCCCCCAGCTGCTGATCTACGTGGCCAGCAACCTGGAGTCCGGCGTGCCTGACAGGTTTTC CGGCTCCGGCAGCGGCACCGACTTCACCCTGAAGATCAGCAGGGTGGAAGCCGAGGACGTGGGCGT GTACTACTGCCAGCAGAGCAACGAGGAGCCCCCTACCTTCGGACAGGGCACCAAGCTGGAGATCAAG GCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCG TCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGT TACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATA GCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCA CCTAGAGATTTCGCTGCCTATCGGAGCCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTA CATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCT TTCCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGC GTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTT TGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGG TCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCG GAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACG CTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCT CCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATG GATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCC AACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAAC CTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAG CCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAA GCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGC CTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTG AGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGT CTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATC CCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAG AACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATG GGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTG GCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:27) Конструкція S1-11C2-CD28T-CD28-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR підкреслені) MALPVTALLLPLALLLHAARPEIQLVQSGAEVKKPGATVKISCKASGYTFTNYGMNWVQQAPGQGLEWM GWMNTYTGEPTYADKFQGRVTFTLDTSARTVYMELSSLRSEDTAVYFCARAGGQLRPGAMDYWGQGTMV TVSSGGGGSGGGGSGGGGSDIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSFMNWYLQKPGQPPQLL IYVASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSNEEPPTFGQGTKLEIKAAALDNEKSNGTI IHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRK HYQPYAPPRDFAAYRSRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSA DAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMK GERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRA MDGPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSAT EPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEEC PDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPE QDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:28) Construction S1-11C2-CD28T-CD28, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGA GATTCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGAGCCACCGTGAAGATCAGCTGCAAG GCCAGCGGCTACACATTCACCAACTACGGCATGAACTGGGTGCAACAGGCCCCGGCCAGGGACTGG AGTGGATGGGCTGGATGAACACATACACCGGCGAGCCCACCTACGCCGACAAGTTCCAGGGCAGGGT GACATTCACACTCGATACCAGCGCCAGAACCGTGTATATGGAACTGAGCAGCCTGAGGAGCGAGAGACA CCGCTGTGTACTTCTGCGCAAGGGCTGGAGGCCAGCTGAGACCTGGCGCTATGGACTACTGGGGCCA GGGCACCATGGTGACCGTGAGCTCCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGGAGG CTCCGACATCGTGCTGACCCAGACACCTCTCTCCCTGTCCGTGACCCCCGGACAGCCTGCCTCCATTT CCTGTAAGGCCTCCCAGAGCGTGGACTATGACGGCGACAGCTTCATGAACTGGTACCTGCAGAAGCCC GGACAACCCCCCAGCTGCTGATCTACGTGGCCAGCAACCTGGAGTCCGGCGTGCCTGACAGGTTTTC CGGCTCCGGCAGCGGCACCGACTTCACCCTGAAGATCAGCAGGGTGGAAGCCGAGGACGTGGGCGT GTACTACTGCCAGCAGAGCAACGAGGAGCCCCCTACCTTCGGACAGGGCACCAAGCTGGAGATCAAG GCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCG TCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGT TACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATA GCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCA CCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAG CAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAA GCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTAT AATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAG GGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC ACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTAC ATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGC CCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGG CCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTG GTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCG AGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGAT GATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCG GGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGT GTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGA GGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGG AGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGA GGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCT CACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCC GTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:29) Construction S1-11C2-CD28T-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPEIQLVQSGAEVKKPGATVKISCKASGYTFTNYGMNWVQQAPGQGLEWM GWMNTYTGEPTYADKFQGRVTFTLDTSARTVYMELSSLRSEDTAVYFCARAGGQLRPGAMDYWGQGTMV TVSSGGGGSGGGGSGGGGSDIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSFMNWYLQKPGQPPQLL IYVASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSNEEPPTFGQGTKLEIKAAALDNEKSNGTI IHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRK HYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKN PQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGR GSLLTCDGVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQ PCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEAC RVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGR WITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLV AYIAFKR (SEQ ID NO:30) Конструкція S1-11C2-CD28T-41BB, ДНК (сигнальна послідовність виділена жирним) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGA GATTCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGAGCCACCGTGAAGATCAGCTGCAAG GCCAGCGGCTACACATTCACCAACTACGGCATGAACTGGGTGCAACAGGCCCCCGGCCAGGGACTGG AGTGGATGGGCTGGATGAACACATACACCGGCGAGCCCACCTACGCCGACAAGTTCCAGGGCAGGGT GACATTCACACTCGATACCAGCGCCAGAACCGTGTATATGGAACTGAGCAGCCTGAGGAGCGAGGACA CCGCTGTGTACTTCTGCGCAAGGGCTGGAGGCCAGCTGAGACCTGGCGCTATGGACTACTGGGGCCA GGGCACCATGGTGACCGTGAGCTCCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCGTGCTGACCCAGACACCTCTCTCCCTGTCCGTGACCCCCGGACAGCCTGCCTCCATTT CCTGTAAGGCCTCCCAGAGCGTGGACTATGACGGCGACAGCTTCATGAACTGGTACCTGCAGAAGCCC GGACAACCCCCCCAGCTGCTGATCTACGTGGCCAGCAACCTGGAGTCCGGCGTGCCTGACAGGTTTTC CGGCTCCGGCAGCGGCACCGACTTCACCCTGAAGATCAGCAGGGTGGAAGCCGAGGACGTGGGCGT GTACTACTGCCAGCAGAGCAACGAGGAGCCCCCTACCTTCGGACAGGGCACCAAGCTGGAGATCAAG GCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCG TCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGT TACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTCGCTTTTCCGTCGTTAAGCGGGGGAGA AAAAAGCTGCTGTACATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGC TGCTCCTGCCGCTTTCCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGC AGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAG AGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAAC CCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATG AAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGG ATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGG CCGGGGATCTCTCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACG GGAAGGGCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAA GGAGGCCTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGG GCGTCGCACAACCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCG ATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCC CCTGTGTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGG CGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAA CACAGTATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGC CGTGCACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTG CGAGGAGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCG AGTACCCAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGAC GACAGTCATGGGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACT GTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:31) Construction S1-11C2-CD28T-41BB, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPEIQLVQSGAEVKKPGATVKISCKASGYTFTNYGMNWVQQAPGQGLEWM GWMNTYTGEPTYADKFQGRVTFTLDTSARTVYMELSSLRSEDTAVYFCARAGGQLRPGAMDYWGQGTMV TVSSGGGGSGGGGSGGGGSDIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSFMNWYLQKPGQPPQLL IYVASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSNEEPPTFGQGTKLEIKAAALDNEKSNGTI IHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRFSVVKRGRKKLLYIFKQPFMRPVQT TQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGK PRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGS GEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGE GVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGR CEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEI PGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVV GLVAYIAFKR (SEQ ID NO:32) Конструкція S1-11C2-C8K-CD28, ДНК (сигнальна послідовність виділена жирним) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGA GATTCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGAGCCACCGTGAAGATCAGCTGCAAG GCCAGCGGCTACACATTCACCAACTACGGCATGAACTGGGTGCAACAGGCCCCCGGCCAGGGACTGG AGTGGATGGGCTGGATGAACACATACACCGGCGAGCCCACCTACGCCGACAAGTTCCAGGGCAGGGT GACATTCACACTCGATACCAGCGCCAGAACCGTGTATATGGAACTGAGCAGCCTGAGGAGCGAGGACA CCGCTGTGTACTTCTGCGCAAGGGCTGGAGGCCAGCTGAGACCTGGCGCTATGGACTACTGGGGCCA GGGCACCATGGTGACCGTGAGCTCCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCGTGCTGACCCAGACACCTCTCTCCCTGTCCGTGACCCCCGGACAGCCTGCCTCCATTT CCTGTAAGGCCTCCCAGAGCGTGGACTATGACGGCGACAGCTTCATGAACTGGTACCTGCAGAAGCCC GGACAACCCCCCCAGCTGCTGATCTACGTGGCCAGCAACCTGGAGTCCGGCGTGCCTGACAGGTTTTC CGGCTCCGGCAGCGGCACCGACTTCACCCTGAAGATCAGCAGGGTGGAAGCCGAGGACGTGGGCGT GTACTACTGCCAGCAGAGCAACGAGGAGCCCCCTACCTTCGGACAGGGCACCAAGCTGGAGATCAAG GCCGCTGCCTTCGTGCCTGTTTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAAC TCCTGCACCAACTATCGCTTCCCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCG GCGCCGTGCACACTAGAGGCCTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACA TGCGGGGTACTGCTGCTGTCTCTGGTGATTACCCTCTACTGCAACCACAGAAACAGATCCAAAAGAAGC CGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCA GCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGC ACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATG ACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCA GGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGG AGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTT ATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGG ATCTCTCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGG GCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGC CTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCG CACAACCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTG TCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGT GTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTG TGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAG TATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGC ACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGG AGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACC CAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGT CATGGGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCAT CTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:33) Construction S1-11C2-C8K-CD28, amino acids (signal sequence is shown in bold; CDR підкреслені) MALPVTALLLPLALLLHAARPEIQLVQSGAEVKKPGATVKISCKASGYTFTNYGMNWVQQAPGQGLEWM GWMNTYTGEPTYADKFQGRVTFTLDTSARTVYMELSSLRSEDTAVYFCARAGGQLRPGAMDYWGQGTMV TVSSGGGGSGGGGSGGGGSDIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSFMNWYLQKPGQPPQLL IYVASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSNEEPPTFGQGTKLEIKAAAFVPVFLPAKP TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNR SKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRR EEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGGKGHDGLYQGLSTATK DTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEA CPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSSMAPCVE ADDAVCRAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVC EDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQP VVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:34) Structure S1-11C2-C8K-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGGA GATTCAGCTGGTGCAGAGCGGCGCCGAGGTGAAAAAGCCCGGAGCCACCGTGAAGATCAGCTGCAAG GCCAGCGGCTACACATTCACCAACTACGGCATGAACTGGGTGCAACAGGCCCCGGCCAGGGACTGG AGTGGATGGGCTGGATGAACACATACACCGGCGAGCCCACCTACGCCGACAAGTTCCAGGGCAGGGT GACATTCACACTCGATACCAGCGCCAGAACCGTGTATATGGAACTGAGCAGCCTGAGGAGCGAGAGACA CCGCTGTGTACTTCTGCGCAAGGGCTGGAGGCCAGCTGAGACCTGGCGCTATGGACTACTGGGGCCA GGGCACCATGGTGACCGTGAGCTCCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCGTGCTGACCCAGACACCTCTCTCCCTGTCCGTGACCCCCGGACAGCCTGCCTCCATTT CCTGTAAGGCCTCCCAGAGCGTGGACTATGACGGCGACAGCTTCATGAACTGGTACCTGCAGAAGCCC GGACAACCCCCCCAGCTGCTGATCTACGTGGCCAGCAACCTGGAGTCCGGCGTGCCTGACAGGTTTTC CGGCTCCGGCAGCGGCACCGACTTCACCCTGAAGATCAGCAGGGTGGAAGCCGAGGACGTGGGCGT GTACTACTGCCAGCAGAGCAACGAGGAGCCCCCTACCTTCGGACAGGGCACCAAGCTGGAGATCAAG GCCGCTGCCTTCGTGCCTGTTTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAAC TCCTGCACCAACTATCGCTTCCCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCG GCGCCGTGCACACTAGAGGCCTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACA TGCGGGGTACTGCTGCTGTCTCTGGTGATTACCCTCTACTGCAACCACAGAAACCGCTTTTCCGTCGTT AAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCA GGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAA GTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCT GGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAA CCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTA TTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCA GCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGT GGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGG GTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTC TCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCT GTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGAT TCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTT CAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCA GGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGT TGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCA CGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGGCCT GGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATC AGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAG TTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCGTGACGCGGGCACAACCGACAAT CTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAG AGATGACCTAGGTAA (SEQ ID NO:35) Construction S1-11C2-C8K-41BB, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPEIQLVQSGAEVKKPGATVKISCKASGYTFTNYGMNWVQQAPGQGLEWM GWMNTYTGEPTYADKFQGRVTFTLDTSARTVYMELSSLRSEDTAVYFCARAGGQLRPGAMDYWGQGTMV TVSSGGGGSGGGGSGGGGSDIVLTQTPLSLSVTPGQPASISCKASQSVDYDGDSFMNWYLQKPGQPPQLL IYVASNLESGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCQQSNEEPPTFGQGTKLEIKAAAAFVPVFLPAKP TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNR FSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNEL NLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGL STATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLG GAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMS APCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCL PCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVM GSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:36) Construction S2-1A1-CD28T-CD28-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCCGGCGCCGAAGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA GGCCTCCGGCTACACCTTCACCACCTACTGGATGCACTGGGTCAGACAGGCTCCCGGACAGGGCCTG GAATGGATGGGCGAAATCAACCCCTCCTCCGGCAGGACCAACTACAACGAGAAGTTCAAGACCAGGGT GACCATGACCAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGTCCAGCCTGAGGAGCGAGGAC ACCGCCGTGTACTACTGTGCCAAGCTGGGACCCGGCCCCCAGTACTATGCCATGGACTACTGGGGCCA AGGCACCATGGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCCAGATGACCCAGAGCCCCTCCAGCCTGTCCGCTAGCGTGGGCGACAGGGTCACCATTA CCTGCCACGCCAGCCAGAACATCAACGTGTGGCTGAGCTGGTATCAGCAGAAACCCGGCAAGGCTCCC AAGCTGCTGATCTACAAGGCCAGCAAGCTGCACACCGGCGTGCCCAGCAGGTTTAGCGGTTCTGGCTC CGGCACCGACTTCACCCTCACCATCAGCAGCCTGCAGCCCGAAGACTTCGCTACCTACTACTGCCAGC AGGGACAAAGCTACCCCTGGACCTTCGGCCAGGGAACCAAGCTGGAAATCAAGGCCGCTGCCCTTGAT AATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCT GGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTC ACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATA TGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCT GCCTATCGGAGCCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCAAACAGCCG TTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAGGAGGAGGA GGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAG AACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGG ACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGC AGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGG CACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCC CTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACG TGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCT TCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTC ACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAG ACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAG CCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTG CAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAG CCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGA ACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAAC GCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCAC CCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCA GAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGT CGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGG GCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:37) Конструкція S2-1A1-CD28T-CD28-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLE WMGEINPSSGRTNYNEKFKTRVTMTRDTSTSTVYMELSSLRSEDTAVYYCAKLGPGPQYYAMDYWGQGT MVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNINVWLSWYQQKPGKAPKLLIY KASKLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQSYPWTFGQGTKLEIKAAALDNEKSNGTIIH VKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHY QPYAPPRDFAAYRSRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADA PAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE RRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMD GPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEP CKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPD GTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQD LIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:38) Construct S2-1A1-CD28T-CD28, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCCGGCGCCGAAGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA GGCCTCCGGCTACACCTTCACCACCTACTGGATGCACTGGGTCAGACAGGCTCCCGGACAGGGCCTG GAATGGATGGGCGAAATCAACCCCTCCTCCGGCAGGACCAACTACAACGAGAAGTTCAAGACCAGGGT GACCATGACCAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGTCCAGCCCTGAGGAGCGAGGAC ACCGCCGTGTACTACTGTGCCAAGCTGGGACCCGGCCCCCAGTACTATGCCATGGACTACTGGGGCCA AGGCACCATGGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCCAGATGACCCAGAGCCCCTCCAGCCCTGTCCGCTAGCGTGGGCGACAGGGTCACCATTA CCTGCCACGCCAGCCAGAACATCAACGTGTGGCTGAGCTGGTATCAGCAGAAACCCGGCAAGGCTCCC AAGCTGCTGATCTACAAGGCCAGCAAGCTGCACACCGGCGTGCCCAGCAGGTTTAGCGGTTCTGGCTC CGGCACCGACTTCACCCTCACCATCAGCAGCCTGCAGCCCGAAGACTTCGCTACCTACTACTGCCAGC AGGGACAAAGCTACCCCTGGACCTTCGGCCAGGGAACCAAGCTGGAAATCAAGGCCGCTGCCCTTGAT AATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCT GGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTC ACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATA TGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCT GCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCA ACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGG ACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGA CGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCC ACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACGTGGAA GAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTCTCC TGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTCACTCC GGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGACAGT CTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTG TACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCAGAT GTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGG CTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAACCTA CAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGCCAG CTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCCGGA GCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGAGCA GGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCGTGA CGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGCCTG GTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:39) Construction S2-1A1-CD28T-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLE WMGEINPSSGRTNYNEKFKTRVTMTRDTSTSTVYMELSSLRSEDTAVYCAKLGPGPQYYAMDYWGQGT MVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNIVNWLSWYQQKPGKAPKLLIY KASKLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQSYPWTFGQGTKLEIKAAALDNEKSNGTIIH VKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHY QPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSL LTCDGVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCG ANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITR STPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAF CR (SEQ ID NO:40) Construct S2-1A1-CD28T-41BB, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCCGGCGCCGAAGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA GGCCTCCGGCTACACCTTCACCACCTACTGGATGCACTGGGTCAGACAGGCTCCCGGACAGGGCCTG GAATGGATGGGCGAAATCAACCCCTCCTCCGGCAGGACCAACTACAACGAGAAGTTCAAGACCAGGGT GACCATGACCAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGTCCAGCCCTGAGGAGCGAGGAC ACCGCCGTGTACTACTGTGCCAAGCTGGGACCCGGCCCCCAGTACTATGCCATGGACTACTGGGGCCA AGGCACCATGGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCCAGATGACCCAGAGCCCCTCCAGCCCTGTCCGCTAGCGTGGGCGACAGGGTCACCATTA CCTGCCACGCCAGCCAGAACATCAACGTGTGGCTGAGCTGGTATCAGCAGAAACCCGGCAAGGCTCCC AAGCTGCTGATCTACAAGGCCAGCAAGCTGCACACCGGCGTGCCCAGCAGGTTTAGCGGTTCTGGCTC CGGCACCGACTTCACCCTCACCATCAGCAGCCTGCAGCCCGAAGACTTCGCTACCTACTACTGCCAGC AGGGACAAAGCTACCCCTGGACCTTCGGCCAGGGAACCAAGCTGGAAATCAAGGCCGCTGCCCTTGAT AATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCT GGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTC ACCGTGGCTTTTATAATCTTCTGGGTTCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTAC ATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTT CCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGT ATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTG GACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTC TCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGA GAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCT CTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCC TTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGA TGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAA CGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCT TGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCC ACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGC CGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCT GCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAG GAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCT GCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCC TGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAAC CGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGG ATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGC AGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:41) Construction S2-1A1-CD28T-41BB, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLE WMGEINPSSGRTNYNEKFKTRVTMTRDTSTSTVYMELSSLRSEDTAVYCAKLGPGPQYYAMDYWGQGT MVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNIVNWLSWYQQKPGKAPKLLIY KASKLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQSYPWTFGQGTKLEIKAAALDNEKSNGTIIH VKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRFSVVKRGRKKLLYIFKQPFMRPVQTTQ EEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPR RKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGE GRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGV AQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCE ACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPG RWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAVVVGL WAIAFKR (SEQ ID NO:42) Construct S2-1A1-C8K-CD28, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCCGGCGCCGAAGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA GGCCTCCGGCTACACCTTCACCACCTACTGGATGCACTGGGTCAGACAGGCTCCCGGACAGGGCCTG GAATGGATGGGCGAAATCAACCCCTCCTCCGGCAGGACCAACTACAACGAGAAGTTCAAGACCAGGGT GACCATGACCAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGTCCAGCCCTGAGGAGCGAGGAC ACCGCCGTGTACTACTGTGCCAAGCTGGGACCCGGCCCCCAGTACTATGCCATGGACTACTGGGGCCA AGGCACCATGGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCCAGATGACCCAGAGCCCCTCCAGCCCTGTCCGCTAGCGTGGGCGACAGGGTCACCATTA CCTGCCACGCCAGCCAGAACATCAACGTGTGGCTGAGCTGGTATCAGCAGAAACCCGGCAAGGCTCCC AAGCTGCTGATCTACAAGGCCAGCAAGCTGCACACCGGCGTGCCCAGCAGGTTTAGCGGTTCTGGCTC CGGCACCGACTTCACCCTCACCATCAGCAGCCTGCAGCCCGAAGACTTCGCTACCTACTACTGCCAGC AGGGACAAAGCTACCCCTGGACCTTCGGCCAGGGAACCAAGCTGGAAATCAAGGCCGCTGCCTTCGTG CCTGTTTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGCACCAACTATC GCTTCCCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCCGTGCACACTA GAGGCCTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGGGGTACTGCTG CTGTCTCTGGTGATTACCCTCTACTGCAACCACAGAAACAGATCCAAAAGAAGCCGCCTGCTCCATAGC GATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCT AGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCA GGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGC GCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAAT GAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGG AAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACAT GCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGT GGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCG CGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCT CTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTG CTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGC CTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGAT GCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGT GTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTC CAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGA TACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGA TGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGG CCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCA CAACCAGTCGTGACGCGGGGCACAACGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGT GGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:43) Construction S2-1A1-C8K-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLE WMGEINPSSGRTNYNEKFKTRVTMTRDTSTSTVYMELSSLRSEDTAVYCAKLGPGPQYYAMDYWGQGT MVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNIVNWLSWYQQKPGKAPKLLIY KASKLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQSYPWTFGQGTKLEIKAAAAFVPVFLPAKPT TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRS KRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRRE EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEAC PTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSSMAPCVEA DDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCE DTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPV VTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:44) Structure S2-1A1-C8K-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCCGGCGCCGAAGTGAAGAAGCCCGGAGCCAGCGTGAAGGTGAGCTGCAA GGCCTCCGGCTACACCTTCACCACCTACTGGATGCACTGGGTCAGACAGGCTCCCGGACAGGGCCTG GAATGGATGGGCGAATCAACCCCTCCTCCGGCAGGACCAACTACAACGAGAAGTTCAAGACCAGGGGT GACCATGACCAGGGACACCAGCACCAGCACCGTGTACATGGAGCTGTCCAGCCTGAGGAGCGAGGAC ACCGCCGTGTACTACTGTGCCAAGCTGGGACCCGGCCCCCAGTACTATGCCATGGACTACTGGGGCCA AGGCACCATGGTGACCGTGAGCAGCGGAGGCGGAGGATCTGGTGGCGGTGGTTCTGGCGGCGGAGG CTCCGACATCCAGATGACCCAGAGCCCCTCCAGCCTGTCCGCTAGCGTGGGCGACAGGGTCACCATTA CCTGCCACGCCAGCCAGAACATCAACGTGTGGCTGAGCTGGTATCAGCAGAAACCCGGCAAGGCTCCC AAGCTGCTGATCTACAAGGCCAGCAAGCTGCACACCGGCGTGCCCAGCAGGTTTAGCGGTTCTGGCTC CGGCACCGACTTCACCCTCACCATCAGCAGCCTGCAGCCCGAAGACTTCGCTACCTACTACTGCCAGC AGGGACAAAGCTACCCCTGGACCTTCGGCCAGGGAACCAAGCTGGAAATCAAGGCCGCTGCCTTCGTG CCTGTTTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGCACCAACTATC GCTTCCCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCCGTGCACACTA GAGGCCTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGGGGTACTGCTG CTGTCTCTGGTGATTACCCTCTACTGCAACCACAGAAACCGCTTTTCCGTCGTTAAGCGGGGGAGAAAA AAGCTGCTGTACATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTG CTCCTGCCGCTTTCCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCA GATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGA GTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAACC CCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGA AAGGAGAGCGGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGA TACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGC CGGGGATCTCTCCTTACATGTGGGGACGTGGAAAAAATCCGGGGCCTATGGGTGCCGGCGCCACGG GAAGGGCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAG GAGGCCTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGG CGTCGCACAACCTTGTGGTGCTAACCAGACAGTCTGTGAAACCATGCCTGGATTCAGTGACATTCAGCGA TGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCC CCTGTGTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGG CGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAA CACAGTATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGC CGTGCACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGGCCTGGGCAGACGCTGAGTG CGAGGAGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCG AGTACCCAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGAC GACAGTCATGGGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACT GTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:45) Construction S2-1A1-C8K-41BB, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTTYWMHWVRQAPGQGLE WMGEINPSSGRTNYNEKFKTRVTMTRDTSTSTVYMELSSLRSEDTAVYCAKLGPGPQYYAMDYWGQGT MVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCHASQNIVNWLSWYQQKPGKAPKLLIY KASKLHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGQSYPWTFGQGTKLEIKAAAAFVPVFLPAKPT TTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRF SVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELN LGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRKGHDGLYQGLS TATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGG AKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSA PCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLP CTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMG SSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:46) Construction S2-7A4-CD28T-CD28-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTACTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTTGCTTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGTCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCCTTGATAATGAA AAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTG GCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTAT CGGAGCCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCAAACAGCCGTTTATG AGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAGGAGGAGGAGGGCG GGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAA CTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGA CCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGG ATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGAC GGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCA CCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACGTGGAAG AAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTCTCCT GCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTCACTCCG GTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGACAGTC TGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGT ACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCAGATG TGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGC TCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAACCTAC AGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGCCAGC TGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCCGGAG CACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGAGCAG GACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCGTGAC GCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGG TAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:47) Конструкція S2-7A4-CD28T-CD28-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYCGRAGYYYYFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAGQSVTSSSFAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRSFGQGTKVELKRAAALDNEKSNGTIIHV KGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHY QPYAPPRDFAAYRSRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADA PAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE RRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMD GPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEP CKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPD GTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQD LIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:48) Конструкція S2-7A4-CD28T-CD28, ДНК (сигнальна послідовність виділена жирним) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTACTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTTGCTTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGTCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCCTTGATAATGAA AAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTG GCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTAT CGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTA TAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCT GAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAA GATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTT TGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTA GGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACGTGGAAGAAAA TCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTCTCCTGCTG TTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTCACTCCGGTGA ATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGACAGTCTGTG AACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGTACCG AATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCAGATGTGCC TATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTG GCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAACCTACAGC GACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGCCAGCTGA GAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCCGGAGCAC ACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGAGCAGGAC CTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCGTGACGCG GGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGGTAG CCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:49) Construction S2-7A4-CD28T-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYCGRAGYYYIFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAQSVTSSSFAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRSFGQGTKVELKRAALDNEKSNGTIIHV KKGHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHY QPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSL LTCDGVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCG ANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITR STPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAF CR (SEQ ID NO:50) Construct S2-7A4-CD28T-41BB, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTTCTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTTGCTTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGTCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCCTTGATAATGAA AAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTG GCTTTTATAATCTTCTGGGTTCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCA AACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAG GAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGC AGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAG CGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATA ATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGG GGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCA CATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACA TGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGC CCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGG CCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTG GTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCG AGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGAT GATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCG GGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGT GTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGA GGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGG AGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGA GGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCT CACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCC GTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:51) Construction S2-7A4-CD28T-41BB, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYCGRAGYYYIFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAQSVTSSSFAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRSFGQGTKVELKRAALDNEKSNGTIIHV KKGHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRFSVVKRGRKKLLYIFKQPFMRPVQTTQE EDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGE GRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGV AQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCE ACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPG RWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAVVVGL WAIAFKR (SEQ ID NO:52) Construct S2-7A4-C8K-CD28, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTTCTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTTGCTTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGTCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCTTCGTGCCTGTT TTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGCACCAACTATCGCTTC CCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCCGTGCACACTAGAGGC CTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGGGGTACTGCTGCTGTC TCTGGTGATTACCCTCTACTGCAACCACAGAAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTA CATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAG ATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGC CAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAG AGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGC TGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAA GGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCA AGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGG GACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGA CTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTA CACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTA ACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTT GCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCA GTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTG TGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAG ACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATAC CGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGG ATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCC CTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAA CCAGTCGTGACGCGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGT CGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:53) Construction S2-7A4-C8K-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYCGRAGYYYIFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAQSVTSSSFAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRSFGQGTKVELKRAAAFVPVFLAKPTT TPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRS KRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRRE EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEAC PTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSSMAPCVEA DDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCE DTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPV VTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:54) Structure S2-7A4-C8K-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTACTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTTGCTTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGTCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCTTCGTGCCTGTT TTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGCACCAACTATCGCTTC CCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCCGTGCACACTAGAGGC CTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGGGGTACTGCTGCTGTC TCTGGTGATTACCCTCTACTGCAACCACAGAAACCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCT GCTGTACATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCT GCCGCTTTCCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGC ACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATG ACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCA GGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGG AGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTT ATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGG ATCTCTCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGG GCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGC CTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCG CACAACCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTG TCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGT GTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTG TGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAG TATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGC ACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGG AGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACC CAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGT CATGGGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCAT CTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:55) Конструкція S2-7A4-C8K-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYCGRAGYYYYFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAGQSVTSSSFAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRSFGQGTKVELKRAAAFVPVFLAKPTT TPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRFS VVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNL GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLST ATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCDGVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGA KEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAP CVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPC TVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGS SQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:56) Construction S2-7A5-CD28T-CD28-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTACTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTAGCTTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGGCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCCTTGATAATGAA AAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTG GCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTAT CGGAGCCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCAAACAGCCGTTTATG AGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAGGAGGAGGAGGGCG GGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAA CTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGA CCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGG ATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGAC GGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCA CCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACGTGGAAG AAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTCTCCT GCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTCACTCCG GTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGACAGTC TGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGT ACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCAGATG TGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGC TCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAACCTAC AGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGCCAGC TGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCCGGAG CACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGAGCAG GACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCGTGAC GCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGG TAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:57) Конструкція S2-7A5-CD28T-CD28-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYCGRAGYYYYFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAGQSVTSSSLAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRAFGQGTKVELKRAAALDNEKSNGTIIHV KGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHY QPYAPPRDFAAYRSRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADA PAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE RRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMD GPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEP CKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPD GTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQD LIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:58) Конструкція S2-7A5-CD28T-CD28, ДНК (сигнальна послідовність виділена жирним) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTACTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTAGCTTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGGCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCCTTGATAATGAA AAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTG GCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTC CACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTAT CGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTA TAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCT GAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAA GATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTT TGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTA GGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACGTGGAAGAAAA TCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTCTCCTGCTG TTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTCACTCCGGTGA ATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGACAGTCTGTG AACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGTACCG AATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCAGATGTGCC TATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTG GCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAACCTACAGC GACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGCCAGCTGA GAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCCGGAGCAC ACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGAGCAGGAC CTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCGTGACGCG GGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGGTAG CCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:59) Construction S2-7A5-CD28T-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYCGRAGYYYIFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAQSVTSSSLAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRAFGQGTKVELKRAALDNEKSNGTIIHV KKGHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTRKHY QPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSL LTCDGVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCG ANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVC EAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITR STPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAF CR (SEQ ID NO:60) Construct S2-7A5-CD28T-41BB, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTTCTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTAGCTTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGGCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCCTTGATAATGAA AAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTG GCTTTTATAATCTTCTGGGTTCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTCA AACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGAG GAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGC AGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAG CGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATA ATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGG GGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCA CATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACA TGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGC CCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGG CCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTG GTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCG AGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGAT GATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCG GGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGT GTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGA GGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGG AGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGA GGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCT CACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCC GTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:61) Construction S2-7A5-CD28T-41BB, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYCGRAGYYYIFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAQSVTSSSLAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRAFGQGTKVELKRAALDNEKSNGTIIHV KKGHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRFSVVKRGRKKLLYIFKQPFMRPVQTTQE EDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRR KNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGE GRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGV AQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCE ACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPG RWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAVVVGL WAIAFKR (SEQ ID NO:62) Construct S2-7A5-C8K-CD28, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTTCTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTAGCTTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGGCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCTTCGTGCCTGT TTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGCACCAACTATCGCTTC CCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCCGTGCACACTAGAGGC CTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGGGGTACTGCTGCTGTC TCTGGTGATTACCCTCTACTGCAACCACAGAAACAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTA CATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAG ATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGC CAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAG AGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGC TGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAA GGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCA AGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGGG GACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCGA CTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTA CACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCTA ACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCTT GCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGCA GTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGTG TGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCAG ACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATAC CGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATGG ATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCCC CTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACAA CCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGGT CGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:63) Construction S2-7A5-C8K-CD28, amino acids (signal sequence is shown in bold; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYCGRAGYYYYFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAGQSVTSSSLAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRAFGQGTKVELKRAAAFVPVFLPAKPTT TPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRS KRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRRE EYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKD TYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEAC PTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSSMAPCVEA DDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCE DTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPV VTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:64) Structure S2-7A5-C8K-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACAGCTTCACCAGTTATGATATCAACTGGGTGCGACAGGCCACTGGACAAGGGCTTGA GTGGATGGGGTGGATGAACCCGAACAGTGGTAAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCA CCATGACCAGGGACACCTCCATAAGCACAGCCTACATGGAACTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGGGAGAGCCGGTTACTACTACTACTTCGGTATGGACGTCTGGGGCCAAGGGAC CACGGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGAA ATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAG GGCCGGTCAGAGTGTTACCAGCAGCTCCTTAGCTTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGC TCCTCATCTATCAGACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGG ACAGATTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATG GTGGCTCACGGGCGTTCGGCCAAGGGACCAAGGTGGAACTCAAACGAGCCGCTGCCTTCGTGCCTGT TTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGCACCAACTATCGCTTC CCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCCGTGCACACTAGAGGC CTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGGGGTACTGCTGCTGTC TCTGGTGATTACCCTCTACTGCAACCACAGAAACCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCT GCTGTACATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCT GCCGCTTTCCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGC ACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATG ACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCA GGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGG AGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTT ATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGG ATCTCTCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGG GCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGC CTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCG CACAACCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTG TCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGT GTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTG TGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAG TATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGC ACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGG AGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACC CAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGT CATGGGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCAT CTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:65) Конструкція S2-7A5-C8K-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYSFTSYDINWVRQATGQGLEW MGWMNPNSGNTGYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAVYYCGRAGYYYYFGMDVWGQGTTV TVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGERATLSCRAGQSVTSSSLAWYQQKPGQAPRLLIYQ TSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGGSRAFGQGTKVELKRAAAFVPVFLAKPTT TPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRNRFS VVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNL GRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLST ATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCDGVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGA KEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAP CVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPC TVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGS SQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:66) Construction S2-14C1-CD28T-CD28-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGA GTGGATGGGATGGATCAACCCTAATAGTGGTGGCACAAACTCTGCACAGAAGTTTCAGGGCAGGGTCA CCATGACCAGGGACACGTCCATCAGTACAGCCTACATGGAGCTGAACAGGCTGAGATCTGACGACACG GCCGTTTATTACTGTGCGAGAGGATGGCTACAGACGTACTACTTTGACAACTGGGGCCAGGGAACCCT GGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGACATC GTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCTACTGCAAGTC CAGCCAGACTGTTTTGACCAGCTCCAACAATAAGAACTTCTTAGCTTGGTACCAACAGAAACTAGGACA GCCTCCTAAGCTGCTCATTTCCTGGGCCTCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCA GCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAATTTATTACT GTCAGCACTATTATACTAGTCCACTCACTTTCGGCGGCGGGACCAAGGTGGAGATCAAACGAGCCGCT GCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCC TTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGAT TACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGA GATTTCGCTGCCTATCGGAGCCGCTTTTCCGTCGTTAAGCGGGGGAGAAAAAAGCTGCTGTACATTTTC AAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTCCTGCCGCTTTCCTGA GGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAG CAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAA GCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTAT AATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAG GGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC ACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTAC ATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGC CCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGG CCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTG GTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCG AGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGAT GATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCG GGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGT GTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGA GGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGG AGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGA GGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCT CACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCC GTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:67) Конструкція S2-14C1-CD28T-CD28-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEW MGWINPNSGGTNSAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARGWLQTYYFDNWGQGTLVT VSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATIYCKSSQTVLTSSNNKNFLAWYQQKLGQPPKL LISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQHYYTSPLTFGGGTKVEIKRAALDNEKSNG TIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTR KHYQPYAPPRDFAAYRSRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRS ADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGM KGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCDGVEENPGPMGAGATGR AMDGPRLLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSA TEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEE CPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPP EQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:68) Construct S2-14C1-CD28T-CD28, DNA (signal sequence shown in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGA GTGGATGGGATGGATCAACCCTAATAGTGGGCACAAACTCTGCACAGAAGTTTCAGGGCAGGGTCA CCATGACCAGGGACACGTCCATCAGTACAGCCTACATGGAGCTGAACAGGCTGAGATCTGACGACACCG GCCGTTTATTACTGTGCGAGAGGATGGCTACAGACGTACTACTTTGACAACTGGGGCCAGGGAACCCT GGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGACATC GTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCTACTGCAAGTC CAGCCAGACTGTTTTGACCAGCTCCAACAATAAGAACTTCTTAGCTTGGTACCAACAGAAACTAGGACA GCCTCCTAAGCTGCTCATTTCCTGGGCCTCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCA GCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAATTTATTACT GTCAGCACTATTATACTAGTCCACTCACTTTCGGCGGCGGGACCAAGGTGGAGATCAAACGAGCCGCT GCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCC TTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGAT TACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGA GATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGG CCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCA GAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAG CTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGC AAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTCTCCTTACATGTGG GGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTATGGATGGCCCGCG ACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTCCAACGGGCCTCT ACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAACCTTGTGGTGCT AACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCAGCCACCGAGCCT TGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGAAGCCGATGATGC AGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGGCCTGCCGGGTGT GTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGTGAGGAGTGTCCA GACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCGTCTGCGAGGATA CCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGAGGAGATCCCTGGGAGATG GATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGTACCCAAGAACCGGAGGCC CCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCATGGGATCCTCACA ACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAGCATCTTGGCAGCCGTGG TCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:69) Construction S2-14C1-CD28T-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEW MGWINPNSGGTNSAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARGWLQTYYFDNWGQGTLVT VSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATIYCKSSQTVLTSSNNKNFLAWYQQKLGQPPKL LISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQHYYTSPLTFGGGTKVEIKRAALDNEKSNG TIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLHSDYMNMTPRRPGPTR KHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRK NPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSGSGEG RGSLLTCDGVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLGEGVA QPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTGRCEA CRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECEEIPGR WITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAVVVGLV AYIAFKR (SEQ ID NO:70) Конструкція S2-14C1-CD28T-41BB, ДНК (сигнальна послідовність виділена жирним) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGA GTGGATGGGATGGATCAACCCTAATAGTGGTGGCACAAACTCTGCACAGAAGTTTCAGGGCAGGGTCA CCATGACCAGGGACACGTCCATCAGTACAGCCTACATGGAGCTGAACAGGCTGAGATCTGACGACACG GCCGTTTATTACTGTGCGAGAGGATGGCTACAGACGTACTACTTTGACAACTGGGGCCAGGGAACCCT GGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGACATC GTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCTACTGCAAGTC CAGCCAGACTGTTTTGACCAGCTCCAACAATAAGAACTTCTTAGCTTGGTACCAACAGAAACTAGGACA GCCTCCTAAGCTGCTCATTTCCTGGGCCTCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCA GCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAATTTATTACT GTCAGCACTATTATTACTAGTCCACTCACTTTCGGCGGCGGGACCAAGGTGGAGATCAAACGAGCCGCT GCCCTTGATAATGAAAGTCAAACGGAACAATCATTCACGTGAAGGCAAGCACCTCTGTCCGTCACCC TTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTGTTACTCT CTGCTCGTCACCGTGGCTTTTTATAATCTTCTGGGTTCGCTTTTCCGTCGTTAAGCGGGGAGAAAAAAG CTGCTGTACATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGAGGACGGCTGCTC CTGCCGCTTTCCTGAGGAGGAGGAGGCGGGTGCGAACTGAGGGTGAAGTTTTCCAGATCTGCAGAT GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTA TGACGTTTTGGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAAGACGAAAAAACCCCC AGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAG GAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATAC TTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGG GGATCTCTCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAA GGGCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAG GCCTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGT CGCACAACCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGT TGTCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCT GTGTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGG TGTGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACAC AGTATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGT GCACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCAGACGCTGAGTGCGA GGAGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCGAGT ACCCAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGAC AGTCATGGGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGATTCCTGTCTACTGTAG CATCTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:71) Construction S2-14C1-CD28T-41BB, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEW MGWINPNSGGTNSAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARGWLQTYYFDNWGQGTLVT VSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATIYCKSSQTVLTSSNNKNFLAWYQQKLGQPPKL LISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQHYYTSPLTFGGGTKVEIKRAALDNEKSNG TIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLACYSLLVTVAFIIFWVRFSVVKRGRKKLLYIFKQPFMRPVQ TTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGG KPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRAKRSG SGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAKEACPTGLYTHSGECCKACNLG EGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPCVEADDAVCRCAYGYYQDETTG RCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCTVCEDTERQLRECTRWADAECE EIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQPVVTRGTTDNLIPVYCSILAAV VVGLVAYIAFKR (SEQ ID NO:72) Construction S2-14C1-C8K-CD28, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGA GTGGATGGGATGGATCAACCCTAATAGTGGTGGCCACAAACTCTGCACAGAAGTTCAGGGCAGGGTCA CCATGACCAGGGACACGTCCATCAGTACAGCCTACATGGAGCTGAACAGGCTGAGATCTGACGACACG GCCGTTTATTACTGTGCGAGAGGATGGCTACAGACGTACTACTTTGACAACTGGGGCCAGGGAACCCT GGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGACATC GTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCTACTGCAAGTC CAGCCAGACTGTTTTGACCAGCTCCAACAATAAGAACTTCTTAGCTTGGTACCAACAGAAACTAGGACA GCCTCCTAAGCTGCTCATTTCCTGGGCCTCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCA GCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAATTTATTACT GTCAGCACTATTATACTAGTCCACTCACTTTCGGCGGCGGGACCAAGGTGGAGATCAAACGAGCCGCT GCCTTCGTGCCTGTTTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGC ACCAACTATCGCTTCCCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCC GTGCACACTAGAGGCCTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGG GGTACTGCTGCTGTCTCTGGTGATTACCCTCTACTGCAACCACAGAAACAGATCCAAAAGAAGCCGCCT GCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTA CGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAG CGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTT TTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGG GTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGC GGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGAC GCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGCGGGGAGGGCCGGGGATCTC TCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCGGCGCCACGGGAAGGGCTAT GGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGGAGGCGCTAAGGAGGCCTGTC CAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACCTTGGCGAGGGCGTCGCACAA CCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTGACATTCAGCGATGTTGTCTCA GCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCCATGTCCGCCCCCTGTGTCGA AGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGAAACTACCGGGCGGTGTGAGG CCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAGGATAAGCAAAACACAGTATGT GAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGACCCTTGCTTGCCGTGCACCG TCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGGCCTGGGCAGACGCTGAGTGCGAGGAGAT CCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACAGTACAGCCCCCGAGTACCCAA GAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCTGGCGTGGTGACGACAGTCAT GGGATCCTCACAACCAGTCGTGACGCGGGGCACCAACGACAATCTGATTCCTGTCTACTGTAGCATCTT GGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATGACCTAGGTAA (SEQ ID NO:73) Construction S2-14C1-C8K-CD28, amino acids (signal sequence highlighted in bold; CDR underlined) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEW MGWINPNSGGTNSAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARGWLQTYYFDNWGQGTLVT VSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATIYCKSSQTVLTSSNNKNFLAWYQQKLGQPPKL LISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQHYYTSPLTFGGGTKVEIKRAAAFVPVFLPA KPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHR NRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSRSADAPAYQQGQNQLYNELNLG RREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTA TKDTYDALHMQALPPRAKRSGSGEGRGSLLTCDGVEENPGPMGAGATGRAMDGPRLLLLLLGVSLGGAK EACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQSMSAPC VEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDPCLPCT VCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSS QPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:74) Structure S2-14C1-C8K-41BB, DNA (signal sequence highlighted in bold) ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCGCA GGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTGTCCTGCAAG GCTTCTGGATACACCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGA GTGGATGGGATGGATCAACCCTAATAGTGGTGGCACAAACTCTGCACAGAAGTTTCAGGGCAGGGTCA CCATGACCAGGGACACGTCCATCAGTACAGCCTACATGGAGCTGAACAGGCTGAGATCTGACGACACG GCCGTTTATTACTGTGCGAGAGGATGGCTACAGACGTACTACTTTGACAACTGGGGCCAGGGAACCCT GGTCACCGTATCCTCAGGAGGCGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGAAGTGACATC GTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATCTACTGCAAGTC CAGCCAGACTGTTTTGACCAGCTCCAACAATAAGAACTTCTTAGCTTGGTACCAACAGAAACTAGGACA GCCTCCTAAGCTGCTCATTTCCTGGGCCTCTACCCGGGAATCCGGGGTCCCTGACCGATTCAGTGGCA GCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAATTTATTACT GTCAGCACTATTATACTAGTCCACTCACTTTCGGCGGCGGGACCAAGGTGGAGATCAAACGAGCCGCT GCCTTCGTGCCTGTTTTTCTGCCCGCGAAACCCACAACTACCCCCGCCCCTCGGCCCCCAACTCCTGC ACCAACTATCGCTTCCCAACCCCTGTCTCTGAGACCTGAGGCATGCCGCCCCGCGGCAGGCGGCGCC GTGCACACTAGAGGCCTGGACTTCGCCTGCGATATTTATATCTGGGCCCCCCTTGCCGGGACATGCGG GGTACTGCTGCTGTCTCTGGTGATTACCCTCTACTGCAACCACAGAAACCGCTTTTCCGTCGTTAAGCG GGGGAGAAAAAAGCTGCTGTACATTTTCAAACAGCCGTTTATGAGGCCGGTCCAAACGACTCAGGAAGA GGACGGCTGCTCCTGCCGCTTTCCTGAGGAGGAGGAGGGCGGGTGCGAACTGAGGGTGAAGTTTTCC AGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACG CAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGA CGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAA ATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTG CTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGGGCCAAGAGAAGTGGCAGC GGGGAGGGCCGGGGATCTCTCCTTACATGTGGGGACGTGGAAGAAAATCCGGGGCCTATGGGTGCCG GCGCCACGGGAAGGGCTATGGATGGCCCGCGACTGCTTCTCCTGCTGTTGTTGGGCGTGTCTCTCGG AGGCGCTAAGGAGGCCTGTCCAACGGGCCTCTACACTCACTCCGGTGAATGTTGCAAAGCCTGTAACC TTGGCGAGGGCGTCGCACAACCTTGTGGTGCTAACCAGACAGTCTGTGAACCATGCCTGGATTCAGTG ACATTCAGCGATGTTGTCTCAGCCACCGAGCCTTGCAAGCCTTGTACCGAATGTGTGGGCCTTCAGTCC ATGTCCGCCCCCTGTGTCGAAGCCGATGATGCAGTGTGCAGATGTGCCTATGGATATTACCAGGACGA AACTACCGGGCGGTGTGAGGCCTGCCGGGTGTGTGAAGCCGGCTCTGGCCTCGTGTTCAGTTGCCAG GATAAGCAAAACACAGTATGTGAGGAGTGTCCAGACGGAACCTACAGCGACGAGGCGAACCACGTCGA CCCTTGCTTGCCGTGCACCGTCTGCGAGGATACCGAACGCCAGCTGAGAGAGTGTACGCGCTGGGCA GACGCTGAGTGCGAGGAGATCCCTGGGAGATGGATCACCCGGAGCACACCTCCTGAGGGATCAGACA GTACAGCCCCGAGTACCCAAGAACCGGAGGCCCCTCCAGAGCAGGACCTGATCGCTTCTACAGTTGCT GGCGTGGTGACGACAGTCATGGGATCCTCACAACCAGTCGTGACGCGGGGCACAACCGACAATCTGAT TCCTGTCTACTGTAGCATCTTGGCAGCCGTGGTCGTGGGCCTGGTAGCCTACATCGCCTTTAAGAGATG ACCTAGGTAA (SEQ ID NO:75) Конструкція S2-14C1-C8K-41BB, амінокислоти (сигнальна послідовність виділена жирним; CDR підкреслені) MALPVTALLLPLALLLHAARPQVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEW MGWINPNSGGTNSAQKFQGRVTMTRDTSISTAYMELNRLRSDDTAVYYCARGWLQTYYFDNWGQGTLVT VSSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATIYCKSSQTVLTSSNNKNFLAWYQQKLGQPPKL LISWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAIYYCQHYYTSPLTFGGGTKVEIKRAAAFVPVFLPA KPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHR NRFSVVKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYN ELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQ GLSTATKDTYDALHMQALPPRAKRSGSGEGRGSLLTCGDVEENPGPMGAGATGRAMDGPRLLLLLLGVS LGGAKEACPTGLYTHSGECCKACNLGEGVAQPCGANQTVCEPCLDSVTFSDVVSATEPCKPCTECVGLQS MSAPCVEADDAVCRCAYGYYQDETTGRCEACRVCEAGSGLVFSCQDKQNTVCEECPDGTYSDEANHVDP CLPCTVCEDTERQLRECTRWADAECEEIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTV MGSSQPVVTRGTTDNLIPVYCSILAAVVVGLVAYIAFKR (SEQ ID NO:76) STEAP1 NM_012449 human (NP_036581) amino acids MESRKDITNQEELWKMKPRRNLEEDDYLHKDTGETSMLKRPVLLHLHQTAHADEFDCPSELQHTQELF PQWHLPIKIAAIIASLTFLYTLLREVIHPLATSHQQYFYKIPILVINKVLPMVSITLLALVYLPGVIAAIVQLHNGTKY KKFPHWLDKWMLTRKQFGLLSFFFAVLHAIYSLSYPMRRSYRYKLLNWAYQQVQQNKEDAWIEHDVWRME IYVSLGIVGLAILALLAVTSIPSVSDSLTWREFHYIQSKLGIVSLLLGTIHALIFAWNKWIDIKQFVWYTPPTFMIA VFLPIVVLIFKSILFLPCLRKKILKIRHGWEDVTKINKTEICSQL (SEQ ID NO:77) Сигнальний пептид CAR, ДНК ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCCG (SEQ ID NO:78) Сигнальний пептид CAR: MALPVTALLLPLALLLHAARP (SEQ ID NO:79). scFv-лінкер G4S, ДНК GGCGGTGGAGGCTCCGGAGGGGGGGGCTCTGGCGGAGGGGGCTCC (SEQ ID NO:80) scFv-лінкер G4S: GGGGSGGGGSGGGGS (SEQ ID NO:81) scFv-лінкер Whitlow, ДНК GGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGG (SEQ ID NO:82) scFv-лінкер Whitlow: GSTSGSGKPGSGEGSTKG (SEQ ID NO:83). 4-1BB, nucleic acid sequence (intracellular domain) AAGCGCGGCAGGAAGAAGCTCCTCTACATTTTTAAGCAGCCTTTTATGAGGCCCGTACAGACAACA CAGGAGGAAGATGGCTGTAGCTGCAGATTTCCCGAGGAGGAGGAAGGTGGGTGCGAGCTG (SEQ ID NO:84) 4-1BB, amino acids (intracellular domain) KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL (SEQ ID NO:85) OX40, amino acids RRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI (SEQ ID NO:86) INCLUDING BY REFERENCE All publications, patents, and patent applications mentioned in this specification are hereby incorporated by reference. by reference to the same extent as if each individual publication, patent or application patent were specifically and individually identified for incorporation by reference. However The citation of a reference in this document should not be construed as an endorsement of what is The reference is prior art to the present invention. In the event that any of the definitions or terms presented in the referenced materials incorporated by reference, differs from terms and discussions presented in this document, the terms and definitions according to with this description. EQUIVALENTS The above written description is considered sufficient to enable a person skilled in the art to industry to carry out the present invention in practice. The above description and examples have been described in detail some preferred embodiments of the present invention and the best mode contemplated therein are described. by the authors of this invention. However, it should be borne in mind that no matter how detailed the above may appear in the text, the present invention may be carried out using many methods, and the present invention should be interpreted in accordance with the appended claims and any what are its equivalents. The following examples, including the experiments conducted and the results achieved, are provided for illustration purposes only. illustrative purposes and should not be construed as limiting the present invention. EXAMPLE 1 PNT-2, LNCaP, PC-3, 22Rv1, C4-2B and DU145 cell lines were cultured in RPMI1640 medium (Lonza) + 10% FBS (Corning) + 1X penicillin-streptomycin-L-glutamine (Corning) (R10) and maintained at cell densities from 0.5-2.0×106 cells / ml. PNT-2 and DU145 are cell lines for negative To investigate the expression of STEAP1 on the cell surface, cells were incubated with an antibody to STEAP1 (2F3) or isotype control antibody IgG1 (BD Pharmingen) in buffer for staining (BD Pharmingen) for 30 minutes at 4 °C. The cells were then incubated before data collection washed and resuspended in propidium iodide staining buffer (BD Pharmingen). STEAP1 expression on target cells is shown in FIGURE 1. EXAMPLE 2 Plasmids encoding the T7 promoter, the CAR construct, and the beta-globin stabilizing sequence, linearized by digesting 10 μg of DNA overnight with EcoRI and BamHI (NEB). Then, the DNA was digested for 2 hours at 50 °C with proteinase K (Thermo Fisher, 600 U / ml), purified with phenol / chloroform, and precipitated by adding sodium acetate and two volumes of ethanol. The cell pellets were then dried, resuspended in RNase / DNase-free water, and was counted using NanoDrop. One μg of linear DNA was then used for in vitro transcription using mMESSAGE mMACHINE T7 Ultra (Thermo Fisher) according to according to the manufacturer's instructions. RNA was further purified using the MEGAClear kit (Thermo Fisher) according to the manufacturer's instructions and quantified using NanoDrop. mRNA integrity assessed by agarose gel mobility. PBMCs were isolated from leukocytes of healthy donors (Hemacare) by Ficoll-pack density gradient centrifugation according to the instructions manufacturer. PBMCs were stimulated using OKT3 (50 ng / ml, Miltenyi Biotec) in R10+IL- 2 (300 IU / mL, Proleukin®, Prometheus®, Therapeutics and Diagnostics). Seven days after stimulation T cells were washed twice in Opti-MEM medium (Thermo Fisher Scientific) and resuspended to final concentration of 2.5×107 cells / ml in Opti-MEM medium. Electroporation was performed using ten μg of mRNA. Cell electroporation was performed using the Gemini X2 system (Harvard Apparatus BTX) to deliver a single pulse of 400 V for 0.5 ms in 2 mm cuvettes (Harvard Apparatus BTX). Cells were directly transferred to R10+IL-2 medium and left for recovery for 6 hours. To study the expression of CAR T cells, they were stained with LNGFR or biotinylated protein L (Thermo Scientific) in staining buffer (BD Pharmingen) for 30 minutes at 4 °C. The cells were then washed and stained with anti-LNGFR-PE or PE-streptavidin (BD Pharmingen) in staining buffer for 30 minutes at 4 °C. Then before data collection, cells were washed and resuspended in iodide staining buffer propidium (BD Pharmingen). Expression of T cells with CAR to STEAP1 in electroporated T cells shown in FIGURE 2. EXAMPLE 3 To study cytolytic activity in electroporated T cells with CAR to STEAP1 effector cells were cultured with target cells in an E:T ratio of 1:1, in in R10 medium. Sixteen hours after co-cultivation, the supernatants were analyzed by using Luminex (EMD Millipore) and target cell viability was assessed using the assay Propidium iodide (PI) uptake by CD3-negative cells by flow cytometry. The cytolytic activity of CAR-electroporated T cells is shown in FIGURE 3 and the production cytokines is shown in FIG. 4. EXAMPLE 4 To assess the proliferation of CAR-expressing T cells in response to target cells expressing STEAP1, T- cells were labeled with CFSE before co-cultivation with target cells in at a ratio of E:T of 1:1 in R10 medium. After five days, T-cell proliferation was assessed using CFSE dilution flow cytometry analysis. T- of cells with CAR to STEAP1 is shown in FIG. 5. LIST OF SEQUENCES <110> AMGEN INC. <120> CHIMERIC RECEPTORS FOR STEAP1 AND METHODS OF USE THEREOF <130> A-2280-WO-PCT <140> PCT / US2019 / 042245 <141> 17.07.2019 <150> 62 / 700,178 <151> 2018-07-18 <160> 147 <170> PatentIn version 3.5 <210> 1 <211> 294 <212> DNA <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28T" <400> 1 cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60 tcacccttgt tccctggtcc atccaagcca ttctgggtgt tggtcgtagt gggtggagtc 120 ctcgcttgtt actctctgct cgtcaccgtg gcttttataa tcttctgggt tagatccaaa 180 agaagccgcc tgctccatag cgattacatg aatatgactc cacgccgcccc tggccccaca 240 aggaaacact accagcctta cgcaccacct agagatttcg ctgcctatcg gagc 294 <210> 2 <211> 98 <212> White <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28T" <400> 2 Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys 1 5 10 15 His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp 20 25 30 Val Leu Val Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu Leu Val 35 40 45 Thr Val Ala Phe Ile Ile Phe Trp Val Arg Ser Lys Arg Ser Arg Leu 50 55 60 Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg Pro Gly Pro Thr 65 70 75 80 Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr 85 90 95 Arg Ser <210> 3 <211> 90 <212> DNA <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28T" <400> 3 cttgataatg aaaagtcaaa cggaacaatc attcacgtga agggcaagca cctctgtccg 60 tcacccttgt tccctggtcc atccaagcca 90 <210> 4 <211> 30 <212> White <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28T" <400> 4 Leu Asp Asn Glu Lys Ser Asn Gly Thr Ile Ile His Val Lys Gly Lys 1 5 10 15 His Leu Cys Pro Ser Pro Leu Phe Pro Gly Pro Ser Lys Pro 20 25 30 <210> 5 <211> 81 <212> DNA <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28" <400> 5 ttctgggtgt tggtcgtagt gggtggagtc ctcgcttgtt actctctgct cgtcaccgtg 60 gcttttataa tcttctgggt t 81 <210> 6 <211> 27 <212> White <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28" <400> 6 Phe Trp Val Leu Val Val Val Gly Gly Val Leu Ala Cys Tyr Ser Leu 1 5 10 15 Leu Val Thr Val Ala Phe Ile Ile Phe Trp Val 20 25 <210> 7 <211> 123 <212> DNA <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28" <400> 7 agatccaaaa gaagccgcct gctccatagc gattacatga atatgactcc acgccgccct 60 ggccccacaa ggaacacta ccagccttac gcaccaccta gagatttcgc tgcctatcgg 120 agc 123 <210> 8 <211> 41 <212> White <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28" <400> 8 Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr 1 5 10 15 Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro 20 25 30 Pro Arg Asp Phe Ala Ala Tyr Arg Ser 35 40 <210> 9 <211> 336 <212> DNA <213> Unknown <220> <221> source <223> / note="Description of the unknown: Sequence of CD3-zeta" <400> 9 agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg 60 tataacgagc tcaacctggg acgcagggaa gagtatgacg ttttggacaa gcgcagagga 120 cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat 180 gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg 240 agaaggggaa aagggcacga cggtttgtac cagggactca gcactgctac gaaggatact 300 tatgacgctc tccacatgca agccctgcca cctagg 336 <210> 10 <211> 112 <212> Білок <213> Невідомо <220> <221> source <223> / note="Description of the unknown: Sequence of CD3-zeta" <400> 10 Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly 1 5 10 15 Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr 20 25 30 Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys 35 40 45 Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys 50 55 60 Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg 65 70 75 80 Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala 85 90 95 Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg 100 105 110 <210> 11 <211> 117 <212> DNA <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28" <400> 11 attgaggtga tgtatccacc gccttacctg gataacgaaa agagtaacgg taccatcatt 60 cacgtgaaag gtaaacacct gtgtccttct cccctcttcc ccgggccatc aaagccc 117 <210> 12 <211> 39 <212> White <213> Unknown <220> <221> source <223> / note="Description of unknown: Sequence CD28" <400> 12 Ile Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn 1 5 10 15 Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu 20 25 30 Phe Pro Gly Pro Ser Lys Pro 35 <210> 13 <211> 288 <212> DNA <213> Unknown <220> <221> source <223> / note="Description of unknown: CD8 sequence" <400> 13 gctgcagcat tgagcaactc aataatgtat tttagtcact ttgtaccagt gttcttgccg 60 gctaagccta ctaccacacc cgctccacgg ccacctaccc cagctcctac catcgcttca 120 cagcctctgt ccctgcgccc agaggcttgc cgaccggccg caggggcgc tgttcatacc 180 agaggactgg atttcgcctg cgatatctat atctgggcac ccctggccgg aacctgcggc 240 gtactcctgc tgtccctggt catcacgctc tattgtaatc acaggaac 288 <210> 14 <211> 96 <212> White <213> Unknown <220> <221> source <223> / note="Description of unknown: CD8 sequence" <400> 14 Ala Ala Ala Leu Ser Asn Ser Ile Met Tyr Phe Ser His Phe Val Pro 1 5 10 15 Val Phe Leu Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro 20 25 30 Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu 35 40 45 Ala Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp 50 55 60 Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly 65 70 75 80 Val Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn 85 90 95 <210> 15 <211> 141 <212> DNA <213> Unknown <220> <221> source <223> / note="Unknown Description: Sequence 4-1BB" <400> 15 cgcttttccg tcgttaagcg ggggagaaaa aagctgctgt acattttcaa acagccgttt 60 atgaggccgg tccaaacgac tcaggagaag gacggctgct cctgccgctt tcctgaggag 120 gaggaggggcg ggtgcgaact g 141 <210> 16 <211> 47 <212> White <213> Unknown <220> <221> source <223> / note="Unknown Description: Sequence 4-1BB" <400> 16 Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe 1 5 10 15 Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly 20 25 30 Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu 35 40 45 <210> 17 <211> 2477 <212> DNA <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polynucleotide" <400> 17 atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60 ccgcaggtgc agctggtgca gagcggagcc gaggtgaaga agcccggagc cagcgtgaag 120 gtgagctgca aagccagcgg ctacaccttc tccacctact ggatcgagtg ggtgagacag 180 gccccggaca gaggctggaa tggatgggag agatcctgcc cggcagcggc aacaccgact 240 tcaacgagaa gttccagggc agagtgacct tcaccgccga taccagcagc gacaccgcct 300 acatggaact gagcagcctg agaagcgagg ataccgccgt ctactactgc accagatggg 360 gctactacgg caccaggggc tatttcaacg tgtggggcca gggaaccctc gtgaccgtga 420 gcagcggagg cggaggatct ggtggcggtg gttctggcgg cggaggctcc gagattgtgc 480 tgacccagag ccctgctaca ctgagcctga gccccggcga gagagccaca ctgagctgca 540 gagccagcag cagcgtgagc tacatgcact ggttccagca aaagcccggc caggccccta 600 ggctgctgat ctacagcaca tccaacctgg ccagcggcat ccctgccaga ttcagcggtt 660 ctggctccgg caccgactac accctgacca tctccagcct ggagcccgag gactttgccg 720 tgtattactg ccagcagagg aggagcttcc cctacacatt cggccagggc accaaactgg 780 agatcaaggc cgctgccctt gataatgaaa agtcaaacgg aacaatcatt cacgtgaagg 840 gcaagcacct ctgtccgtca cccttgttcc ctggtccatc caagccattc tgggtgttgg 900 tcgtagtggg tggagtcctc gcttgttact ctctgctcgt caccgtggct tttataatct 960 tctgggttag atccaaaaga agccgcctgc tccatagcga ttacatgaat atgactccac 1020 gccgccctgg ccccacaagg aaacactacc agccttacgc accacctaga gatttcgctg 1080 cctatcggag ccgcttttcc gtcgttaagc ggggagaaa aaagctgctg tacattttca 1140 aacagccgtt tatgaggccg gtccaaacga ctcaggaaga ggacggctgc tcctgccgct 1200 ttcctgagga ggagggggc gggtgcgaac tgagggtgaa gttttccaga tctgcagatg 1260 caccagcgta tcagcagggc cagaaccaac tgtataacga gctcaacctg ggacgcaggg 1320 aagagtatga cgttttggac aagcgcagag gacgggaccc tgagatgggt ggcaaaccaa 1380 gacgaaaaaa cccccgaggag ggtctctata atgagctgca gaaggataag atggctgaag 1440 cctattctga aataggcatg aaaggagagc ggagaagggg aaaagggcac gacggtttgt 1500 accagggact cagcactgct agaaggata cttatgacgc tctccacatg caagccctgc 1560 cacctagggc caagagaagt ggcagcgggg agggccgggg atctctcctt acatgtgggg 1620 acgtggaga aaatccgggg cctatgggtg ccggcgccac gggaagggct atggatggcc 1680 cgcgactgct tctcctgctg ttgttgggcg tgtctctcgg aggcgctaag gaggcctgtc 1740 caacgggcct ctacactcac tccggtgaat gttgcaaagc ctgtaacctt ggcgagggcg 1800 tcgcacaacc ttgtggtgct aaccagacag tctgtgaacc atgcctggat tcagtgacat 1860 tcagcgatgt tgtctcagcc accgagcctt gcaagccttg taccgaatgt gtgggccttc 1920 agtccatgtc cgccccctgt gtcgaagccg atgatgcagt gtgcagatgt gcctatggat 1980 attaccagga cgaaactacc gggcggtgtg aggcctgccg ggtgtgtgaa gccggctctg 2040 gcctcgtgtt cagttgccag gataagcaaa acacagtatg tgaggagtgt ccagacggaa 2100 cctacagcga cgaggcgaac cacgtcgacc cttgcttgcc gtgcaccgtc tgcgaggata 2160 ccgaacgcca gctgagagag tgtacgcgct gggcagacgc tgagtgcgag gagatccctg 2220 ggagatggat cacccggagc acacctcctg agggatcaga cagtacagcc ccgagtaccc 2280 aagaaccgga ggcccctcca gagcaggacc tgatcgcttc tacagttgct ggcgtggtga 2340 cgacagtcat gggatcctca caaccagtcg tgacgcgggg cacaaccgac aatctgattc 2400 ctgtctactg tagcatcttg gcagccgtgg tcgtgggcct ggtagcctac atcgccttta 2460 agagatgacc taggtaa 2477 <210> 18 <211> 822 <212> White <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polypeptide" <400> 18 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val 20 25 30 Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr 35 40 45 Thr Phe Ser Thr Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln 50 55 60 Arg Leu Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp 65 70 75 80 Phe Asn Glu Lys Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser 85 90 95 Ser Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr 100 105 110 Ala Val Tyr Tyr Cys Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr 115 120 125 Phe Asn Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 130 135 140 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val 145 150 155 160 Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala 165 170 175 Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Phe 180 185 190 Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ser Thr Ser 195 200 205 Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 210 215 220 Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala 225 230 235 240 Val Tyr Tyr Cys Gln Gln Arg Arg Ser Phe Pro Tyr Thr Phe Gly Gln 245 250 255 Gly Thr Lys Leu Glu Ile Lys Ala Ala Ala Leu Asp Asn Glu Lys Ser 260 265 270 Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro 275 280 285 Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly 290 295 300 Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile 305 310 315 320 Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met 325 330 335 Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro 340 345 350 Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Phe Ser Val 355 360 365 Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe 370 375 380 Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg 385 390 395 400 Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe Ser 405 410 415 Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr 420 425 430 Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys 435 440 445 Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn 450 455 460 Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu 465 470 475 480 Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly 485 490 495 His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr 500 505 510 Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Ala Lys Arg Ser Gly 515 520 525 Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu 530 535 540 Asn Pro Gly Pro Met Gly Ala Gly Ala Thr Gly Arg Ala Met Asp Gly 545 550 555 560 Pro Arg Leu Leu Leu Leu Leu Leu Leu Gly Val Ser Leu Gly Gly Ala 565 570 575 Lys Glu Ala Cys Pro Thr Gly Leu Tyr Thr His Ser Gly Glu Cys Cys 580 585 590 Lys Ala Cys Asn Leu Gly Glu Gly Val Ala Gln Pro Cys Gly Ala Asn 595 600 605 Gln Thr Val Cys Glu Pro Cys Leu Asp Ser Val Thr Phe Ser Asp Val 610 615 620 Val Ser Ala Thr Glu Pro Cys Lys Pro Cys Thr Glu Cys Val Gly Leu 625 630 635 640 Gln Ser Met Ser Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg 645 650 655 Cys Ala Tyr Gly Tyr Tyr Gln Asp Glu Thr Thr Gly Arg Cys Glu Ala 660 665 670 Cys Arg Val Cys Glu Ala Gly Ser Gly Leu Val Phe Ser Cys Gln Asp 675 680 685 Lys Gln Asn Thr Val Cys Glu Glu Cys Pro Asp Gly Thr Tyr Ser Asp 690 695 700 Glu Ala Asn His Val Asp Pro Cys Leu Pro Cys Thr Val Cys Glu Asp 705 710 715 720 Thr Glu Arg Gln Leu Arg Glu Cys Thr Arg Trp Ala Asp Ala Glu Cys 725 730 735 Glu Glu Ile Pro Gly Arg Trp Ile Thr Arg Ser Thr Pro Pro Glu Gly 740 745 750 Ser Asp Ser Thr Ala Pro Ser Thr Gln Glu Pro Glu Ala Pro Pro Glu 755 760 765 Gln Asp Leu Ile Ala Ser Thr Val Ala Gly Val Val Thr Thr Val Met 770 775 780 Gly Ser Ser Gln Pro Val Val Thr Arg Gly Thr Thr Asp Asn Leu Ile 785 790 795 800 Pro Val Tyr Cys Ser Ile Leu Ala Ala Val Val Val Gly Leu Val Ala 805 810 815 Tyr Ile Ala Phe Lys Arg 820 <210> 19 <211> 2337 <212> DNA <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polynucleotide" <400> 19 atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60 ccgcaggtgc agctggtgca gagcggagcc gaggtgaaga agcccggagc cagcgtgaag 120 gtgagctgca aagccagcgg ctacaccttc tccacctact ggatcgagtg ggtgagacag 180 gcccccggac agaggctgga atggatggga gagatcctgc ccggcagcgg caacaccgac 240 ttcaacgaga agttccaggg cagagtgacc ttcaccgccg ataccagcag cgacaccgcc 300 tacatggaac tgagcagcct gagaagcgag gataccgccg tctactactg caccagatgg 360 ggctactacg gcaccagggg ctatttcaac gtgtggggcc agggaaccct cgtgaccgtg 420 agcagcggag gcggaggatc tggtggcggt ggttctggcg gcggaggctc cgagattgtg 480 ctgacccaga gccctgctac actgagcctg agccccggcg agagagccac actgagctgc 540 agagccagca gcagcgtgag ctacatgcac tggttccagc aaaagcccgg ccaggcccct 600 aggctgctga tctacagcac atccaacctg gccagcggca tccctgccag attcagcggt 660 tctggctccg gcaccgacta caccctgacc atctccagcc tggagcccga ggactttgcc 720 gtgtattact gccagcagag gaggagcttc ccctacacat tcggccaggg caccaaactg 780 gagatcaagg ccgctgccct tgataatgaa aagtcaaacg gaaatcat tcacgtgaag 840 ggcaagcacc tctgtccgtc acccttgttc cctggtccat ccaagccatt ctgggtgttg 900 gtcgtagtgg gtggagtcct cgcttgttac tctctgctcg tcaccgtggc ttttataatc 960 ttctgggtta gatccaaaag aagccgcctg ctccatagcg attacatgaa tatgactcca 1020 cgccgccctg gccccacaag gaaacactac cagccttacg caccacctag agatttcgct 1080 gcctatcgga gcagggtgaa gttttccaga tctgcagatg caccagcgta tcagcagggc 1140 cagaaccaac tgtataacga gctcaacctg ggacgcaggg aagagtatga cgttttggac 1200 aagcgcagag gacgggaccc tgagatgggt ggcaaaccaa gacgaaaaaa ccccaggag 1260 ggtctctata atgagctgca gaaggataag atggctgaag cctattctga aataggcatg 1320 aaaggagagc ggagaagggg aaaagggcac gacggtttgt accagggact cagcactgct 1380 acgaaggata cttatgacgc tctccacatg caagccctgc cacctagggc caagagaagt 1440 ggcagggggg agggccgggg atctctcctt acatgtgggg acgtggaga aaatccgggg 1500 cctatgggtg ccggcgccac gggaagggct atggatggcc cgcgactgct tctctgctg 1560 ttgttgggcg tgtctctcgg aggcgctaag gaggcctgtc caacgggcct ctacactcac 1620 tccggtgaat gttgcaaagc ctgtaacctt ggcgagggcg tcgcacaacc ttgtggtgct 1680 aaccagacag tctgtgaacc atgcctggat tcagtgacat tcagcgatgt tgtctcagcc 1740 accgagcctt gcaagccttg taccgaatgt gtgggccttc agtccatgtc cgccccctgt 1800 gtcgaagccg atgatgcagt gtgcagatgt gcctatggat attaccagga cgaaactacc 1860 gggcggtgtg aggcctgccg ggtgtgtgaa gccggctctg gcctcgtgtt cagttgccag 1920 gataagcaaa acacagtatg tgaggagtgt ccagacggaa cctacagcga cgaggcgaac 1980 cacgtcgacc cttgcttgcc gtgcaccgtc tgcgaggata ccgaacgcca gctgagagag 2040 tgtacgcgct gggcagacgc tgagtgcgag gagatccctg ggagatggat cacccggagc 2100 acacctcctg agggatcaga cagtacagcc ccgagtaccc aagaaccgga ggcccctcca 2160 gagcaggacc tgatcgcttc tacagttgct ggcgtggtga cgacagtcat gggatcctca 2220 caaccagtcg tgacgcgggg caacaccgac aatctgattc ctgtctactg tagcatcttg 2280 gcagccgtgg tcgtgggcct ggtagcctac atcgccttta agagatgacc taggtaa 2337 <210> 20 <211> 775 <212> White <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polypeptide" <400> 20 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val 20 25 30 Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr 35 40 45 Thr Phe Ser Thr Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln 50 55 60 Arg Leu Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp 65 70 75 80 Phe Asn Glu Lys Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser 85 90 95 Ser Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr 100 105 110 Ala Val Tyr Tyr Cys Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr 115 120 125 Phe Asn Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 130 135 140 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val 145 150 155 160 Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala 165 170 175 Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Phe 180 185 190 Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ser Thr Ser 195 200 205 Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 210 215 220 Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala 225 230 235 240 Val Tyr Tyr Cys Gln Gln Arg Arg Ser Phe Pro Tyr Thr Phe Gly Gln 245 250 255 Gly Thr Lys Leu Glu Ile Lys Ala Ala Ala Leu Asp Asn Glu Lys Ser 260 265 270 Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro 275 280 285 Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly 290 295 300 Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile 305 310 315 320 Phe Trp Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met 325 330 335 Asn Met Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro 340 345 350 Tyr Ala Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe 355 360 365 Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu 370 375 380 Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp 385 390 395 400 Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys 405 410 415 Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala 420 425 430 Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys 435 440 445 Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr 450 455 460 Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Ala Lys Arg Ser 465 470 475 480 Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu 485 490 495 Glu Asn Pro Gly Pro Met Gly Ala Gly Ala Thr Gly Arg Ala Met Asp 500 505 510 Gly Pro Arg Leu Leu Leu Leu Leu Leu Leu Gly Val Ser Leu Gly Gly 515 520 525 Ala Lys Glu Ala Cys Pro Thr Gly Leu Tyr Thr His Ser Gly Glu Cys 530 535 540 Cys Lys Ala Cys Asn Leu Gly Glu Gly Val Ala Gln Pro Cys Gly Ala 545 550 555 560 Asn Gln Thr Val Cys Glu Pro Cys Leu Asp Ser Val Thr Phe Ser Asp 565 570 575 Val Val Ser Ala Thr Glu Pro Cys Lys Pro Cys Thr Glu Cys Val Gly 580 585 590 Leu Gln Ser Met Ser Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys 595 600 605 Arg Cys Ala Tyr Gly Tyr Tyr Gln Asp Glu Thr Thr Gly Arg Cys Glu 610 615 620 Ala Cys Arg Val Cys Glu Ala Gly Ser Gly Leu Val Phe Ser Cys Gln 625 630 635 640 Asp Lys Gln Asn Thr Val Cys Glu Glu Cys Pro Asp Gly Thr Tyr Ser 645 650 655 Asp Glu Ala Asn His Val Asp Pro Cys Leu Pro Cys Thr Val Cys Glu 660 665 670 Asp Thr Glu Arg Gln Leu Arg Glu Cys Thr Arg Trp Ala Asp Ala Glu 675 680 685 Cys Glu Glu Ile Pro Gly Arg Trp Ile Thr Arg Ser Thr Pro Pro Glu 690 695 700 Gly Ser Asp Ser Thr Ala Pro Ser Thr Gln Glu Pro Glu Ala Pro Pro 705 710 715 720 Glu Gln Asp Leu Ile Ala Ser Thr Val Ala Gly Val Val Thr Thr Val 725 730 735 Met Gly Ser Ser Gln Pro Val Val Thr Arg Gly Thr Thr Asp Asn Leu 740 745 750 Ile Pro Val Tyr Cys Ser Ile Leu Ala Ala Val Val Val Gly Leu Val 755 760 765 Ala Tyr Ile Ala Phe Lys Arg 770 775 <210> 21 <211> 2355 <212> DNA <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polynucleotide" <400> 21 atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60 ccgcaggtgc agctggtgca gagcggagcc gaggtgaaga agcccggagc cagcgtgaag 120 gtgagctgca aagccagcgg ctacaccttc tccacctact ggatcgagtg ggtgagacag 180 gcccccggac agaggctgga atggatggga gagatcctgc ccggcagcgg caacaccgac 240 ttcaacgaga agttccaggg cagagtgacc ttcaccgccg ataccagcag cgacaccgcc 300 tacatggaac tgagcagcct gagaagcgag gataccgccg tctactactg caccagatgg 360 ggctactacg gcaccagggg ctatttcaac gtgtggggcc agggaaccct cgtgaccgtg 420 agcagcggag gcggaggatc tggtggcggt ggttctggcg gcggaggctc cgagattgtg 480 ctgacccaga gccctgctac actgagcctg agccccggcg agagagccac actgagctgc 540 agagccagca gcagcgtgag ctacatgcac tggttccagc aaaagcccgg ccaggcccct 600 aggctgctga tctacagcac atccaacctg gccagcggca tccctgccag attcagcggt 660 tctggctccg gcaccgacta caccctgacc atctccagcc tggagcccga ggactttgcc 720 gtgtattact gccagcagag gaggagcttc ccctacacat tcggccaggg caccaaactg 780 gagatcaagg ccgctgccct tgataatgaa aagtcaaacg gaacaatcat tcacgtgaag 840 ggcaagcacc tctgtccgtc acccttgttc cctggtccat ccaagccatt ctgggtgttg 900 gtcgtagtgg gtggagtcct cgcttgttac tctctgctcg tcaccgtggc ttttataatc 960 ttctgggttc gcttttccgt cgttaagcgg gggagaaaaa agctgctgta cattttcaaa cagccgttta tgaggccggt ccaaacgact caggagagg acggctgctc ctgccgcttt cctgaggagg aggagggcgg gtgcgaactg agggtgaagt tttccagatc tgcagatgca 1140 ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcaggga gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg agaagggga aagggcacga cggtttgtac caggactca gcactgctac gaggatact tatgacgctc tccacatgca agccctgcca cctagggcca agagaagtgg cagcggggag ggccggggat ctctccttac atgtggggac 1500. gtggaagaaa atccggggcc tatgggtgcc ggcgccacgg gaagggctat ggatggcccg cgactgcttc tcctgctgtt gttgggcgtg tctctcggag gcgctaagga ggcctgtcca 1620 acgggcctct acactcactc cggtgaatgt tgcaaagcct gtaaccttgg cgagggcgtc 1680 gcacaacctt gtggtgctaa ccagacagtc tgtgaaccat gcctggattc agtgacattc 1740 agcgatgttg tctcagccac cgagccttgc aagccttgta ccgaatgtgt gggccttcag 1800 tccatgtccg ccccctgtgt cgaagccgat gatgcagtgt gcagatgtgc ctatggatat 1860 taccaggacg aaactaccgg gcggtgtgag gcctgccggg tgtgtgaagc cggctctggc 1920 ctcgtgttca gttgccagga taagcaaaac acagtatgtg aggagtgtcc agacggaacc 1980 tacagcgacg aggcgaacca cgtcgaccct tgcttgccgt gcaccgtctg cgaggatacc 2040 gaacgccagc tgagagagtg tacgcgctgg gcagacgctg agtgcgagga gatccctggg 2100 agatggatca cccggagcac acctcctgag ggatcagaca gtacagcccc gagtacccaa 2160 gaaccggagg cccctccaga gcaggacctg atcgcttcta cagttgctgg cgtggtgacg 2220 acagtcatgg gatcctcaca accagtcgtg acgcggggca caaccgacaa tctgattcct 2280 gtctactgta gcatcttggc agccgtggtc gtgggcctgg tagcctacat cgcctttaag 2340 agatgaccta ggtaa 2355 <210> 22 <211> 781 <212> White <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polypeptide" <400> 22 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val 20 25 30 Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr 35 40 45 Thr Phe Ser Thr Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln 50 55 60 Arg Leu Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp 65 70 75 80 Phe Asn Glu Lys Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser 85 90 95 Ser Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr 100 105 110 Ala Val Tyr Tyr Cys Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr 115 120 125 Phe Asn Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 130 135 140 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val 145 150 155 160 Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala 165 170 175 Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Phe 180 185 190 Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ser Thr Ser 195 200 205 Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 210 215 220 Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala 225 230 235 240 Val Tyr Tyr Cys Gln Gln Arg Arg Ser Phe Pro Tyr Thr Phe Gly Gln 245 250 255 Gly Thr Lys Leu Glu Ile Lys Ala Ala Ala Leu Asp Asn Glu Lys Ser 260 265 270 Asn Gly Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro 275 280 285 Leu Phe Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly 290 295 300 Gly Val Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile 305 310 315 320 Phe Trp Val Arg Phe Ser Val Val Lys Arg Gly Arg Lys Lys Leu Leu 325 330 335 Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu 340 345 350 Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys 355 360 365 Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln 370 375 380 Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu 385 390 395 400 Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly 405 410 415 Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu 420 425 430 Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly 435 440 445 Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser 450 455 460 Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro 465 470 475 480 Pro Arg Ala Lys Arg Ser Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu 485 490 495 Thr Cys Gly Asp Val Glu Glu Asn Pro Gly Pro Met Gly Ala Gly Ala 500 505 510 Thr Gly Arg Ala Met Asp Gly Pro Arg Leu Leu Leu Leu Leu Leu Leu 515 520 525 Gly Val Ser Leu Gly Gly Ala Lys Glu Ala Cys Pro Thr Gly Leu Tyr 530 535 540 Thr His Ser Gly Glu Cys Cys Lys Ala Cys Asn Leu Gly Glu Gly Val 545 550 555 560 Ala Gln Pro Cys Gly Ala Asn Gln Thr Val Cys Glu Pro Cys Leu Asp 565 570 575 Ser Val Thr Phe Ser Asp Val Val Ser Ala Thr Glu Pro Cys Lys Pro 580 585 590 Cys Thr Glu Cys Val Gly Leu Gln Ser Met Ser Ala Pro Cys Val Glu 595 600 605 Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr Gly Tyr Tyr Gln Asp Glu 610 615 620 Thr Thr Gly Arg Cys Glu Ala Cys Arg Val Cys Glu Ala Gly Ser Gly 625 630 635 640 Leu Val Phe Ser Cys Gln Asp Lys Gln Asn Thr Val Cys Glu Glu Cys 645 650 655 Pro Asp Gly Thr Tyr Ser Asp Glu Ala Asn His Val Asp Pro Cys Leu 660 665 670 Pro Cys Thr Val Cys Glu Asp Thr Glu Arg Gln Leu Arg Glu Cys Thr 675 680 685 Arg Trp Ala Asp Ala Glu Cys Glu Glu Ile Pro Gly Arg Trp Ile Thr 690 695 700 Arg Ser Thr Pro Pro Glu Gly Ser Asp Ser Thr Ala Pro Ser Thr Gln 705 710 715 720 Glu Pro Glu Ala Pro Pro Glu Gln Asp Leu Ile Ala Ser Thr Val Ala 725 730 735 Gly Val Val Thr Thr Val Met Gly Ser Ser Gln Pro Val Val Thr Arg 740 745 750 Gly Thr Thr Asp Asn Leu Ile Pro Val Tyr Cys Ser Ile Leu Ala Ala 755 760 765 Val Val Val Gly Leu Val Ala Tyr Ile Ala Phe Lys Arg 770 775 780 <210> 23 <211> 2415 <212> DNA <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polynucleotide" <400> 23 atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60 ccgcaggtgc agctggtgca gagcggagcc gaggtgaaga agcccggagc cagcgtgaag 120 gtgagctgca aagccagcgg ctacaccttc tccacctact ggatcgagtg ggtgagacag 180 gccccccggac agaggctgga atggatggga gagatcctgc ccggcagcgg caacaccgac 240 ttcaacgaga agttccaggg cagagtgacc ttcaccgccg ataccagcag cgacaccgcc 300 tacatggaac tgagcagcct gagaagcgag gataccgccg tctactactg caccagatgg 360 ggctactacg gcaccagggg ctatttcaac gtgtggggcc agggaaccct cgtgaccgtg 420 agcagcggag gcggaggatc tggtggcggt ggttctggcg gcggaggctc cgagattgtg 480 ctgacccaga gccctgctac actgagcctg agccccggcg agagagccac actgagctgc 540 agagccagca gcagcgtgag ctacatgcac tggttccagc aaaagcccgg ccaggcccct 600 aggctgctga tctacagcac atccaacctg gccagcggca tccctgccag attcagcggt 660 tctggctccg gcaccgacta caccctgacc atctccagcc tggagcccga ggactttgcc 720 gtgtattact gccagcagag gaggagcttc ccctacacat tcggccaggg caccaaactg 780 gagatcaagg ccgctgcctt cgtgcctgtt tttctgcccg cgaaacccac aactaccccc 840 gcccctcggc ccccaactcc tgcaccaact atcgcttccc aacccctgtc tctgagacct 900 gaggcatgcc gccccgcggc aggcggcgcc gtgcacacta gaggcctgga cttcgcctgc 960 gatatttata tctgggcccc ccttgccgggg acatgcgggg tactgctgct gtctctggtg attaccctct actgcaacca cagaacaga tccaaaaga gccgcctgct ccatagcgat 1140. tgactccacg ccgccctggc cccacaagga aacactacca gccttacgca ccacctagg atttcgctgc ctatcggagc agggtgaagt tttccagatc tgcagatgca ccagcgtatc agcagggcca gaaccaactg tataacgagc tcaacctggg acgcaggga gagtatgacg ttttggacaa gcgcagagga cgggaccctg agatgggtgg caaaccaaga cgaaaaaacc cccaggaggg tctctataat gagctgcaga aggataagat ggctgaagcc tattctgaaa taggcatgaa aggagagcgg agaagggga aagggcacga cggtttgtac caggactca gcactgctac gaggatact tatgacgctc tccacatgca agccctgcca cctagggcca agagaagtgg cagcggggag ggccggggat ctctccttac atgtggggac 1560 gtggaagaaa atccggggcc tatgggtgcc ggcgccacgg gaagggctat ggatggcccg cgactgcttc tcctgctgtt gttgggcgtg tctctcggag gcgctaagga ggcctgtcca 1680 acgggcctct acactcactc cggtgaatgt tgcaaagcct gtaaccttgg cgagggcgtc 1740 gcacaacctt gtggtgctaa ccagacagtc tgtgaaccat gcctggattc agtgacattc 1800 agcgatgttg tctcagccac cgagccttgc aagccttgta ccgaatgtgt gggccttcag 1860 tccatgtccg ccccctgtgt cgaagccgat gatgcagtgt gcagatgtgc ctatggatat 1920 taccaggacg aaactaccgg gcggtgtgag gcctgccggg tgtgtgaagc cggctctggc 1980 ctcgtgttca gttgccagga taagcaaaac acagtatgtg aggagtgtcc agacggaacc 2040 tacagcgacg aggcgaacca cgtcgaccct tgcttgccgt gcaccgtctg cgaggatacc 2100 gaacgccagc tgagagagtg tacgcgctgg gcagacgctg agtgcgagga gatccctggg 2160 agatggatca cccggagcac acctcctgag ggatcagaca gtacagcccc gagtacccaa 2220 gaaccggagg cccctccaga gcaggacctg atcgcttcta cagttgctgg cgtggtgacg 2280 acagtcatgg gatcctcaca accagtcgtg acgcggggca caaccgacaa tctgattcct 2340 gtctactgta gcatcttggc agccgtggtc gtgggcctgg tagcctacat cgcctttaag 2400 agatgaccta ggtaa 2415 <210> 24 <211> 801 <212> White <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polypeptide" <400> 24 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val 20 25 30 Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr 35 40 45 Thr Phe Ser Thr Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln 50 55 60 Arg Leu Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp 65 70 75 80 Phe Asn Glu Lys Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser 85 90 95 Ser Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr 100 105 110 Ala Val Tyr Tyr Cys Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr 115 120 125 Phe Asn Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 130 135 140 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val 145 150 155 160 Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala 165 170 175 Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Phe 180 185 190 Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ser Thr Ser 195 200 205 Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 210 215 220 Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala 225 230 235 240 Val Tyr Tyr Cys Gln Gln Arg Arg Ser Phe Pro Tyr Thr Phe Gly Gln 245 250 255 Gly Thr Lys Leu Glu Ile Lys Ala Ala Ala Phe Val Pro Val Phe Leu 260 265 270 Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala 275 280 285 Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg 290 295 300 Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys 305 310 315 320 Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu 325 330 335 Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Ser Lys 340 345 350 Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met Thr Pro Arg Arg 355 360 365 Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala Pro Pro Arg Asp 370 375 380 Phe Ala Ala Tyr Arg Ser Arg Val Lys Phe Ser Arg Ser Ala Asp Ala 385 390 395 400 Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu 405 410 415 Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp 420 425 430 Pro Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu 435 440 445 Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile 450 455 460 Gly Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr 465 470 475 480 Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met 485 490 495 Gln Ala Leu Pro Pro Arg Ala Lys Arg Ser Gly Ser Gly Glu Gly Arg 500 505 510 Gly Ser Leu Leu Thr Cys Gly Asp Val Glu Glu Asn Pro Gly Pro Met 515 520 525 Gly Ala Gly Ala Thr Gly Arg Ala Met Asp Gly Pro Arg Leu Leu Leu 530 535 540 Leu Leu Leu Leu Gly Val Ser Leu Gly Gly Ala Lys Glu Ala Cys Pro 545 550 555 560 Thr Gly Leu Tyr Thr His Ser Gly Glu Cys Cys Lys Ala Cys Asn Leu 565 570 575 Gly Glu Gly Val Ala Gln Pro Cys Gly Ala Asn Gln Thr Val Cys Glu 580 585 590 Pro Cys Leu Asp Ser Val Thr Phe Ser Asp Val Val Ser Ala Thr Glu 595 600 605 Pro Cys Lys Pro Cys Thr Glu Cys Val Gly Leu Gln Ser Met Ser Ala 610 615 620 Pro Cys Val Glu Ala Asp Asp Ala Val Cys Arg Cys Ala Tyr Gly Tyr 625 630 635 640 Tyr Gln Asp Glu Thr Thr Gly Arg Cys Glu Ala Cys Arg Val Cys Glu 645 650 655 Ala Gly Ser Gly Leu Val Phe Ser Cys Gln Asp Lys Gln Asn Thr Val 660 665 670 Cys Glu Glu Cys Pro Asp Gly Thr Tyr Ser Asp Glu Ala Asn His Val 675 680 685 Asp Pro Cys Leu Pro Cys Thr Val Cys Glu Asp Thr Glu Arg Gln Leu 690 695 700 Arg Glu Cys Thr Arg Trp Ala Asp Ala Glu Cys Glu Glu Ile Pro Gly 705 710 715 720 Arg Trp Ile Thr Arg Ser Thr Pro Pro Glu Gly Ser Asp Ser Thr Ala 725 730 735 Pro Ser Thr Gln Glu Pro Glu Ala Pro Pro Glu Gln Asp Leu Ile Ala 740 745 750 Ser Thr Val Ala Gly Val Val Thr Thr Val Met Gly Ser Ser Gln Pro 755 760 765 Val Val Thr Arg Gly Thr Thr Asp Asn Leu Ile Pro Val Tyr Cys Ser 770 775 780 Ile Leu Ala Ala Val Val Val Gly Leu Val Ala Tyr Ile Ala Phe Lys 785 790 795 800 Arg <210> 25 <211> 2433 <212> DNA <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polynucleotide" <400> 25 atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60 ccgcaggtgc agctggtgca gagcggagcc gaggtgaaga agcccggagc cagcgtgaag 120 gtgagctgca aagccagcgg ctacaccttc tccacctact ggatcgagtg ggtgagacag 180 gcccccggac agaggctgga atggatggga gagatcctgc ccggcagcgg caacaccgac 240 ttcaacgaga agttccaggg cagagtgacc ttcaccgccg ataccagcag cgacaccgcc 300 tacatggaac tgagcagcct gagaagcgag gataccgccg tctactactg caccagatgg 360 ggctactacg gcaccagggg ctatttcaac gtgtggggcc agggaaccct cgtgaccgtg 420 agcagcggag gcggaggatc tggtggcggt ggttctggcg gcggaggctc cgagattgtg 480 ctgacccaga gccctgctac actgagcctg agccccggcg agagagccac actgagctgc 540 agagccagca gcagcgtgag ctacatgcac tggttccagc aaaagcccgg ccaggcccct 600 aggctgctga tctacagcac atccaacctg gccagcggca tccctgccag attcagcggt 660 tctggctccg gcaccgacta caccctgacc atctccagcc tggagcccga ggactttgcc 720 gtgtattact gccagcagag gaggagcttc ccctacacat tcggccaggg caccaaactg 780 gagatcaagg ccgctgcctt cgtgcctgtt tttctgcccg cgaaacccac aactaccccc 840 gccctcggc ccccaactcc tgcaccaact atcgcttccc aacccctgtc tctgagacct 900 gaggcatgcc gccccgcggc aggcggcgcc gtgcacacta gaggcctgga cttcgcctgc 960 gatattata tctgggcccc cttgccggg acatgcgggg tactgctgct gtctctggtg 1020 attaccctct actgcaacca cagaaaccgc ttttccgtcg ttaagcgggg gagaaaaaag 1080 ctgctgtaca ttttcaaaca gccgttatg aggccggtcc aaacgactca ggaagaggac 1140 ggctgctcct gccgctttcc tgaggaggag gagggcgggt gcgaactgag ggtgaagtttt 1200 tccagatctg cagatgcacc agcgtatcag cagggccaga accaactgta taacgagctc 1260 aacctgggac gcagggaaga gtatgacgtt ttggacaagc gcagaggacg ggaccctgag 1320 atgggtggca aaccaagacg aaaaacccc caggagggtc tctataatga gctgcagaag 1380 gataagatgg ctgaagccta ttctgaaata ggcatgaaag gagagcggag aaggggaaaa 1440 gggcacgacg gtttgtacca gggactcagc actgctacga aggatactta tgacgctctc 1500 cacatgcaag ccctgccacc tagggccaag agaagtggca gcggggaggg ccggggatct 1560 ctccttacat gtggggacgt ggaagaaaat ccggggccta tgggtgccgg cgccacggga 1620. agggctatgg atggcccgcg actgcttctc ctgctgttgt tgggcgtgtc tctcggaggc 1680 gctaaggagg cctgtccaac gggcctctac actcactccg gtgaatgttg caaagcctgt aaccttggcg agggcgtcgc acaaccttgt ggtgctaacc agacagtctg tgaaccatgc ctggattcag tgacattcag cgatgttgtc tcagccaccg agccttgcaa gccttgtacc gaatgtgtgg gccttcagtc catgtccgcc ccctgtgtcg aagccgatga tgcagtgtgc agatgtgcct atggatatta ccaggacgaa actaccggggc ggtgtgaggc ctgccgggtg tgtgaagccg gctctggcct cgtgttcagt tgccaggata agcaaaacac agtatgtgag gagtgtccag acggaaccta cagcgacgag gcgaaccacg tcgacccttg cttgccgtgc accgtctgcg aggataccga acgccagctg aggagtgta cgcgctgggc aggacgctgag 2160 tgcgaggaga tccctgggag atggatcacc cggagcacac ctcctgaggg atcagacagt acagccccga gtacccaaga accggaggcc cctccagagc aggacctgat cgcttctaca 2280 gttgctggcg tggtgacgac agtcatggga tcctcacaac cagtcgtgac gcggggcaca 2340 accgacaatc tgattcctgt ctactgtagc atcttggcag ccgtggtcgt gggcctggta 2400 gcctacatcg cctttaagag atgacctagg taa 2433 <210> 26 <211> 807 <212> White <213> Artificial sequence <220> <221> source <223> / note="Artificial sequence description: Synthetic polypeptide" <400> 26 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val 20 25 30 Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr 35 40 45 Thr Phe Ser Thr Tyr Trp Ile Glu Trp Val Arg Gln Ala Pro Gly Gln 50 55 60 Arg Leu Glu Trp Met Gly Glu Ile Leu Pro Gly Ser Gly Asn Thr Asp 65 70 75 80 Phe Asn Glu Lys Phe Gln Gly Arg Val Thr Phe Thr Ala Asp Thr Ser 85 90 95 Ser Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr 100 105 110 Ala Val Tyr Tyr Cys Thr Arg Trp Gly Tyr Tyr Gly Thr Arg Gly Tyr 115 120 125 Phe Asn Val Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 130 135 140 Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Glu Ile Val 145 150 155 160 Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly Glu Arg Ala 165 170 175 Thr Leu Ser Cys Arg Ala Ser Ser Ser Val Ser Tyr Met His Trp Phe 180 185 190 Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile Tyr Ser Thr Ser 195 200 205 Asn Leu Ala Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly 210 215 220 Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro Glu Asp Phe Ala 225 230 235 240 Val Tyr Tyr Cys Gln Gln Arg Arg Ser Phe Pro Tyr Thr Phe Gly Gln 245 250 255 Gly Thr Lys Leu Glu Ile Lys Ala Ala Ala Phe Val Pro Val Phe Leu 260 265 270 Pro Ala Lys Pro Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala 275 280 285 Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg 290 295 300 Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys 305 310 315 320 Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu 325 330 335 Leu Ser Leu Val Ile Thr Leu Tyr Cys Asn His Arg Asn Arg Phe Ser 340 345 350 Val Val Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile Phe Lys Gln Pro 355 360 365 Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp Gly Cys Ser Cys 370 375 380 Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu Leu Arg Val Lys Phe 385 390 395 400 Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln Gly Gln Asn Gln Leu 405 410 415 Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu Tyr Asp Val Leu Asp 420 425 430 Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly Lys Pro Arg Arg Lys 435 440 445 Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln Lys Asp Lys Met Ala 450 455 460 Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu Arg Arg Arg Gly Lys 465 470 475 480 Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr Ala Thr Lys Asp Thr 485 490 495 Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro Arg Ala Lys Arg Ser 500 505 510 Gly Ser Gly Glu Gly Arg Gly Ser Leu Leu Thr Cys Gly Asp Val Glu 515 520 525 Glu Asn Pro Gly Pro Met Gly Ala Gly Ala Thr Gly Arg Ala Met Asp 530 535 540 Gly Pro Arg Leu Leu Leu Leu Leu Leu Leu Gly Val Ser Leu Gly Gly 545 550 555 560 Ala Lys Glu Ala Cys Pro Thr Gly Leu Tyr Thr His Ser Gly Glu Cys 565 570 575 Cys Lys Ala Cys Asn Leu Gly Glu Gly Val Ala Gln Pro Cys Gly Ala 580 585 590 Asn Gln Thr Val Cys Glu Pro Cys Leu Asp Ser Val Thr Phe Ser Asp 595 600 605 Val Val Ser Ala Thr Glu Pro Cys Lys Pro Cys Thr Glu Cys Val Gly 610 615 620 Leu Gln Ser Met Ser Ala Pro Cys Val Glu Ala Asp Asp Ala Val Cys 625 630 635 640 Arg Cys Ala Tyr Gly Tyr Tyr Gln Asp Glu Thr Thr Gly Arg Cys Glu 645 650 655 Ala Cys Arg Val Cys Glu Ala Gly Ser Gly Leu Val Phe Ser Cys Gln 660 665 670 Asp Lys Gln Asn Thr Val Cys Glu Glu Cys Pro Asp Gly Thr Tyr Ser 675 680 685 Asp Glu Ala Asn His Val Asp Pro Cys Leu Pro Cys Thr Val Cys Glu 690 695 700 Asp Thr Glu Arg Gln Leu Arg Glu Cys Thr Arg Trp Ala Asp Ala Glu 705 710 715 720 Cys Glu Glu Ile Pro Gly Arg Trp Ile Thr Arg Ser Thr Pro Pro Glu 725 730 735 Gly Ser Asp Ser Thr Ala Pro Ser Thr Gln Glu Pro Glu Ala Pro Pro 740 745 750 Glu Gln Asp Leu Ile Ala Ser Thr Val Ala Gly Val Val Thr Thr Val 755 760 765 Met Gly Ser Ser Gln Pro Val Val Thr Arg Gly Thr Thr Asp Asn Leu 770 775 780 Ile Pro Val Tyr Cys Ser Ile Leu Ala Ala Val Val Val Gly Leu Val 785 790 795 800 Ala Tyr Ile Ala Phe Lys Arg 805 <210> 27 <211> 2493 <212> DNA <213> Artificial sequence <220> <221> source <223> / note="Description of artificial sequence: Synthetic polynucleotide" <400> 27 atggcactcc ccgtaactgc tctgctgctg ccgttggcat tgctcctgca cgccgcacgc 60 ccggagattc agctggtgca gagcggcgcc gaggtgaaaa agcccggagc caccgtgaag 120 atcagctgca aggccagcgg ctacacattc accaactacg gcatgaactg ggtgcaacag 180 gccccggcc agggactgga gtggatgggc tggatgaaca catacaccgg cgagcccacc 240 tacgccgaca agttccaggg cagggtgaca ttcacactcg ataccagcgc cagaaccgtg 300 tatatggaac tgagcagcct gaggagcgag gacaccgctg tgtacttctg cgcaagggct 360 ggaggccagc tgagacctgg cgctatggac tactggggcc agggcaccat ggtgaccgtg 420 agctccggag gcggaggatc tggtggcggt ggttctggcg gcggaggctc cgacatcgtg 480 ctgacccaga caccctctc cctgtccgtg acccccggac agcctgcctc catttcctgt 540 aaggcctcc agagcgtgga ctatgacggc gacagcttca tgaactggta cctgcagaag 600 cccggacaac ccccccagct gctgatctac gtggccagca acctggagtc cggcgtgcct 660 gacaggtttt ccggctccgg cagcggcacc gacttcaccc tgaagatcag cagggtggaa 720 gccgaggacg tgggcgtgta ctactgccag cagagcaacg aggagccccc taccttcgga 780 cagggcacca agctggagat caaggccgct gcccttgata atgaaaagtc aaacggaaca 840 atcattcacg tgaagggcaa gcacctctgt ccgtcaccct tgttccctgg tccatccaag 900 ccattctggg tgttggtcgt agtgggtgga gtcctcgctt gttactctct gctcgtcacc 960 gtggctttta taatcttctg ggttagatcc aaaagaagcc gcctgctcca tagcgattac 1020 atgaatatga ctccacgccg ccctggcccc acaaggaaac actaccagcc ttacgcacca 1080 cctagagatt tcgctgccta tcggagccgc ttttccgtcg ttaagcgggg gagaaaaaag 1140 ctgctgtaca ttttcaaaca gccgtttatg aggccggtcc aaacgactca ggaagaggac 1200 ggctgctcct gccgctttcc tgaggaggag gagggcgggt gcgaactgag ggtgaagttt 1260 tccagatctg cagatgcacc agcgtatcag cagggccaga accaactgta taacgagctc 1320 aacctgggac gcagggaaga gtatgacgtt ttggacaagc gcagaggacg ggaccctgag 1380 atgggtggca aaccaagacg aaaaaacccc caggagggtc tctataatga gctgcagaag 1440 gataagatgg ctgaagccta ttctgaaata ggcatgaaag gagagcggag aaggggaaaa 1500 gggcacgacg gtttgtacca gggactcagc actgctacga aggatactta tgacgctctc 1560 cacatgcaag ccctgccacc tagggccaag agaagtggca gcggggaggg ccggggatct 1620 ctccttacat gtggggacgt ggaagaaaat ccggggccta tgggtgccgg cgccacggga 1680 agggctatgg atggcccgcg actgcttctc ctgctgttgt tgggcgtgtc tctcggaggc 1740 gctaaggagg cctgtccaac gggcctctac actcactccg gtgaatgttg caaagcctgt 1800 aaccttggcg agggcgtcgc acaaccttgt ggtgctaacc agacagtctg tgaaccatgc 1860 ctggattcag tgacattcag cgatgttgtc tcagccaccg agccttgcaa gccttgtacc 1920 gaatgtgtgg gccttcagtc catgtccgcc ccctgtgtcg aagccgatga tgcagtgtgc 1980 agatgtgcct atggatatta ccaggacgaa actaccgggc ggtgtgaggc ctgccgggtg 2040 tgtgaagccg gctctggcct cgtgttcagt tgccaggata agcaaaacac agtatgtgag 2100 gagtgtccag acggaaccta cagcgacgag gcgaaccacg tcgacccttg cttgccgtgc 2160 accgtctgcg aggataccga acgccagctg agagagtgta cgcgctgggc agacgctgag 2220 tgcgaggaga tccctgggag atggatcacc cggagcacac ctcctgaggg atcagacagt 2280 acagccccga gtacccaaga accggaggcc cctccagagc aggacctgat cgcttctaca 2340 gttgctggcg tggtgacgac agtcatggga tcctcacaac cagtcgtgac gcggggcaca 2400 accgacaatc tgattcctgt ctactgtagc atcttggcag ccgtggtcgt gggcctggta 2460 gcctacatcg cctttaagag atgacctagg taa 2493 <210> 28 <211> 827 <212> Protein <213> Artificial imitation <220> <221> Jerelo <223> / note="Description of artificial sequence: Synthetic polypeptide" <400> 28 Put Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Wing Leu Leu Leu 1 5 10 15 His Ala Ala Arg Pro Glu Ile Gln Leu Val Gln Ser Gly Ala Glu Val 20 25 30 Lys Lys Pro Gly Ala Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr 35 40 45 Thr Phe Thr Asn Tyr Gly Met Asn Trp Val Gln Gln Ala Pro Gly Gln 50 55 60 Gly Leu Glu Trp Met Gly Trp Met Asn Thr Tyr Thr Gly Glu Pro Thr 65 70 75 80 Tyr Ala Asp Lys Phe Gln Gly Arg Val Thr Phe Thr Leu Asp Thr Ser 85 90 95 Ala Arg Thr Val Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr 100 105 ...
Claims
1. A chimeric antigen receptor that contains an antigen-binding molecule that specifically binds to STEAP1, at least one costimulatory domain, and the activation domain, which is the signaling domain of CD3-zeta, where the antigen-binding the molecule contains: a) the variable region of the heavy chain, which contains regions that determine complementarity, (CDR) 1, 2 and 3 with amino acid sequences SEQ ID NO: 89, SEQ ID NO: 90 and SEQ ID NO: 91, respectively, and the variable region of the lung chain containing CDRs 1, 2 and 3 with the amino acid sequences SEQ ID NO: 94, SEQ ID NO: 95 and SEQ ID NO: 96, respectively; or b) a VH region comprising SEQ ID NO: 88 and a VL region comprising SEQ ID NO: 93; wherein at least one costimulatory domain is a costimulatory a CD28 domain comprising SEQ ID NO: 2, SEQ ID NO: 4 or SEQ ID NO: 4 in combinations with SEQ ID NO: 6 or SEQ ID NO: 8; or a CD8 costimulatory domain, which comprises SEQ ID NO: 14; or a 4-1BB costimulatory domain which comprises SEQ ID NO: 16; and the antigen-binding molecule is an scFv, and the VH and VL are linked at least one linker; and wherein CD3-zeta comprises the sequence SEQ ID NO:
10.
2. The chimeric antigen receptor according to claim 1, which comprises a VH region with the sequence SEQ ID NO: 88 and the VL region with the sequence SEQ ID NO:
93.
3. The chimeric antigen receptor of claim 2, wherein at least one costimulatory The domain is a 4-1BB costimulatory domain, which contains SEQ ID NO:
16.
4. The chimeric antigen receptor of claim 2, wherein at least one costimulatory The domain is a costimulatory domain of CD28, which comprises SEQ ID NO:
2.
5. The chimeric antigen receptor according to claim 4, wherein the costimulatory domain is additionally contains SEQ ID NO:
16.
6. The chimeric antigen receptor of claim 2, wherein at least one costimulatory receptor domain is a CD28 costimulatory domain that contains SEQ ID NO: 4 in combinations with SEQ ID NO:
6.
7. The chimeric antigen receptor of claim 6, wherein the costimulatory domain is additionally contains SEQ ID NO:
16.
8. A polynucleotide encoding the chimeric antigen receptor of claim 1.
9. A vector comprising the polynucleotide of claim 8, which is a lentiviral vector. vector.
10. An immune cell comprising the vector of claim 9, wherein the immune cell is a T- cell.
11. A pharmaceutical composition comprising the immune cell of claim 10.
12. The chimeric antigen receptor of claim 1, wherein the linker comprises a G4S scFv linker or Whitlow scFv linker.
13. A method of treating prostate cancer in a subject in need thereof, comprising: comprises administering to a subject the polynucleotide of claim 8.
14. A method of treating prostate cancer in a subject in need thereof, comprising: comprises administering to a subject the chimeric antigen receptor of claim 1.
15. A method of treating prostate cancer in a subject in need thereof, comprising: comprises administering to a subject a cell according to claim 10.
16. A method of treating prostate cancer in a subject in need thereof, comprising: comprises administering to a subject the pharmaceutical composition of claim 11.
17. The method of any one of claims 13-16, wherein the cancer is metastatic castration-resistant resistant prostate cancer.
Citation Information
Patent Citations
Engineered gamma delta t-cells
US20160175358A1
T cell modifying compounds and uses thereof
US20170183420A1
Bispecific t cell activating antigen binding molecules
WO2017055388A2
Synthetic immune receptors and methods of use thereof
WO2018102795A2
